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General introduction - Atherosclerosis
Chapter 1
| 
| Chapter 1 10
A brief history of atherosclerosis
In the course of human history, infectious diseases, spread by pathogenic micro-
organisms, are held accountable for the loss of millions worldwide1. The rise of the 20th 
century however, found humankind in the brink of medical breakthrough with vaccine 
development2 dramatically reducing mortality rates, while life expectancy was increased 
from a two decades-span to 80 years1,3. Yet, along with medical and technological 
prosperity came the Western-world model of life, accompanied by chronic pathological 
conditions like cancer, Alzheimer’s and cardiovascular disease4.
Cardiovascular disease is the principal cause of death in modern society, with 
44% of all adults in the United States estimated to develop some form of cardiovascular 
disorder by year 20305. Among the different cardiovascular syndromes, the highest 
mortality rate is observed in coronary heart disease, with myocardial infarction being 
its most well-known manifestation5,6. Acute coronary syndromes have a common main 
underlying pathology; atherosclerosis7. Atherosclerotic disease has been described in 
humans since the ancient years8, but it is the modern-era nutritional habits9 that deem 
it the prevailing component of human mortality10. 
It was in 1907 when the Russian scientist Alexander I. Ignatowski reported that 
rabbits being fed a high-fat diet, develop atherosclerotic disease in their aorta11. A few 
years later, in 1913, Nikolai N. Anitschkow revealed that the component responsible 
for the development of atherosclerosis was the high cholesterol content of the high-fat 
diet12. Yet, it took until the 1980s to fully assess the contribution of the immune system 
in the form of inflammatory monocytes on the disease progression13,14,15. From that 
point and to this day, the research community has advanced greatly in understanding 
the pathology of atherosclerosis16,17. Up to now however, the field is still divided over 
whether atherosclerosis is a lipid or an immune-mediated disease, giving rise to the 
ongoing debate of “the lipid versus the immune hypothesis”.
1.  Atherosclerosis pathology
Atherosclerosis is a multifactorial disease with a complex background and 
a chronic, yet silent mode of action; it begins through an individual’s early teenage 
years and can remain undetected for decades until clinical symptoms, requiring an 
expert’s intervention, appear18. The pathology of atherosclerosis is established with the 
formation of multiple lipid-rich plaques in the large branches of the arterial tree19. The 
most susceptible sites within the human body are the ones most sensitive to shear stress 
changes20 such as the carotid bifurcation, aortic arch, abdominal aorta and coronary 
arteries of the heart. 
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The arterial wall is paved with a layer of tightly packed endothelial cells (ECs), to 
assist normal vascular tone, nutrient permeability to the tissues and blood distribution 
over the different body compartments21. Disturbed blood flow, in the presence of 
increased serum (very) low density lipoprotein (V/LDL)22,23, can induce damage on the 
endothelial cell bed24,25 resulting among others, in modulation of the EC tight junctions 
through molecules like PE-CAM-1 and VE-cadherin26 and upregulation of adhesion 
molecules such as VCAM-1 or ICAM-127. The damage inflicted upon the endothelial cell 
junctions permits the lipoprotein molecules to infiltrate the subendothelial space28, bind 
proteoglycan molecules29,30 and undergo chemical modifications31. This process retains 
the lipoprotein molecules in the subendothelial space. Concurrently, loss of the vascular 
EC pattern32 and adhesion molecule upregulation33 but also chemokine secretion upon 
EC activation34, initiates the permeation of inflammatory immune cells in the area17. 
Accumulated phagocytes are able to digest the modified LDL molecules giving rise to 
a thin intimal layer called fatty streak35. Fatty streaks can be detected already at an 
infant age, usually depending on the genetic and environmental background of the 
mother36. These early atheromata are harmless and can disappear during development, 
for instance by lowering serum cholesterol levels37. In fact, through an individual’s 
life initial-phase atherosclerotic plaques can appear and disappear multiple times. 
However, increasing lipid deposition over time at a pre-established atherosclerotic site 
leads to higher plaque volume and advanced atherosclerotic disease stages38. 
The point of advancement from a thin-intimal layer to a progressed atherosclerotic 
plaque depends greatly on the function of phagocytes. Upon increased non-resolved 
inflammation in the plaque area, phagocytic cells become apoptotic39,40. In an attempt 
to clear the apoptotic material accumulating within the vessel wall, a process termed 
efferocytosis takes place41. However, as more and more lipids accumulate in the area, 
this programmed apoptotic mechanism begins to fail, while being replaced by non-
specific secondary necrosis42. Necrotic material accumulation and destruction of the 
cellular plaque composition leaves behind debris, termed necrotic core regions43,44, 
and increased plaque burden45. Upon further progression, the atherosclerotic plaque is 
also characterized by an increase in smooth muscle cell content46, extracellular matrix 
protein synthesis and degradation47 and neovessel formation48. Smooth muscle cells 
(SMCs) are mainly considered protective, by producing extracellular material in the form 
of collagen-rich fibers that stabilize the plaques49,50. In addition, SMCs can increase their 
proliferation rate and migrate on the outskirt of the plaque, to form a protective fibrous 
cap51,52. On the contrary, intraplaque neovascularization, which arises from the hypoxic 
conditions present in the plaque53, increases the inflammatory burden in the area, by 
giving passage to immune cell infiltration inside the intima54. Furthermore, the plaque 
site is subjected to a high risk for microvessel leakage which can lead to intraplaque 
hemorrhage55. Advanced plaques do not have the ability to recede37, increasing thus 
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the chances for an acute cardiovascular event, particularly when they reach the critical 
stage of a fibroatheroma56,57. Uncontrollable progression of a plaque can cause an artery 
to become stenotic and disturb normal blood flow. An advanced plaque can get eroded 
or rupture, causing the formation of a thrombus58,59. Formation of a thrombus at the 
ruptured site can cause vessel occlusion and result in a myocardial infarction episode60 
(Figure 1). However, a thrombus can also get destabilized, and travel to distant narrower 
vessels, obstructing thus the blood supply and resulting in impaired tissue oxygenation 
in the form of a stroke61. At this point, the disease has rapidly progressed to an acute 
clinical stage whereupon surgical intervention is demanded. 
General intervention strategies include endarterectomy surgery to remove the 
plaque62, as well as balloon angioplasty, with or without stent placement63,64, to restore 
the normal blood flow; alternatively, vascular bypass operation65 helps to divert the 
blood circulation via a non-occluded vessel. Yet, all these intervention methods usually 
lead to complications, like restenosis66. In the case of atherosclerosis diagnosed prior 
to clinical manifestation of a cardiac syndrome, pharmacological treatment through 
statin use can decrease the (V)LDL content, providing plaque stability67,68. However, 
lipoprotein reduction alone, without taking the inflammatory context into account, is 
not able to lower the plaque burden and lead to atherosclerotic plaque regression69. 
Interestingly, not all late stage plaques cause clinical events. In fact the plaque 
characteristics that lead to an acute cardiac event appear to shift nowadays from the 
classical stratification70 and at the moment it is unknown why some plaques appear 
“vulnerable” enough as to rupture, yet may not cause clinical symptoms, while plaque 
erosion can lead to acute events without rupture71. 
Figure 1: Myocardial infarction site. Coronary arteries show high preponderance in 
atherosclerotic plaque formation. Fatty streaks are harmless intima protrusions with 
reversible plaque formation. However, increasing lipid deposition leads to advanced plaques, 
or fibroatheromas, characterized by necrotic cores and surrounded by a fibrous cap. Advanced 
plaques tend to either obstruct the blood flow or rupture and release their highly thrombotic 
material to the lumen, increasing the chance for an ischemic episode at a narrower vessel.
13General Introduction -  Atherosclerosis | 
Finally, it is important to remember that the progression rate of atherosclerosis, 
aside from the obvious link between high cholesterol levels and poor dietary choices9, 
also depends on various determinants acting independently or simultaneously, such 
as diabetes72, hypertension73, smoking74 or even an individual’s gender75. All the above 
indicate the complex nature of the disease and how crucial it is to control atherosclerosis 
development at an early stage.
Our current knowledge on the processes that shape atherosclerosis, derives 
mainly from experimental animal models or from observational studies of human 
material collected at the end-stage of the disease. Of the animals used, the most 
common are genetically modified mouse models76. Rabbits77 or non-human primates78 
are models that translate more accurately to the human condition, since rodents do 
not develop spontaneous atherosclerosis; yet, the accelerated pace of atherosclerosis 
development in mice, as well as the fast breeding and relative ease in genetic modulation, 
grants mice useful to study of lipid-induced atherosclerosis. However, the translation 
of mouse atherosclerotic disease to the human situation is as if referring to the 
hereditary condition of familial hypercholesterolemia79; an accelerated atherosclerosis 
syndrome which occurs only in a small proportion of the population with plaques 
showing differential characteristics as compared to the end-stage atherosclerotic tissue 
collected in most human studies80. A typical example of the difference between mouse 
and human atherosclerosis is that mouse plaques rarely advance to an end-stage and 
cannot form spontaneous thrombi81; two processes that are not only typical in human 
atherosclerosis but also, as explained above, the most crucial phase of the disease. It is 
therefore important to remember that extrapolation of mouse research into the human 
condition is not always a straight line. Yet, mouse atherosclerotic plaques still show many 
common characteristics with human plaques and are useful to study the mechanisms 
underlying specific pathways, as well as to develop new therapeutic interventions.
2.  Lipid-induced responses
Circulation of cholesterol particles at normal levels is a physiological process 
required for steroid hormone production82, bile acid synthesis83 and cell membrane 
structure84. Plasma cholesterol levels are influenced, up to an extent, by the cholesterol 
amount absorbed through the diet85. Dietary cholesterol absorption is mediated in part 
by the intestines, the function of which has gained increasing attention in the field of 
atherosclerosis86. However, cholesterol homeostasis is mainly regulated by the liver87, 
a key organ responsible for its synthesis and degradation88. In brief, the synthesis of 
cholesterol is controlled by SREBP-proteins89 and the enzyme HMG-CoA reductase90. 
Cholesterol molecules are delivered to the blood in the form of VLDL or its hydrolyzed 
product, LDL91 (Figure 2). Excess low-density lipoprotein particles are controlled by 
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the hepatic LDL-receptors (LDLr)92, which are responsible for their uptake, thereby 
reducing blood cholesterol levels. The endocytosed cholesterol is broken down into bile 
acids and transferred to the intestines for excretion93.
When cholesterol levels in the cell increase, the transcription factor LXR launches 
a complex regulation pathway which aims to reduce cholesterol production and uptake, 
but also increase the excretion of cholesterol from the cell94. For example, LXR can inhibit 
the uptake of cholesterol by negatively regulating the expression of LDLr95, can interrupt 
cholesterol synthesis by acting on the SREBPs96, but can also increase the transcription 
of the cholesterol efflux proteins ABCA197 and ABCG198 which release the accumulated 
intracellular cholesterol. The action of LXR on ABCA199 and ABCG1100 results in the 
production of high-density lipoprotein (HDL) particles. Hepatic cholesterol is released 
through ABCA1 in the form of apolipoprotein-AI and apolipoprotein-E particles, that 
later assemble into HDL101. 
The function of HDL is considered mainly beneficial102, with high serum 
levels long being proven as protective against the development of cardiovascular 
syndromes103,104. In addition, increased HDL and apoAI have been proven indispensable 
during atherosclerotic plaque regression105–107. This grants HDL the name “good” 
cholesterol. On the contrary, excessive levels of “bad” cholesterol  or (V)LDL in the 
blood have, as mentioned above, been associated with the prevalence of coronary heart 
disease108,109, while non-HDL cholesterol reduction has been proven time and again to 
lower the clinical risk for atherosclerosis-mediated cardiac syndromes110,111. In fact, 
elevated serum LDL levels are associated with atherosclerotic plaque progression112.
Specifically, lipoprotein molecules that have already penetrated the endothelial 
cell barrier, and have been further subjected to modifications such as oxidation31, are 
subsequently taken up by locally proliferating macrophages, which then become foam 
cells113. Intraplaque macrophages internalize oxidized LDL through receptors such 
as protein CD36, that serves as a scavenger receptor114. The uptake of LDL by foam 
cells leads to a circle with an end-goal to process the cholesterol molecules so as to 
be less toxic for the tissue and therefore reverse the local damage. This begins by the 
intracellular break-down of cholesterol into cholesteryl esters, in order for the cells to 
battle its toxicity115. Cholesterol esterification is followed by circles of hydrolysis which 
prepare the molecules for efflux from the cell116. Free cholesterol is released from the 
cells through ABCA1 and ABCG1 and is removed from the arterial wall and back into the 
liver as HDL-apoAI particles117, in a process named reverse cholesterol transport118,119. 
These particles can then be internalized by the scavenger receptor SR-BI in the liver120 
and subsequently get cleared away by the intestines121. However, as lipid accumulation in 
the cell persists, reverse cholesterol transport fails and the internalized free cholesterol 
becomes toxic for the cell, leading thus to foam cell apoptosis122. As explained before, 
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incessant local apoptosis intensifies the already initiated inflammatory response in the 
arterial wall leading thus to the formation of advanced atherosclerotic plaques41.
Figure 2: Cholesterol metabolism pathway. Cholesterol is synthesized in the liver and 
released in the circulation via (V)LDL molecules. High concentration of serum cholesterol 
leads to the accumulation of low-density lipoprotein particles in the subendothelial space 
where they get modified and internalized by foam cells, through protein CD36. Cholesteryl 
esters are intracellularly broken down into free cholesterol which is then released via the 
efflux receptors ABCA1/G1. The free cholesterol molecules are packed into HDL particles 
that can be transferred to the liver. Lipoproteins are being internalized in the liver through 
receptors LDLr and SR-BI and cholesterol is further degraded into bile acids which are 
transported into the intestines for excretion. Abbreviations: (V)LDL: (very) low-density 
lipoprotein, HDL: high-density lipoprotein, LDLr: low-density lipoprotein receptor, CD36: 
cluster of differentiation 36, ABCA1/G1: ATP-binding cassete A1/G1, SR-BI: scavenger receptor 
B type I.
The discovery of the cholesterol regulation pathway has developed into an 
important tool in atherosclerosis research, since the most common experimental 
mouse models used to study the disease are the LDL-receptor-deficient (LDLr-/-) and 
apoE-deficient (apoE-/-) mice76. The function of both models relies on the increased 
circulation of V/LDL particles, which generates atherosclerosis in the arterial tree, 
primarily the aortic arch and root. Specifically, the apoE-/- mice lack apolipoprotein 
E particles and therefore VLDL cannot be cleared away by the liver, with these mice 
showing spontaneous hyperlipidemia and atherosclerotic plaque formation123. In 
contrast, the LDLr-/- model does not develop atherosclerosis unless placed on a high-fat 
diet, whereupon V/LDL is retained at high concentrations in the blood since it cannot 
bind the LDL-receptor and get cleared away through the liver124. Both models show 
many similarities in the development of atherosclerosis. However, it is important to note 
that they can also have crucial differences, as for example in certain immune system-
mediated pathways125. It is important to keep this in mind126, particularly when it comes 
to the regulation of subtle responses that may however fine-tune crucial pathways.
Overall, for cholesterol to be optimally regulated through the body, the liver, 
the intestines and the circulatory system are at a close interrelated communication; 
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malfunction of a process in one of these compartments can influence the other and thus 
disturb cholesterol homeostasis and increase the risk for cardiovascular disease127.
3.  The role of the immune system
It is apparent that serum cholesterol deregulation is a major component for 
the initiation of atherosclerosis. However, it is the dysfunction of the immune system 
that propagates the disease into an advanced stage128. The immune system response 
generally, as well as in atherosclerosis, is classified into a fast reaction elicited by 
innate immune cells129, such as neutrophils, monocytes and mast cells, and a slower, 
more specific, reaction through adaptive immune T and B lymphocytes and NKT cells130 
(Figure 3). Most immune cell types play a detrimental role in the plaque development, 
however the remarkable aspect of the immune system is that while most cell actions 
augment atherosclerosis, there are certain immune cell subsets and pathways that upon 
manipulation appear to act in a protective manner against it131.
Figure 3: Immune cell types involved in atherosclerosis. The main cellular constituents 
of an atherosclerotic plaque are the macrophages. Macrophages proliferate locally in the 
plaque after their monocytic precursors penetrate the endothelial wall layer. Macrophages 
are able to internalize oxidized LDL, thus becoming foam cells. Other innate immune 
cells, like neutrophils and mast cells, also infiltrate the subendothelial space and release 
their granular contents in the area. Secreted pro-inflammatory cytokines and proteases 
enhance the endothelial damage and break down collagen fibers, intensifying thus the local 
inflammation. Macrophages and dendritic cells (DCs) can also drive the adaptive immune 
response, by processing and presenting lipid antigens to T cells and B cells in secondary 
lymphoid organs. Lymphocytes initiate lipid specific responses that mainly propagate 
the inflammatory cascade, resulting thus in apoptosis, necrosis and destabilization of the 
atherosclerotic plaque. Adapted from Hansson & Hermansson, Nat. Immunol. 2011; 12, 204-
212
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3.1  Macrophages
As discussed, macrophages, through their capacity to ingest lipoprotein particles, 
are the major immune cell type within atherosclerotic plaques, both in quantity and 
importance. Macrophages appear within the plaque upon differentiation from locally 
infiltrated monocytes132,133. 
Monocytes are innate cells, generated from the bone marrow, which patrol the 
bloodstream in a guarding fashion and are ready to act upon sensing tissue damage134. 
Once a danger signal is received, monocytes will concentrate in the affected location, 
penetrate the endothelium and infiltrate the area in an attempt to control the damage135. 
In the case of atherosclerosis this happens as soon as lipoproteins accumulate in the 
subendothelial space136. Thereupon the damaged endothelial cells send out signals, for 
instance in the form of chemokine monocyte chemoattractant protein-1 (MCP-1/CCL2) 
among a complex array of chemokine signals137. MCP-1, as the name suggests, attracts 
monocytes in the plaque area, guided there by their expression of chemokine receptor 
CCR2138. Of note, the interaction between CCR2 and CCL2 is one of the most well 
described pathways in the generation of atherosclerosis139.140. Circulating monocytes can 
be divided into various subcategories, depending on their action and according to the 
expression pattern of certain proteins on their membrane134. In humans, monocytes are 
sorted into three classes based on the expression levels of proteins CD16 and CD14141 
with one of the subsets considered a predictor for future coronary events142. In mice, 
this classification relies on the expression of protein Ly6C143. In atherosclerosis, it has 
been proven that Nur77 is a key regulator of the anti-inflammatory Ly6Clow monocyte 
subset, since its deletion enhances pro-inflammatory monocyte responses and leads to 
atherosclerosis progression144,145. In contrast, Ly6Chigh inflammatory monocytes circulate 
at an increased rate over high-fat diet, and drive atherosclerosis development146 upon 
migration in the inflamed tissue. For example, Ly6Chigh monocyte migration regulated by 
protein RP105147 was shown to positively affect atherogenesis148.
 Once infiltrated within the subendothelial tissue, monocytes differentiate 
into plaque macrophages149,150. Uptake of (V)LDL molecules by macrophages results 
in the formation of lipid-laden foam cells113,151. The term “foam cell” derives from the 
distinct microscopic pattern of light-yellow lipid spheres that grant the cells a foamy 
appearance152. Foam cell formation, aside from its significance in cholesterol metabolism, 
affects also the immune response. Macrophages are cells designed to phagocytize 
foreign or toxic material within a tissue, to reduce the spread of the damage153. This is a 
process which activates the cells through specific receptors such as pattern recognition 
receptors, like the toll-like receptors (TLRs)154. Particularly, TLR4 has been found to 
bind oxLDL molecules, activate foam cells155 and initiate a downstream cascade that 
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leads to the secretion of cytokines like IL-1β and IL-6, which further augment the 
inflammation in the tissue by acting on the T cells156. In addition, macrophages are a rich 
source of matrix metalloproteinases156, which degrade the extracellular matrix of the 
plaque and affect plaque stability157. The phagocytic capacity of atherogenic proteins by 
macrophages, is proven to induce endoplasmic reticulum stress and thereby leads to cell 
apoptosis158. As mentioned before, induction of apoptosis during initial atherosclerosis 
stages can be beneficial, while persistent apoptosis at a later stage increases plaque 
development159 and instability160. 
Macrophages appear in multiple subsets during atherosclerosis development, 
defined by their differential responses161. In the past, it was thought that macrophages 
are classified as either classical, inflammatory, M1 macrophages or alternative, healing, 
M2 macrophages162. However, more and more studies indicate that there are in fact 
multiple macrophage subsets and each one acts differently within the atherosclerotic 
plaque163. M1 macrophages were abundantly found in the plaques of patients suffering 
an ischemic episode, as compared to M2 macrophages which were increased in stable 
plaques164. In general, M1 macrophages are reported to enhance inflammation within 
the plaque, for instance through the production of toxic reactive oxygen species165. On the 
other hand, M2 macrophages have recently been proven responsible for atherosclerotic 
plaque regression166. This is the reason why therapeutic means for plaque reduction 
mainly aim on the action of macrophages. A third macrophage subset that seems to 
populate atherosclerotic plaques at high numbers are the Mox macrophages which are 
induced by accumulating oxidized lipids in the atherosclerotic environment and seem 
to be proatherogenic167. These three macrophage types appear to be the most frequent 
inside the atherosclerotic plaque. However, the macrophage classification scheme is a 
matter of debate. While some believe that macrophages are distinguished in many more 
subsets, according to their induction mechanisms and downstream properties168, this 
is not a notion accepted by the entire scientific community. This further illustrates how 
plastic these cells can be, while highlighting the need for additional research in order to 
fully decipher the role of macrophages.
3.2  Dendritic cells
To make matters even more complex, monocytes can also differentiate into 
an additional innate cell subset, the dendritic cells (DCs)169. The difference between 
macrophages and DCs is an intricate matter, mainly due to their common share of most 
protein markers. The main difference lies in the expression levels of proteins CD11c170 
and F4/80171 which are considered DC or macrophage-specific respectively. However, 
it rather seems that these two cell types share an interrelated plastic state because it 
has been shown that under inflammatory conditions, such as inside an atherosclerotic 
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plaque, macrophages upregulate the expression of CD11c172,173, while DCs possess a 
cholesterol regulation machinery, take up lipoproteins and can become foam cells174,175. 
Interestingly, within the atherosclerotic plaque it is not just these two cell types that can 
become foam cells. Recently it was proven that smooth muscle cells also acquire a foam 
cell phenotype176. This indicates that local inflammatory pressure can exert atypical 
effects on the cell types involved. Particularly in the case of immune cells, their state 
and abilities are plastic enough as to alternate from one phenotype to the other. 
Dendritic cells can also arise from hematopoietic progenitor cells and, similar 
to macrophages, develop into different subsets in atherosclerosis pathology177; the 
main being conventional (cDC) and plasmacytoid DCs (pDCs). cDCs can act in an anti-
inflammatory manner, for instance through the control of Flt3, which was shown to be 
atheroprotective178. On the contrary, pDCs seem to affect atherosclerosis progression 
in a positive manner179. Importantly, while uptake of oxLDL by DCs is known to elicit 
a proinflammatory DC-action180, the manner by which they take up and process LDL is 
very crucial in the downstream response that they will exert. For example, ex vivo pulsing 
of DCs with oxLDL was shown to reduce atherosclerotic plaque development181. In 
addition, oxLDL-induced apoptosis on DCs has also been found to be atheroprotective182, 
suggesting that the plasticity of this cell type can prove useful in immune therapeutics 
against atherosclerosis. Lastly, chemokine receptor CCR7 on the surface of DCs was 
decreased in advanced atherosclerotic plaques as compared to control arteries183, 
while it was upregulated during atherosclerosis regression184. CCR7 is known to drive 
the migration of cells out of the atherosclerotic plaque and into the lymph nodes, and 
therefore considered important in regressing plaques185.
Dendritic cells normally populate lymphoid tissues186 and are classified as 
professional antigen presenting cells (APCs)187. As such, in atherosclerosis188, they 
can degrade the ingested lipid material in their lysosomal compartment, cleave the 
lipid proteins into smaller peptides and present various peptide fractions on their 
membranes through major histocompatibility complexes I or II (MHC-I/II)189,190. This 
comprises the initial step for an antigen-specific adaptive immune response. Antigen 
presentation to adaptive immune cells, primarily T cells, requires three signals in 
order to take place191. Signal I is provided through specific antigen presentation by the 
MHC-machinery to the T cell receptor192. While MHC-I is expressed in all cells, since 
it is conserved for the fight against viral responses193, MHC-II is expressed mainly by 
APCs187, but also, upon induction, by some non-conventional APCs, like mast cells187. 
The MHC-binding is followed by signal II, which requires the binding of co-stimulatory 
molecules, such as CD86 or OX40L, to specific T cell costimulatory receptors, like CD28 
or OX40 respectively194. The fashion of the costimulatory interplay is crucial since it can 
alter the T cell response from an effector into an inhibitory one195. However, there is 
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still requirement for a third signal, to ensure that the T cell response does not happen 
in a non-specific manner. Signal III is provided by cytokine molecules196, usually derived 
from activated APCs, for example in the form of IL-12, ΤΝFα, or IL-10197,198. Similarly to 
costimulatory interactions, the qualitative and quantitative balance of the local cytokine 
cocktail can result in the generation of different T cell subsets199. 
Even though both macrophages and DCs present lipid-specific antigens to T 
cells their main difference was thought to be their migratory capacity. However, this 
is a notion which is being disputed at recent times200 and complicates even further the 
distinction between these two cell types. Nonetheless, in atherosclerosis, DCs can take 
up antigens at an immature state, travel to distant secondary lymphoid organs, like the 
spleen and local draining lymph nodes (eg. the heart lymph nodes), whereupon they 
maturate and present antigens to naïve lymphocytes in the area201. Atherosclerosis 
specific antigenic fragments, that are presented by APCs to lymphocytes and elicit 
an adaptive immune response, are one of the most unfamiliar territories in the 
mechanism that shapes atherosclerosis. So far, progress has been made as to identify 
some of these immunogenic peptides. It has been reported in the past that oxLDL can 
trigger an autoimmune response through T cell activation202. In contrast, apoB100, a 
particle carried by (V)LDL molecules, has been found to induce a protective adaptive 
immune response through T cells203, similarly to heat shock proteins 60/65204. This 
is particularly interesting since it means that specific tolerogenic peptides can be the 
basis for vaccination strategies against atherosclerosis205. In fact, very recently three 
new peptides of the apoB molecules were discovered to confer protection against the 
development of atherosclerosis206, underlining the possibilities that open up towards 
vaccine development.
3.3  T cells
 Naïve T lymphocytes of the CD4+ or CD8+ subset migrate from the thymus 
and populate peripheral lymphoid tissues, like the spleen207. Activation of naïve T cells 
leads to a subsequent increase in their proliferation rate, which practically means that 
the T cell receptor is specifically designed to interact with the exact type of antigenic 
fragment that was presented to their ancestor208,209. This process is termed “T cell clonal 
expansion” and initiates effector and memory responses that will secure immunity 
upon encounter of the same antigen at a later timepoint. T cells have been generally 
proven to enhance atherosclerotic plaque development210,211 and high levels of memory 
T cells were reported to circulate in atherosclerosis patients212,213. Essentially, after 
getting activated, T cells migrate through the circulation into the atherosclerotic plaque, 
in order to direct the immune response locally214. 
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T cell subset skewing primarily depends on the MHC-machinery, which APCs 
will use for antigenic fragment presentation. Presentation through MHC-I activates 
CD8+ T cells215, while interaction through MHC-II activates CD4+ T cells216. This is usually 
dependent on the means through which APCs have acquired the antigen and the length 
of the peptide217. 
CD8+ T cells are found at high frequencies in early atherosclerotic plaques, as 
compared to CD4+ T cells; yet over disease progression, both T cell subsets seem to 
accumulate and equalize in numbers218. CD8+ T cells are mainly suggested to act in a 
cytotoxic manner, through the secretion of cytokines like interferon-γ (IFNγ)219 and 
granzyme B220 that induce monocyte proliferation and apoptosis respectively. Hence, 
the role of CD8+ T cells in atherosclerosis is considered detrimental. However, there 
is accumulating evidence that under certain conditions CD8+ T cells can also act 
protectively221. As in the case of macrophage apoptosis, the stage of plaque development 
may be a key regulator that defines the protective versus the detrimental contribution 
of CD8+ T cells in atherosclerosis. Lately it was postulated that a subtype of CD8+ T 
cells, namely Qa-1 restricted CD8+ T cells, possess regulatory properties222. In addition, 
CD25+CD8+ T cells were reported to expand in an apoB100 specific manner, which 
resulted in the secretion of the anti-inflammatory cytokine IL-10223. It seems thus that 
CD8+ T cell subsets in atherosclerosis are now beginning to get explored in more detail.
In contrast, the role of CD4+ T cells in atherosclerosis has been analyzed in more 
depth. CD4+ T cells can develop into many different subsets, according to the cytokine 
signals that they receive224. For example, T-helper 1 (TH1) and T-helper 2 (TH2) cells 
differentiate according to the balance of cytokines IL-12/IL-18 and IL-4225. Depending 
on where the cytokine scale leans toward, the transcription factors T-bet or GATA-3 will 
control the differentiation of a CD4+ T cell into either a TH1 or a TH2 cell respectively. TH1 
cells are the most frequent T cell subset in the atherosclerotic plaque214 and they are 
proatherogenic226, mainly through the secretion of cytokine IFNγ227. The function of TH2 
cells however, is not so clearly determined. TH2 cells are the main secretors of cytokines 
IL-4, IL-5 and IL-13; with IL-4228 reported to counteract the actions of IFNγ229. Even 
though TH2 cells have been proven to neutralize the effect of TH1 cells226, they seem to 
exert both pro-inflammatory and anti-inflammatory effects in atherosclerosis. This is 
attributed to the quality of their secreted cytokine material. For example, IL-4 was also 
shown to induce foam cell formation230 and act in a proatherogenic manner231. On the 
contrary, IL-5 seems to exert a protective effect, by positively affecting the production 
of athero-protective antibodies by B cells232. Another important CD4+ T cell subset is 
the TH17. These cells arise upon the influence of cytokines IL-6, IL-1β, ΤGFβ and IL-21, 
and through activation of transcription factor RORγt, and are considered the main 
secretors of cytokine IL-17233. Their role in atherosclerosis is still unclear, primarily 
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due to contradictory reports on the effects of IL-17. While a previous study reported 
reduced plaque formation in the absence of IL-17234, a follow-up report did not find any 
effect of IL-17 in atherosclerotic plaque development235. Interestingly, IFNγ secretion 
by TH17 cells seems to associate with the progression of coronary atherosclerosis236, 
with HDL-particles reported to attenuate TH1 and TH17 responses237. Therefore, there is 
still a lot to explore on the function of this cell type in atherosclerosis. TH17 cells are 
thought to be the counterparts of the anti-inflammatory CD4+ TREG cell type238. The role 
of TREG cells is essential in atherosclerosis, since they are the main athero-protective cell 
type239. TREG cells are generated through cytokines IL-10 and TGF-β, which activate the 
transcription factor FoxP3 and lead to the production of the anti-inflammatory cytokine 
IL-10240. The presence of TREG cells is reduced upon atherosclerosis progression241 and 
they are negatively associated with the development of myocardial infarction242. Their 
anti-atherogenic manner is attributed mainly to the secretion of IL-10 which can skew 
macrophages into an M2-phenotype243 and hamper TH1244 responses. In fact, TREG cells 
inhibit inflammatory responses upon atherosclerosis progression while stabilizing 
plaques during atherosclerosis regression245. Thus, TREG cells have become a very 
attractive target for immune-cell based therapies in atherosclerosis246. 
Finally, there are accumulating reports on additional T cell subsets and their 
role in cardiovascular syndromes, such as TH22 and TH9 cells247. These cells are mainly 
defined according to their main secreting cytokine, however, their role is relatively 
understudied in atherosclerosis. It is important to not forget that even though cytokine 
secretion profiles are appointed to certain T cell subtypes, this does not mean that these 
cytokines are cell-type specific. A classic example is cytokine IL-17, which even though 
it characterizes TH17 cells, it has been found to be produced also by other cells like γδ T 
cells, mast cells and neutrophils248. The same can be said for IL-4, which has been linked 
mainly to TH2 cells, yet it can also be secreted by mast cells249. 
Interestingly, even after a T cell has been activated and skewed to a specific subset 
inside the lymphoid tissues, upon migration within the plaque it may get exposed to 
differential signals, in terms of quality and quantity. This process can result in a switch 
of the pre-activated T cell into a different subset250. For example, GATA-3 expression 
on TH1 cells can effectively alter them into a TH2 phenotype251. More specifically for 
atherosclerosis, it was recently reported that inside progressing plaques, TREG cells 
acquire a dysfunctional IFNγ secreting phenotype252. This indicates how strong the local 
inflammatory response can be, as to shape de novo the T cell response from an anti-
inflammatory to a pro-inflammatory one. In the end it is the balance between different 
cytokines that will shape the net-effect of the immune response inside the plaque area.
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3.4  Natural Killer T cells
As mentioned before, antigenic fragments are generally presented through the 
MHC-I/II molecules. However, there is an additional presentation molecule on the 
APCs, namely protein CD1d, that is designed to strictly present glycolipid antigens to 
a distinct population of T cells, termed Natural Killer T (NKT) cells253. The NKT cell 
population migrates from the thymus into the periphery, particularly the spleen and 
liver, and is reactive to endogenous and exogenous lipid antigens254. NKT cells possess 
a special T cell receptor chain255 that distinguishes them from other T cell populations 
and, upon activation, secrete vast amounts of TH1256 and TH2257 cytokines. However, 
they also carry characteristic proteins of the innate immune NK cell population and 
are therefore considered to act as a bridge between innate and adaptive immunity. 
Evidently, due to their lipid specific nature, NKT cells are important in atherosclerosis 
development258; particularly during the initial phase259, when the adaptive response has 
not yet been established. NKT cells are considered to be proatherogenic260 due to their 
potent cytokine secretion, that positively enhances plaque inflammation, particularly 
through IFNγ261 and granzyme B262 secretion. However, they have been found to act also 
at later stages263, by affecting atherosclerotic plaque stability through augmentation 
of local apoptosis. The atherosclerotic ligand presented via CD1d to NKT cells is still 
unknown. Nevertheless, protein MTP, which is involved in hepatic VLDL formation264, 
has been found to affect CD1d expression265, suggesting that there is an endogenous 
lipid ligand present in atherosclerosis that activates NKT cells266. It is important to note 
that different ligands can affect NKT cells in a way that can be either proinflammatory or 
anti-inflammatory260. In the future, it would be interesting to fully decipher the ligands 
that activate these cells in atherosclerotic plaques as it would make room for NKT cell 
specific therapeutic intervention.
3.5  B cells
B lymphocytes are another important adaptive cell type in atherosclerosis267. B 
cells are the antibody producing machinery of the body and in atherosclerosis they have 
been found to produce both proatherogenic IgG2c268, as well as, anti-atherogenic IgM269 
antibody fragments. The overall role of B cells in atherosclerosis was initially thought 
to be protective, since their absence increased plaque development270.  However, these 
cells are also distinguished in various subsets with contrasting abilities271. Mainly, B 
cells are separated into B1 cells, which are considered atheroprotective269,272, and 
B2 proatherogenic cells273. In atherosclerosis, different B cell antibody fragments 
show different effects. For example, IgM has been found to be indispensable in the 
protection against atherosclerosis274, while apoB100-specific IgG fragments are 
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proatherogenic275. Interestingly, a very recent study reported that atherosclerotic 
mice which lack IgM, show elevation of the IgE antibody fragment, that is specific for 
mast cell activation276. In addition, the GM-CSF producing IRA B cells have also been 
reported to be proatherogenic268. On the contrary, the contribution of IL-10 secreting 
B cells in atherosclerosis is still somewhat unclear277 with one study postulating 
an atheroprotective role278, while another did not report an effect in atherosclerosis 
development279. B cells reside in large amounts in the spleen and lymph nodes, 
particularly in the follicular centers and marginal zone280, but in atherosclerosis they 
can also be found inside the peritoneal cavity281, which is rich also in mast cells282 and 
foam cells. Their antibody producing capacity in particular, is what makes these cells an 
obvious target in the development of a vaccination therapy.
3.6  Neutrophils
Another important cell type in atherosclerosis are the neutrophils283. This innate 
granulocytic population, generated in the bone marrow, patrols the blood vessels at 
high frequencies, and relocates inside the damaged tissue, through signals received 
by their chemokine receptors284. Neutrophils are characterized by their very short 
lifespan285 and are rich in chemokine receptors, the most known being CXCR2, and 
CXCR4286. However, under chronic inflammatory conditions, neutrophils can upregulate 
additional chemokine receptors, such as CCR2 and CXCR3287. In atherosclerosis they 
increase upon hyperlipidemia and accelerate the early phase of plaque development288. 
Neutrophils can crawl on the endothelial cell wall of arterial sites exposed to high 
shear stress289, infiltrate the subendothelium290,291 and inflict local damage, increasing 
therefore the penetration rate of additional immune cells, like monocytes292.  They are 
considered proatherogenic due to their release of proteases and production of MPO293 
and ROS294, which induce tissue apoptosis. Despite the notion that they only affect early 
atherogenesis, neutrophils have been reported to act also in end-stage atherosclerosis, 
mainly through the secretion of matrix metalloproteinases295. In support of their role 
during end-stage atherosclerosis, neutrophils are positively associated with acute 
coronary events296. Interestingly, one manner through which they affect advanced 
atherosclerosis involves CXCR4; however, this CXCR4 mediated effect of neutrophils 
was surprisingly found to be protective instead of damaging297. In addition, neutrophils 
possess the unique ability to “explode” under inflammatory conditions, resulting in the 
formation of what is called neutrophil extracellular traps (NETs)298. The presence of 
NETs in atherosclerosis was described relatively recently299,300 and, as expected, this was 
reported to be proatherogenic301. Lastly, neutrophil infiltration can also be regulated by 
other immune cells, such as the mast cells that were found to recruit neutrophils inside 
the plaques through a CXCR2/CXCL1 interaction302.
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3.7  Mast cells
One of the most important granulocytic populations involved in atherosclerosis 
are the mast cells303. Mast cells are present within the arterial wall at low numbers, 
even under normal conditions, but accumulate in the area upon atherosclerosis 
progression304. There, mast cells get activated and exert their effects by releasing their 
granular content in the surrounding microenvironment305,306. Mast cells are unique 
cells, characterized by the stem cell factor receptor, c-kit or CD117307. Furthermore, 
mast cells are recognized by their distinct granular mediators, neutral proteases 
tryptase and chymase, histamine as well as proinflammatory cytokines like IL-6, TNFα 
and IFNγ308. In the circulation mast cells can be found solely as progenitors and, similar 
to macrophages, their end-stage maturation takes place only within tissues309. Mast 
cells are largely influenced by the microenvironment at their place of residence and 
are, thus, distinguished in different subtypes (Figure 4). Mouse mast cells are defined 
as either connective tissue (CTMCs) or mucosal mast cells (MMCs), while human mast 
cells are classified according to their protease content, which is either only tryptase or 
tryptase as well as chymase310. The activation of mast cells can occur via multiple ways. 
The typical pathway involves binding of an antigen sensitized-IgE antibody onto their 
characteristic Fcε-receptor311. However, mast cells have been reported to get activated 
via additional pathways, such as for instance through TLRs312, complement receptors313 
and neuropeptide receptors314; all activation pathways that have been also implicated 
in atherosclerosis. 
Figure 4. Mast cell subsets and activation pathways. Mast cells are distinguished in 
various subtypes depending on their place of residence and microenvironment. Mast cell 
activation can occur through the classical pathway involving binding of an IgE fragment onto 
their characteristic FcεR, but can also occur though additional pathways. Adapted from Galli 
et al., Nat. Immunol. 2011; 12, 1035–1044.
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 Mast cells are proatherogenic mediators in atherosclerosis and enhance 
plaque progression and destabilization306, through their protease secretion315 which 
can degrade the extracellular matrix316. They are also reported to enhance foam cell 
formation, by acting on the cholesterol efflux mechanism317. Mast cells possess many 
chemokine receptors, such as CCR2318, which can induce their accumulation in the 
plaque. In addition to their presence inside atherosclerotic plaques, mast cells can also 
be found in the peritoneal cavity of atherosclerotic mice whereupon mast cell granules 
have been shown to degrade apoB100319. 
Although mast cells have been investigated thoroughly in atherosclerosis, the 
exact mast cell activation mechanisms and local behavior within the atherosclerotic 
plaques is still not fully elucidated. Therefore, it is intriguing to clarify the exact 
mechanisms that shape mast cells inside the atherosclerotic plaque. 
There are many additional cell types that are equally important in atherosclerosis-
mediated syndromes which we did not discuss here, such as eosinophils320, NK 
cells321, innate lymphoid cells322, MDSCs323, or γδ324 T cells. Thus, based on the above 
it is apparent that the immune response in atherosclerosis is a very complex matter. 
Therefore, a question emerged, on whether atherosclerosis should be classified as a 
chronic autoimmune disease325. In fact, many modern therapeutic interventions target 
the inflammatory rather than the lipid response. However, we should remember that 
both mechanisms are co-existing and closely interacting; what’s more, they regulate 
each other in an active manner. An example of this interaction comes from bioactive 
lipids such as lysophosphatidic acid (LPA). LPA is a lipid component of LDL that can be 
generated within the plaques upon LDL-modification326. LPA has been proven to activate 
an array of immune cells such as CD4+ T cells327 and mast cells328. In addition, it was only 
recently reported to enhance foam cell formation, for example through inhibiting SR-
BI329, therefore influencing cholesterol metabolism.
It is thus the intricate interrelation between lipid and immune components 
that shapes plaque initiation and development and due to that, future research on the 
mechanisms that target both elements must be the focus of therapeutic means to treat 
atherosclerosis.
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Thesis outline:
 The aim of this dissertation has been to investigate the role of mast cells in 
atherosclerosis, and specifically in immune-mediated pathways that characterize the 
disease. In chapter 2 we will give an overview on the role of mast cells in multiple 
cardiovascular syndromes with a focus on atherosclerosis. Chapter 3 will provide an 
example of the interaction between lipid and immune responses in atherosclerosis. We 
will address the therapeutic capacity offered by blocking the action of lysophosphatidic 
acid receptors. We will provide evidence on how pharmacological inhibition of the 
LPA1/3 axis can alter the immune response at a systemic level and reduce plaque 
development. In chapter 4 we will explore a novel pathway via which mast cells can 
affect atherosclerosis, through acting as non-professional antigen presenting cells. We 
will provide evidence on how this influences the adaptive immune response towards 
a proatherogenic manner. In contrast, chapter 5 will provide evidence on how this 
capacity of mast cells to present antigens can also elicit a protective response, via their 
CD1d-mediated interaction with NKT cells. We will move onto chapter 6 to scrutinize 
the translational impact that mast cells have in atherosclerosis. We will demonstrate 
how we made use of the flow cytometry method to characterize human intraplaque 
mast cells and discuss their phenotype in end-stage atherosclerosis. We will conclude 
the experimental part with chapter 7 where we will debate the therapeutic ability of 
mast cells through their role in atherosclerosis regression. Finally, in chapter 8, we will 
summarize the data of this thesis and discuss the latest therapeutic advancements in 
the field of atherosclerosis.
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Chapter 2
Abstract
Mast cells comprise an innate immune cell population, which 
accumulates in tissues proximal to the outside environment and, upon 
activation, augments the progression of immunological reactions through 
the release and diffusion of either pre-formed or newly generated 
mediators. The released products of mast cells include histamine, 
proteases, as well as a variety of cytokines, chemokines and growth 
factors, which act on the surrounding microenvironment thereby shaping 
the immune responses triggered in various diseased states. Mast cells have 
also been detected in the vessel wall and are implicated in the onset and 
progression of numerous cardiovascular diseases. Notably, modulation of 
distinct mast cell actions using genetic and pharmacological approaches 
highlights the crucial role of this cell type in cardiovascular syndromes. 
The acquired evidence renders mast cells and their mediators potential 
prognostic markers and therapeutic targets in a broad spectrum of 
pathophysiological conditions related to cardiovascular diseases.
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1.  Introduction
Mast cells are innate immune cells characterized by a monolobular nucleus and 
numerous cytoplasmic granules1, morphological features which distinguish them from a 
variety of cell types that comprise the immune system. Originating from hematopoietic 
stem cells within the bone marrow2, mast cell progenitors are released into the 
circulation and, upon the influence of cytokine and chemokine signals, home in tissues 
and further differentiate into mature mast cells3. The place of maturation for mast 
cells is either mucosal surfaces or connective tissue, therefore granting them a wide 
distribution throughout the body. Tissue resident mature mast cells exert their effector 
functions after activation triggered by cytokines, antibodies and proteins specific for 
receptors present on their surface. The most widely studied mast cell activation pathway 
is the antigen-specific activation by Immunoglobulin-E (IgE) antibodies, which bind to 
the high affinity membrane receptor Fcepsilon Receptor-1 (FcεR1)4. However, during 
the last decades, additional agents triggering mast cell activation have been discovered, 
such as the Immunoglobulin-G (IgG) antibodies5, complement system components6, 
but also pathogenic Toll-like receptor peptides7, as well as endogenous ligands like 
substance P (SP)8 and endothelin-1 (ET-1)9.
The mast cell secretory granules contain a variety of molecules such as 
proteoglycans (e.g. heparin and chondroitin sulfate), histamine, cysteinyl cathepsins, 
proteases (e.g. chymase and tryptase) and a broad spectrum of pro-inflammatory as 
well as anti-inflammatory cytokines10. Through their mediator release, mast cells are 
able to act on the adjacent cells and shape the local microenvironment.
In addition, mast cells residing in different tissues exhibit a diverse protease 
content, and can consequently be separated into various subpopulations. However, 
despite the differences in the granule protease composition of each mature mast cell 
subtype, their content can be actively shaped depending on signals received from the 
surrounding microenvironment11,12. Finally, the ultimate protease phenotype in a tissue 
may switch from one to another in a reversible way. Such de novo formation of mast 
cell mediators, which extends itself beyond the granule proteases, depends not only 
on the intrinsic characteristics of each tissue but also on local pathologic conditions 
at any given point, granting remarkable plasticity to mast cells regarding their effector 
functions13,14.
Within the cardiovascular system, mast cells reside in close proximity to blood 
vessels, as well as in the heart of both humans and rodents15, where they participate in 
physiological functions such as angiogenesis and local generation of the vasoconstrictive 
hormone Angiotensin II (Ang II)16. The majority of mast cells populating the human heart 
and vessels consist mainly of tryptase17, while in mice they are recognized as connectice 
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tissue mast cells and contain granules filled with heparin, chymase and tryptase18,19. 
However, particularly in humans, the mast cell protease content in the vessels shows 
remarkable variation among subjects20, attributing each protease a differential role in 
the pathophysiology of cardiovascular diseases. Yet, aside from proteases, there is a 
plethora of additional mast cell mediators which participate in the pathological events 
observed in cardiovascular syndromes (Figure 1). 
Mast cells in the vasculature are mainly distinguished for their adverse effects 
in syndromes such as abdominal aortic aneurysm21, myocardial infarction22, and 
atherosclerosis23, displaying thus a crucial role in the leading cause of death worldwide24. 
It is therefore intriguing to pinpoint the overall importance of mast cells in a wide 
variety of such conditions.
Figure 1: Mast cells in cardiovascular diseases. This figure depicts major cardiovascular 
diseases in which mast cells have been implicated. Specific mast cell mediators, summarized 
here, have been reported in each of these syndromes. Abbreviations: IL-6: Interleukin-6, 
IL-8: Interleukin-8, TNFα: tumor necrosis factor-alpha, IFNγ: Interferon-gamma, TGF-β: 
transforming growth factor-beta, MCP-1: monocyte chemoattractant protein-1, bFGF: basic 
fibroblast growth factor.
2.  Diet-induced obesity 
The incidence of obesity, due to high fat diet, has become a Western society 
epidemic and is closely linked to type 2 diabetes, as well as other metabolic and cardiac 
disorders25. Increased chronic inflammation at a low degree is observed in white 
adipose tissue (WAT) of obese humans and mice, with local infiltration of macrophages26 
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to microvessels and are directly associated with the pathology of this disorder. More 
specifically, Liu et al. reported in 2009 an increased number of mast cells in WAT of 
obese humans and mice, accompanied by elevated serum tryptase levels as well as local 
and systemic levels of inflammatory cytokines, chemokines and proteases, compared 
to lean subjects. Here, mast cells contribute to WAT apoptosis and angiogenesis. This 
effect is exerted via Interleukin-6 (IL-6) and Interferon-gamma (IFNγ) cytokines, which 
in turn increase cysteinyl cathepsin expression, thus promoting diet-induced obesity. 
Importantly, in the cited study, mast cells are observed to infiltrate obese WAT prior 
to macrophages. Likewise, mast cells are shown to co-localize with CD8+ T cells in 
mouse WAT28, suggesting a role in adipose tissue inflammation. An additional study 
reported that mast cell deficient, KitW-sh/W-sh, mice transplanted with hematopoietic-
prostaglandin synthase deficient mast cells are not able to gain weight similarly as 
mice transplanted with wild-type mast cells, pinpointing the importance of mast cell 
derived prostaglandins in adipose tissue function29. As adipocytes themselves are also 
an important source of cytokines30, this adds up to the local inflammatory burden. 
Interestingly, adipocytokines have been linked to mast cells in the context of allergic 
inflammation and asthma31, introducing a possible crosstalk between the resident cells 
of adipose tissue and the infiltrating mast cells. 
2.1. Type II-diabetes mellitus
Notably, obesity comprises an essential risk factor for the development of type 
2-diabetes mellitus32. Non-insulin dependent diabetes is a metabolic disease defined 
by hyperglycemia and insulin-resistance, which is greatly influenced by obesity. Aside 
from their role in obesity, mast cells have been directly linked to type 2-diabetes. Mice 
fed a high-fat diet while lacking mast cells show higher glucose tolerance, compared 
to the wild type strain33. Since tumor necrosis factor-alpha (TNFα) was found to be 
overexpressed in obese mice34, this cytokine has been considered a key mediator in the 
induction of insulin resistance35. However in experiments using TNFα deficient mast 
cells33, TNFα did not contribute to the effect of mast cells in obesity, indicating that the 
metabolic changes induced by this cytokine may have been due to TNFα derived from 
other inflammatory cells than mast cells.
2.2. Diabetic nephropathy
Diabetes mellitus can often lead to serious renal complications, such as diabetic 
nephropathy, a condition showing increasing mortality rates over the years36. Diabetic 
nephropathy is marked by glomerular and tubular basement membrane thickening 
and hypertrophic mesangial matrix, while it can lead to tubulointerstitial fibrosis and 
2
glomerulosclerosis37. In the past, human mast cells have been reported to infiltrate the 
diseased kidney at increasing numbers as diabetic nephropathy progresses38, while 
participating in the initial mechanisms of tubulointerstitial injury39. Furthermore, 
mast cell infiltration in the kidneys of rodents was clearly established in renal diseases, 
the mast cell mediators chymase, tryptase and transforming growth factor-beta1 
(TGF-β1) showing increased levels in injured rat kidney tissue40. Importantly, TGF-β1 
has already been reported to be a key cytokine responsible for the aggravation of renal 
fibrosis41, via collagen overexpression by fibroblasts42. Chymase has been connected to 
various mechanisms that shape renal diseases43, and regarding  diabetes and diabetic 
nephropathy, chymase was suggested to participate in local Ang II formation44. In addition, 
tryptase was reported to enhance renal fibrosis while additionally being implicated in 
collagen synthesis, which illustrates a potential regulatory mechanism of mast cells on 
fibroblasts45. In fact, diabetic rats treated with the mast cell stabilizer tranilast displayed 
diminished chymase-positive mast cell infiltration in mesenteric vessels, diminished 
mesenteric vascular collagen deposition, and ultimately amelioration of the diabetes-
induced vessel fibrosis46, which was considered to result from inhibition of chymase 
and subsequent reduction in the generation of Ang II.
Seemingly, mast cells in both obesity and diabetes function either by establishing 
cell interactions with local and infiltrating cell types, or via their degranulation 
products acting in situ. Through these routes, mast cells may contribute to various life-
threatening cardiovascular syndromes. For instance, in an experimental diabetes model, 
mice showed increased cardiac mast cell activation and defective heart function, which 
led to the development of cardiomyopathy47. However, upon treatment with the mast 
cell stabilizer nedocromyl, the cardiac mast cell numbers were decreased, followed by 
decreased collagen deposition and normalized cytokine levels. Furthermore, in a recent 
patient study examining obese subjects for subclinical atherosclerosis, serum tryptase 
positively correlated with metabolic risk factors, such as body-mass index48, as well 
as atherosclerosis markers, suggesting that mast cell activation composes a tight link 
between obesity and cardiometabolic diseases.
3. Atherosclerosis
 Atherosclerosis is the primary underlying cause of acute cardiovascular 
syndromes, such as stroke and myocardial infarction, principal causes of death 
in Western society49. This vascular disease is a chronic inflammatory condition, 
characterized by thickening of the arterial wall after lipid accumulation, which results 
in the formation of an atheromatous plaque50. Elevated levels of cholesterol-carrying 
low density lipoprotein (LDL), and its subsequent penetration through the vascular 
endothelial cell layer where it gets oxidized (oxLDL) are an initial feature of plaque 
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development. Circulating monocytes begin to accumulate in the area where they 
differentiate into macrophages and ingest oxLDL51. This gives rise to foam cells, the 
innermost cell type of an atherosclerotic plaque52. A progressed plaque consists of 
high numbers of inflammatory cells, enhanced extracellular matrix (ECM) degradation, 
excessive levels of cell apoptosis, and may eventually rupture, leading to thrombus 
formation and possible vessel occlusion. 
3.1. Mast cells in atherosclerosis
The first to illustrate the importance of mast cells in atherosclerosis was Paris 
Constantinides in 1953, when he proposed a protective role for mast cells in rats, 
assigning this role to mast cell heparin53. Thereafter, a long silence in the field of mast 
cells and potential atherogenic mechanisms prevailed, with some frustration about the 
strong ability of mast cells to degrade and inactivate enzymes involved in lipoprotein 
metabolism. A renewed interest in the potential connection between mast cells and 
atherosclerosis was sparked when it was discovered that exocytosed granules of 
activated rat peritoneal mast cells were able to avidly degrade the apolipoprotein B-100 
of LDL54. This initial observation led to the finding of activated mast cells being able 
to convert macrophages into foam cells, the hallmark of atherosclerosis55.  Mast cells 
exert this effect via the “granule carrier pathway” in which the heparin and chymase 
components of the exocytosed mast cell granules act in concert. Thus, heparin first 
binds LDL particles, granule chymase then proteolyzes the bound particles and renders 
them unstable to fuse and form lipid droplets on granule surface, and ultimately 
macrophages phagocytoze the LDL-containing granules. This renewed interest in 
the  mechanisms explaining the potential role of mast cells in atherosclerosis led to a 
search of mast cell proteases in the various layers of the healthy human arterial wall 
and in the various regions of atherosclerotic plaques. Indeed, it could be demonstrated 
that the mast cells in the human aortic wall are of two types, those containing only 
tryptase and those containing both tryptase and chymase20. Ever since numerous 
laboratories profoundly linked mast cells to the development of atherosclerosis and 
acute cardiovascular syndromes, such as atherothrombosis. In the human arterial wall, 
mast cells are located in the inner and outer layer (intima and adventitia) of a healthy 
aortic wall, first at a low density and then, during the progression of atherosclerosis, 
with a propensity to increased density in the vulnerable shoulder region of the 
developing plaque and also in the adventitia20,56. Most importantly, activated mast 
cells accumulate in the shoulder region of human coronary plaques, which is the site 
vulnerable to rupture57. In the atherosclerotic aortic wall of atherosclerosis-prone 
mice, mast cells are located mainly in the adventitia with only sporadic occurrence 
in the intima58, while in humans they gather in both areas56,59. Moreover, mast cells in 
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the advanced atherosclerotic carotid and coronary arteries have been reported to be 
in close proximity to microvessel sprouting59,60 and to be connected with intraplaque 
hemorrhage, i.e. with a key histological sign pointing to vulnerability of a plaque to 
rupture61. Notably, a recent publication on human carotid atherosclerosis described 
mast cells as the only immune cell type directly associated with future cardiovascular 
events62. Acquired evidence heretofore, recently reviewed by our group, appoints mast 
cells a pro-atherogenic role, as they have been reported to enhance leukocyte influx and 
local apoptosis, augment matrix degradation and induce hemorrhagic events, affecting 
plaque initiation, progression and destabilization63.
3.2. Mast cell infiltration mechanisms
In the course of plaque development, mast cells infiltrate the vessels and are found 
in the intima and adventitia of human coronary arteries64,65. One mechanism of mast cell 
infiltration is via chemokine signals between eotaxin and its receptor C-C chemokine 
receptor-366. However, mast cells carry additional chemokine receptors67, which are 
also known to participate in transendothelial migration68 during atherosclerosis 
development, indicating that there may be supplementary signals that attract mast cells 
to enter the arterial intima. Furthermore, activated mast cells can produce chemokines 
themselves69, which may amplify the attraction signals and positively regulate their 
presence; possibly explaining the direct correlation between mast cell numbers and 
plaque progression. In addition, it has recently been reported that vascular endothelial 
cells (ECs) can induce immature mast cell attraction via the adhesion molecules 
E-selectin, P-selectin, vascular cell adhesion molecule-1 and platelet endothelial cell 
adhesion molecule-170. Conversely, pro-inflammatory cytokines released by mast cells 
can induce upregulation of main adhesion molecules (e.g. P-selectin) in endothelial 
cells71.
3.3. Mast cell activation mechanisms
It has been observed that apart from the numerical increase, mast cells appear in 
a degranulated state inside ruptured plaques of human coronary arteries72, proposing 
therefore that mast cells exert their local effects through mediator release. Following that, 
we confirmed, using the atherosclerotic apoE-deficient (apoE-/-) mouse model, that mast 
cells through their activation are responsible for disease progression, after observing 
an increase in plaque size upon systemic mast cell activation73. Concomitantly, Sun et 
al., (2007a) reported that double mutant LDL-receptor (LDLr-/-)KitW-sh\W-sh mice show 
decreased plaque formation, lipid deposition and immune infiltration compared to the 
LDLr-/- strain, confirming a direct connection between mast cells and atherosclerosis. 
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Consequently, scientific research focused on possible target molecules that may activate 
mast cells inside the vascular microenvironment. Evidently, IgE was one of the primary 
candidate molecules to be investigated, with the first studies reporting that IgE serum 
levels were higher in patients suffering from angina pectoris74 or dyslipidemia75. 
Moreover, IgE blood levels were detected to be significantly higher immediately after 
myocardial infarction76. Furthermore, in a recently published experimental study 
targeting immune activation in atherosclerosis, LDLr-/- mice treated with an antibody 
against OX40-ligand showed plaque regression which was partially appointed to 
reduced plasma IgE and lower mast cell infiltration77. Additionally, a few years ago it 
was stated that serum IgE could be detected within atherosclerotic s where it promoted 
cell apoptosis and cytokine expression in apoE-/- mice as well as in humans through 
FcεR1 in synchrony with Toll-like receptor-4 (TLR4)78. With respect to TLR4, despite 
the fact that the above effects were mainly described on macrophages, this receptor 
has also been found on the surface of mast cells where it was able to trigger membrane 
bound-mast cell activation79, thus supporting a possible mast cell-TLR4 specific role in 
atherosclerosis. Moreover, antibodies of the IgG-class were found to activate human 
mast cells in vitro, after formation of immune complexes with oxLDL80, indicating that 
various components of an immune reaction can contribute to intraplaque mast cell 
activation. Interestingly, oxLDL itself is one of the endogenous molecules that can initiate 
an immune response81. In relation to mast cells, oxLDL can directly activate human mast 
cells in vitro, partly through TLR-4 signaling82. In addition, oxLDL constituents, such 
as lysophosphatidic acid have lately been described to concentrate in the plaque and 
locally activate mast cells, contributing to plaque destabilization83, and consequently 
illustrating a strong link between mast cell action and excessive lipid accumulation. 
Furthermore, components of the complement system, such as the anaphylatoxin C5a, 
are able to activate mast cells in the context of atherosclerosis through their specific C5a-
receptor. Examination of human coronary plaques revealed that mast cells were positive 
for C5a-receptor84. A recent study directly linked C5a-specific mast cell activation in 
mice to plaque progression, showing that mast cell stabilization, using cromolyn, 
attenuated C5a-induced progression of vein graft disease, while mast cell activation 
using dinitrophenyl hapten augmented disease and increased plaque development85. 
Yet, apart from C5a, other proteins of the complement system may also act on mast 
cells inside the plaque microenvironment, since it has already been mentioned that 
certain mast cell subsets can get potently regulated by additional complement factors86. 
However, it is also the interaction with adjacent cell types inside the plaque that affects 
mast cell activation. For instance, ET-1, an endothelial vasoconstricting peptide, displays 
elevated levels in atherosclerosis patients87 and induces cardiac mast cell activation in 
rats88. Furthermore, activated mast cells are able to enhance endothelial ET-1 expression 
in vitro89. Additionally, several bioactive molecules, such as reactive oxygen species, 
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present in the inflamed plaque at increased levels, may also function as local mast cell 
activators90. Lastly, an intriguing observation revealed that mast cells inside human 
coronary artery specimens of different atherosclerosis phases, reside proximal to nerve 
fibers91, implicating the central nervous system in mast cell action. One link may be 
SP, a neuropeptide regulating inflammation92 and stress-related cardiac syndromes93. 
Since mast cells were found to express the SP receptor, neurokinin-194, an experimental 
atherosclerosis mouse study was designed to identify the direct link between SP and 
these cells inside the plaque, revealing that mast cell presence and activation were 
enhanced upon intensified SP treatment, followed by plaque destabilization, while 
neurokinin-1 blockade prevented these changes65. Moreover, a very recent publication 
reported that an additional neurotransmitter, neuropeptide Y, can promote mast cell 
activation while also affecting plaque progression in apoE-/- mice95. Admittedly, there 
are probably other unidentified mast cell activators that elicit mediator release inside 
the plaque and further research needs to be conducted in order to identify the precise 
triggers of mast cell activation in atherosclerosis.
3.4 Mast cell mediated atherosclerosis progression
A vast amount of research has approached the role of mast cells in atherosclerosis 
by testing the effects of general mast cell inhibition achieved by pharmacological or 
genetic approaches. Among the evidence collected so far, it has been demonstrated 
that mast cells stabilized in vitro, using anti-allergic drugs, were able to inhibit foam 
cell formation, suggesting a direct role in plaque development96. In accordance, in 
vivo research, using the apoE-/-KitW-sh/W-sh mouse model, reports a reduction in aortic 
atherosclerosis progression, as well as leukocyte influx and inflammation levels97. Adding 
up to the above, a recent study using LDLr-/- mice,  showed that mast cell stabilization 
with cromolyn not only reduced inflammation and atherosclerosis progression but also 
improved the lipid profile of these mice98. It is therefore evident, that mast cells, through 
their activation, can directly affect atherosclerosis progression.
However, as it may be expected, distinct mast cell activation pathways result in 
the release of diverse molecules, which individually affect the complex mechanisms of 
atherosclerosis in different aspects. Mast cell proteases are thought to be important in 
atherosclerosis (Table 1). For instance, chymase accounts for the disruption of vascular 
tissue homeostasis by indirect degradation of ECM via activation of pro-collagenase99 
and pro-matrix-metalloproteinase-9 (pro-MMP9)100. This serine protease can also 
directly degrade ECM by hydrolyzing its main components, such as fibronectin101. 
Furthermore, the direct degradation of fibronectin by chymase leads to vascular 
smooth muscle cell (VSMC) apoptosis102. Chymase can also induce VSMC apoptosis by 
disturbing the nuclear factor-kappa B (NF-κB) anti-apoptotic signaling pathway103. This 
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regulatory effect of mast cells, via chymase, on the VSMCs was recently found to be, at 
least partly, mediated through TLR-4 activation, in an in vivo atherosclerosis model104. 
Nevertheless, together with the induction of apoptosis, chymase can inhibit collagen 
production and hinder VSMC proliferation105. A combination of the above mechanisms 
can induce thinning of the fibrous cap of a plaque, and can lead to rupture. Moreover, 
this protease can also act on the vascular endothelium. Thus, chymase avidly degrades 
various components of the pericellular matrix of ECs, which may result in detachment 
of endothelial cells in turbulent areas of the arterial tree106 and, in combination with 
TNFα, enhance EC apoptosis107. Chymase can also release latent TGF-β1 from the 
pericellular matrix of ECs, and so render it susceptible for activation via interaction 
with binding sites on EC surface108. The activated TGF-β1, again, can affect a multitude 
of signaling machineries involved in tissue remodeling, and it may also regulate the 
activity of infiltrating immune cells. Moreover, chymase is known to induce apoptosis of 
macrophages73, while also stimulating immune effector cytokines and chemokines109. In 
addition, chymase has been demonstrated to degrade various apolipoproteins of high-
density lipoprotein and thereby dampen the efflux of cholesterol from macrophage 
foam cells110,111,112. Also, experiments in the mouse have demonstrated that mast cell 
activation in the peritoneal cavity locally degrades apolipoprotein AI, and via this 
action impairs the entire macrophage reverse cholesterol transport pathway, i.e. 
cholesterol transport from the peritoneal macrophage foam cells to feces111. A number 
of studies report that chymase is responsible for the local production of Ang II113,114. 
More specifically, chymase-induced Ang II was able to induce reactive oxygen species 
production via binding to its receptor and activating NAD(P)H oxidase, aggravating 
hence the local inflammatory burden115. Subsequently, chymase expression, as well 
as Ang II levels, were found elevated in human atherosclerotic aortas116, while, in a 
hamster model, Ang II levels were observed reduced after treatment with tranilast117. 
Ang II is also leading to VSMC apoptosis118 and leukocyte infiltration119. A critical role 
for chymase, as a mediator for atherosclerosis progression, was demonstrated in apoE-
/- mice in which this protease was inhibited, using compound RO5066852. These mice 
showed reduced plaque progression, increased plaque stability, through enhanced 
collagen deposition, and lower intraplaque hemorrhage levels120.
Moreover, both chymase and tryptase were shown to be positively correlated 
with the degree of atherosclerosis in human aortas121. Tryptase is known to degrade 
ECM by activating pro-MMPs122 while also breaking down fibronectin106. In addition, 
this protease has been suggested to actively participate in foam cell formation in vitro, 
through protease activated receptor-2 (PAR-2)123, while enhancing MCP-1 and IL-8 
levels on cultured endothelial cells124. Along that line, tryptase augments neutrophil 
migration by acting as an inducer of chemokine IL-8 secretion from endothelial cells125. 
Furthermore, tryptase acts on macrophages, by increasing lipid accumulation while 
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degrading high-density lipoprotein126 and thus blocking the cholesterol efflux pathway. 
Yet, tryptase can affect various chemokines127. Additional evidence regarding the role 
of tryptase per se was gathered from apoE-/- mice that had recently undergone tryptase 
inhibition using lentiviral constructs. These mice presented increased angiogenesis and 
intraplaque hemorrhages128.
Alongside with the protease secretion, inflammatory cytokines secreted by 
mast cells affect plaque phenotype. Human mast cells incubated with oxLDL-immune 
complexes in vitro were found to upregulate and secrete TNFα, Interleukin-8 and 
macrophage chemoattractant protein-180. Moreover, TNFα, together with IL-6 and IFNγ, 
secreted by mast cells were able to regulate in vitro the expression of endothelial cell 
adhesion molecules71. Interestingly, Sun et al. (2007a) reported that mast cell specific 
IL-6 and IFNγ, but not TNFα, cytokine secretion can promote atherosclerosis in vivo 
upon induction of cathepsin activation and ECM degradation58. Furthermore, mast cells 
inside human coronary artery plaques were also capable of producing basic fibroblast 
growth factor, intensifying the link with intraplaque angiogenesis61. Finally, additional 
mast cell specific mediators such as histamine and heparin have been also reported to 
participate in mast cell mediated atherosclerosis progression; by inducing macrophage 
apoptosis73 or enhancing foam cell formation55  respectively.
Thereupon, the effects of mast cell activation are induced through the differential 
action of their degranulated mediators. which act in the surrounding microenvironment 
and alter the plaque phenotype either by increasing plaque size or by diminishing plaque 
stability. For that reason, a considerable amount of research focuses on the inhibition 
of specific mast cell activation pathways in an attempt to hamper atherosclerosis 
progression while still retaining beneficial mast cell effector functions, for example as 
components of the host-immune response.
Chymase Tryptase
Breakdown of ECM components Breakdown of ECM components
Vascular SMC apoptosis PAR-2 activation
Collagen degradation Increased lipid accumulation
Disruption of vascular EC layer Disruption of vascular EC layer
Vascular EC apoptosis Macrophage apoptosis
Induction of leukocyte infiltration in the 
subendothelial space
Induction of leukocyte infiltration in the 
subendothelial space
HDL and LDLproteolysis HDL proteolysis
Cytokine/chemokine regulation Cytokine/chemokine regulation
Macrophage apoptosis Angiogenesis
Vascular Ang II production Immunoglobulin synthesis
Table 1: Chymase and tryptase effects in atherosclerosis. ECM: extracellular matrix, 
SMC: smooth muscle cells, EC: endothelial cells, Ang II: angiotensin II, ROS: reactive oxygen 
species, PAR-2: protease activated receptor-2, PAF: platelet activating factor, HDL: high-density 
lipoprotein; LDL: low-density lipoprotein.
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4. Restenosis 
The available surgical intervention methods, used so far, to treat an atherosclerotic 
artery are bypass surgery, balloon angioplasty and stent placement; however, this often 
leads to restenosis129. The major differences between a restenotic and an atherosclerotic 
plaque are primarily the acute rate of inflammation and neointima formation induced 
by endothelial damage, as a consequence of the therapeutic intervention, as well as 
increased fibrosis caused by enhanced VSMC proliferation130.
Seemingly, since mast cells have already infiltrated the vessels upon primary 
atherosclerosis development, restenotic plaques contain an increased amount of 
mast cells ready to degranulate upon trigger131, with their mediators aggravating 
the restenotic burden. In particular, chymase-generated Ang II and TGF-β1 are linked 
to fibroblast proliferation and neointimal formation132. Therefore, a general Ang II 
receptor inhibitor used in an experimental model of dog angioplasty showed reduced 
neointima development133, an effect partly caused by blockade of chymase-induced 
Ang II. Moreover, tranilast used on dog carotid arteries after balloon injury was able 
to suppress chymase expression and hinder neointimal formation131. Tryptase is also 
implicated in restenosis, mainly through PAR-2 activation, affecting transendothelial 
leukocyte infiltration. More specifically, PAR-2 deficient mice showed reduced leukocyte 
adhesion in the endothelial wall which contributed to reduced neointima size134. In the 
same manner as Ang II, PAR-2 effects are partly linked to tryptase-induced activation. 
Another mast cell mediator which has attracted attention through the years in 
restenosis is histamine, with prior in vitro data suggesting that it plays a role in EC and 
SMC proliferation and migration135. An in vivo study in which the histamine receptor H1 
was inhibited in mice suffering endothelial damage after coronary angioplasty, reported 
diminished neointima size and reduced cell proliferation inside the plaque133. In line 
with that, in vivo data from pigs that underwent stent placement revealed that local 
histamine concentration is increasing over time136. In contrast to the above mentioned 
in vitro study the authors did not observe any histamine-triggered proliferation in 
cultured SMCs hetherto. Nonetheless, it is important to note that histamine effects 
should not be entirely ascribed to mast cells since macrophages137 and platelets138 can 
show inducible histamine production as well.
4.1 Drug Eluting Stents 
In order to avoid the excessive VSMC proliferation that follows stent or 
angioplasty-generated trauma, Drug Eluting Stents (DES), containing specific anti-
proliferative drugs, have been developed139. With regard to the role of mast cells in DES, 
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a very recent study proposed nitric oxide and ROS-scavenger coated stents as beneficial 
agents in mast cell stabilization inside the implanted artery140.
Interestingly, a striking effect that highlights the importance of mast cells in 
acute coronary events is described under the name Kounis syndrome141, in which 
hypersensitivity reactions, such as anaphylaxis, can occur upon DES placement and 
develop in a synchronized manner with acute coronary events. Recent studies have 
revealed that DES coating elements such as metal, latex and polymer, as well as the 
eluted drugs, can cause hypersensitivity reactions142. It is therefore suggested that mast 
cell activation may lead to increased inflammation, and possible thrombosis, in an acute 
fashion inside a restenotic environment, underlining the influential effect of these cells 
in yet another cardiovascular syndrome.
5. Myocardial infarction
The clinical outcome of a ruptured atherosclerotic plaque is mostly induced by 
the formation of a thrombus, which can destabilize upon high blood flow and relocate 
in smaller vessels, obstructing the circulation. Progressed stenotic plaques inside a 
coronary artery often lead to the occlusion of vessels that supply the heart muscle with 
blood, giving rise to an acute myocardial infarction (MI)143. 
Mast cells have been directly linked to plaque rupture, since they accumulate in 
the shoulder region of ruptured atherosclerotic plaques of patients that have suffered 
an MI57. Similarly, analysis of human coronary specimens after MI, displayed increased 
numbers of degranulated mast cells in the adventitia of ruptured plaques64. These cells 
were mainly positive for chymase, histamine and tryptase. 
Consequently, attention turned to mast cell specific proteins in MI, with the first 
data coming from infarcted cardiac tissues in a hamster model. This study in hamsters 
presented increased chymase activity in the ischemic area, from day 1 and until day 56 
post-MI, while chymase positive mast cell numbers were found elevated, particularly 
in the initial phase of the MI144. Moreover, chymase-mediated Ang II production was 
studied. Specifically, systemic Ang II production was blocked using an ACE blocker 
and the subsequent effects were compared to the overall Ang II effects obtained upon 
using an Ang II receptor inhibitor. This experiment showed a decrease in the mortality 
rate only upon Ang II blockade, suggesting indirectly that chymase-induced Ang II 
production is responsible for the detrimental effects in the ischemic tissue following an 
MI. A follow-up study from the same group, in which chymase was blocked in hamsters 
after mechanical MI induction, reported improved cardiac function and decreased 
mortality rates, highlighting the importance of this protease in infarcted tissues145. 
Therefore, from a therapeutic view, it has been proposed that chymase inhibitors 
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can significantly improve cardiac function upon combination with general Ang II 
inhibitors146. Nevertheless, the effects of chymase appear to be caused not only via Ang II 
but also partly via TGF-β. Chymase inhibition in rats showed reduced TGF-β expression 
in combination with reduced myocardial fibrosis levels and cardiac dysfunction147. 
Lastly, aside from TGF-β, chymase may additionally exert its effects through activation 
of MMP-9, since its inhibition in pigs resulted in lower levels of activated MMP-9 which 
was accompanied by a lower infarct size, as well as reduced inflammation and apoptosis 
levels148. 
Along this line, experiments using the mast cell inhibitor relaxin in a swine MI 
model have confirmed a reduction in the plasma histamine, together with a decrease 
in mast cell degranulation149; but also lower cardiac tissue injury. This points towards 
a role for histamine in MI, while highlighting the importance of mast cells in the 
pathophysiology of the ischemic tissue. In addition, upon examination of inflammatory 
levels in human serum after an acute MI event, MCP-1 was found significantly increased 
and positively correlated to IL-8150, which may illustrate a partial implication of mast 
cells, since they can secrete both cytokines. 
Interestingly, research on late-phase infarcted heart tissues in dogs suggested 
that tryptase contributes to the upregulation of MCP-1 and IL-8 in the cardiac 
endothelium, thereby leading to increased angiogenesis and promotion of the healing 
process in the ischemic myocardium151. Similarly, a recent study in infarcted rat hearts 
locally treated with mast cell granules isolated from rat peritoneal cells, demonstrated 
reduced cardiomyocyte apoptosis, increased angiogenesis levels and improved cardiac 
function152, providing  evidence in favor of a cardioprotective role exerted by mast cell 
granule contents. Thereupon, mast cells through their diverse mediator effects seem to 
participate not only in the generation of an MI, but also in the cardiac tissue recovery 
following it.
6. Arrhythmia 
 Atherosclerosis and MI are both linked to certain types of cardiac arrhythmia153, 
a condition during which the myocardial rhythm appears disrupted as a result of irregular 
electrical activity. One of the classification methods for distinct types of arrhythmia is 
based on the location where the dysfunction occurs, with characteristic examples atrial 
and ventricular arrhythmias154. Atrial fibrillation, the most common type of arrhythmia, 
is tightly connected to pre-established atherosclerosis, with the latest study directly 
associating human carotid intima/media thickness with the occurrence of this type of 
tachycardia155. On the other hand, ventricular arrhythmias are frequently described as a 
result of an MI incident156 upon over-excitation of cardiac nerve fibers.
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Clearly, since mast cells are associated with both atherosclerosis and MI, 
attention was also drawn to their possible implication in cardiac arrhythmias. The 
primary indications in favor of such a relationship were collected in a 1986 review 
which scrutinized the arrhythmogenic effects of histamine in pivotal sectors of the 
heart muscle157. The role of histamine was explored in detail after induction of MI, in 
rodent and canine models, demonstrating that the presence of histamine is directly 
associated with post-MI generation of ventricular arrhythmias158; and moreover, that its 
concentration increases proportionally to the severity of the ischemic incident159. The 
mast cell inhibitor relaxin was able to lower histamine content in the heart and reduce 
ventricular tachycardia, expanding thus the beneficial outcome of mast cell stabilization 
in arrhythmias149. Histamine exerts its function through a series of G-coupled protein 
receptors (H1-H4) which may exhibit differential downstream actions. For instance, 
while H2 receptor is reported to show an arrhythmogenic function160, H3 receptor is 
considered as benefactor for the alleviation of post MI-tachyarrhythmic events161. To 
make matters even more complex, it has recently been suggested that mast cells are not 
the only source of cardiac histamine, and therefore not the only cell type responsible for 
the ventricular arrhythmias observed after an MI incident162. Nonetheless, the majority 
of evidence so far highlights the detrimental role of mast cells in cardiac arrhythmias, 
which appears to be mediated through release of their mediators. For example, after 
blockade of chymase in an infarcted dog model, ventricular arrhythmias as well as 
serum Ang II levels were reduced163, implicating thus chymase release and local Ang 
II formation in the generation of post-MI tachycardia. Furthermore, SP was reported 
to trigger renin release by cardiac mast cells in ex vivo ischemia experiments, with the 
latter further enhancing arrhythmogenicity164,165. 
Finally, recently obtained data connect mast cells not only to arrhythmias 
following pre-established cardiac disorders, but also to newly generated atrial fibrillation 
events which can subsequently lead to acute cardiovascular syndromes. Specifically, 
in a mouse study of atrial fibrillation, less fibrosis in the atrium was observed after 
cromolyn stabilization or genetic reconstitution with mast cell deficient KitW/W-v bone 
marrow. This was appointed to a cross-talk mechanism between cardiac mast cells 
and myocytes or fibroblasts, through platelet-derived growth factor-A166. Based on the 
above, it is evident that the impact of mast cells in this cardiac disease is not entirely 
understood, since it has begun to attract full attention only recently.
7. Aneurysm
The development of an aneurysm is the consequence of vascular wall thinning, 
following accelerated smooth muscle cell death and increased ECM breakdown, 
accompanied by increased levels of inflammation, occurring for example in the abdominal 
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aorta (abdominal aortic aneurysm or AAA) or in the brain (cerebral aneurysm)167. 
Following these events, a vessel can rupture, leading to excessive hemorrhage and 
strongly increased risk of death168. 
7.1 Cerebral aneurysm
 Among research linking mast cells to aneurysm formation, a distinctive 
study, on humans who suffered a cerebral aneurysm rupture, reported mast cells at 
increased numbers near ruptured vessels169. In another study, treatment of rats with 
mast cell inhibitors reduced macrophage infiltration and vessel thickening, and mast 
cells were proposed to induce the expression and activation of pro-MMPs in adjacent 
SMCs170. Furthermore, a report on human tissue specimens confirmed that mast cells, 
together with inflammatory macrophages, are abundant in ruptured aneurysms171. 
Lastly, another study demonstrated that mast cells which reside within the thin 
wall of a remodeled and eroded human intracranial aneurysm, were located in close 
proximity to newly formed microvessels and associated with micro-hemorrhages172. 
These observations suggested that mast cells contribute to the wall remodeling and 
degeneration in the small intracranial arteries which develop saccular aneurysms and 
may ultimately rupture. 
7.2 Abdominal aortic aneurysm
The strongest evidence on the role of mast cells in aneurysms is obtained from 
abdominal aortic aneurysms21. Regarding the recruitment of mast cells inside the 
aneurysmal area, a study revealed that transplantation of mast cells from apoE-/- mice 
with a defect in the MCP-1 receptor, CCR2, in apoE-/-KitW-sh/W-sh mice reduced aortic 
aneurysm formation, in comparison to the apoE-/- strain, as a result of decreased mast 
cell presence; proposing a possible CCR2-mediated signaling pathway for the migration 
of mast cells inside the diseased vessel wall173. 
In terms of mast cell action in aneurysms, the impact of IL-6 and IFNγ has also 
been established in aneurysm formation, and reconstitution experiments in the KitW-
sh/W-sh mice have proven that these cytokines play a fundamental role in the induction 
of aneurysms174. In addition, mast cell deficient mice were protected from aneurysms, 
presenting decreased leukocyte infiltration in the injured area, as well as reduced levels 
of apoptosis and angiogenesis; suggesting thus that mast cells are important effectors 
in these mechanistic changes inside the diseased vessel.  
Furthermore, one of the above mentioned studies described increased Ang II 
formation in aneurysmal and atherosclerotic aortic samples, assigning chymase an 
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important role in both syndromes111. The most remarkable observation in this study 
was the increased numbers of activated mast cells in aneurysmal aortas, which were 
even higher than in atherosclerotic samples. 
The effect of chymase in this disease was also underlined in an experimental 
hamster model in which aneurysm formation was inhibited upon treatment with 
the chymase inhibitor, NK3201175. Additional evidence implicates chymase in the 
progression of aneurysm formation, as high levels of chymase-positive mast cells in 
human aortas directly associate with the development of the disease176. This study also 
provided a causal relation between mast cells and aneurysm formation, by showing 
reduced aneurysm incidence in both chymase deficient and KitW-sh/W-sh mice, but also 
after reconstitution of the KitW-sh/W-sh mice with chymase deficient mast cells. The 
authors suggested that chymase exerts its function through cathepsin expression, ECM 
degradation and angiogenesis. 
Yet, once more, tryptase was also proven to directly participate in the development 
of abdominal aneurysms, after lack of experimental aneurysm formation in tryptase-
deficient mice177. These observations were again combined with data acquired from 
human aortic samples, showing tryptase accumulation inside aneurysmal tissues while 
its circulatory levels directly correlated with aneurysm progression rate. Similarly to 
atherosclerosis, aortic aneurysms display increased expression of chymase, tryptase 
and cathepsin-G, together with angiogenic proteins expression levels and with the 
number of adventitial mast cells, all correlating with the degree of neovascularization178. 
The critical influence of mast cells has also been established after chemical stabilization 
with tranilast in apoE-/- mice and mast cell deficient rats, with both models presenting a 
reduction in aneurysm formation179. 
Finally, a mouse study uncovered a role for IgE in abdominal aortic aneurysms, 
showing aggravated disease progression by IgE mediated activation of not only mast 
cells, but also T cells and macrophages180. Moreover, FcεR1-deficient apoE-/- mice failed 
to develop abdominal aneurysms and presented lower plasma IL-6 levels180. With 
reference to this study, it is important to note that although FcεR-mediated effects are 
generally considered mast cell specific, increasing evidence supports the notion of an 
inducible FcεR-expression pattern in additional immune populations, such as T cells 
and macrophages, depending on the environmental stimuli, emphasizing thus the 
plastic nature of disease-specific immune responses. 
An example of this plasticity comes from a study examining the role of the peptide 
hormone adrenomedullin in human abdominal aortic aneurysms, and revealing that 
this peptide can be released from mast cells and act as an anti-fibrotic agent181. These 
results contradict the previously discussed pro-fibrotic role of mast cells in aneurysm 
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formation, and illustrate the diverse, and possible immune-regulatory, responses of this 
immune-effector cell type upon excessive inflammation levels.
8. Therapeutic potential
Mast cells are rightly regarded as potent inflammatory cells in cardiovascular 
diseases. The massive amount of evidence gathered so far mainly relates to their 
harmful pathophysiological events, thereby leading to the perception that global 
inhibition of mast cell activation could save the local microenvironment from their 
disadvantageous effects. For that very reason, as well as to examine the overall influence 
of mast cells on disease progression, general mast cell inhibitors, such as cromolyn, 
are widely used in experimental models; mainly suggesting that mast cell stabilization 
can mitigate the inflammation levels in acute cardiovascular syndromes. Furthermore, 
pharmacological mast cell stabilizers, already widely used in allergic disorders, were 
considered as promising therapeutic agents in humans suffering from vascular diseases, 
a characteristic example being the use of tranilast in a large patient study for the 
prevention of restenosis; without however presenting any beneficial clinical outcome182. 
The adverse effects of this application can be predicted by recognizing that mast cells do 
not only reside in the heart and vessels, but also comprise the first line of host defense 
against pathogens. Therefore, a possible systemic inhibition may compromise the 
protective responses exerted by mast cells as part of immune protection. 
Therefore, new technologies are applied, in order to scan for novel targeting 
molecules that may avert from the risks of systemic mast cell inhibition183. An appealing 
alternative would be to focus on the type and magnitude of the differential activation 
and inhibition signals, to manage the sort of mast cell reaction needed per occasion184. 
In an attempt to concentrate on the action of specific mast cell mediators, rather than 
the general activation pathway, chemical inhibitors of serine proteases and histamine 
receptor antagonists have been designed and tested in animal models, and they have, 
indeed showed some very promising results185. However, the inhibition of molecules 
with such a broad spectrum of effects can also increase the risk of hindering multiple 
downstream mechanisms, not all of them being harmful. For instance, both proteases 
are able to degrade pro-inflammatory cytokines186, probably upon highly inflammatory 
conditions, an effect which may prove beneficial. Thus, elucidation of the net effect, 
beneficial or harmful, in such highly complex in vivo conditions requires rigorous 
experimental testing in suitable animal models of the disease conditions in question.
Mast cells have also been described to be important mediators in immune 
suppression. An intriguing paradigm is an allograft study in which these cells were 
directed to enter tolerant grafts, after responding to high IL-9 levels secreted by T 
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regulatory lymphocytes187. In favor of this immune regulatory role, mast cells have 
been found to possess an interesting ability to communicate with distant targets via 
secretion of small membrane vesicles containing cytokines and other mediators, named 
exosomes and microparticles188. These vesicles are proven to carry molecules via which 
they elicit immune-regulatory mechanisms189; suggesting that enhancement of immune 
tolerance, rather than chemical inhibition of mast cell activation, may prove more 
advantageous as a therapeutic method.
The above illustrated examples on the importance, as well as the complexity of 
mast cells, suggest that manipulation of this cell type should be approached in a delicate 
way, superseding the general consideration of them being detrimental effector cells that 
need to be blocked at any cost. After all, it is not by accident that a very recent review on 
the field of cancer immunology has addressed mast cells as “sentinel cells” that may be 
alternatively modulated190, rather than inhibited, in order to provide beneficial immune 
reactions and contribute to improved prognosis.
9. Conclusion
This review aimed to highlight the potential effects of mast cells in cardiovascular 
diseases, which are characterized by increased morbidity and mortality rates worldwide. 
In conclusion, mast cells can be considered to be important effector cells of the immune 
system, acting as a driving force of the local response, either by their direct cell-cell 
interaction with adjacent vascular cell types (Figure 2), or via their mediator release; 
resulting in targeted stimulation of cells residing in the microenvironment in which 
the mast cells have been activated. The plethora of secreted molecules, together with 
the multiple activation pathways, allows the identification of specialized therapeutic 
interventions focusing on the distinct features of each disease, while refraining from 
interfering with their beneficial characteristics. Therefore, modulation of individual 
pathways in mast cell function, rather than systemic mast cell blockade, may serve 
as a promising strategy to alleviate the progression of cardiovascular diseases, with 
an ultimate aim to reduce the excess morbidity and mortality associated with these 
disorders.
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Figure 2: Mast cell interaction with adjacent cell types in the vasculature. This 
schematic overview illustrates the major cell interaction mechanisms between mast cells and 
various cell types present in the vessels. Activated mast cells are able to affect key biological 
processes, such as proliferation and apoptosis, of resident cell types in the cardiovascular 
system.
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Abstract
Lysophosphatidic acid (LPA) is a natural lysophospholipid present 
at high concentrations within lipid-rich atherosclerotic plaques. Upon 
local accumulation in the damaged vessels, LPA can act as a potent 
activator for various types of immune cells, through its specific membrane 
receptors LPA1/3. LPA elicits chemotactic, pro-inflammatory and apoptotic 
effects that lead to atherosclerotic plaque progression. In this study we 
aimed to inhibit LPA signaling by means of LPA1/3 antagonism using the 
small molecule Ki16425. We show that LPA1/3 inhibition significantly 
impaired atherosclerosis progression. Treatment with Ki16425 also 
resulted in reduced CCL2 production and secretion, which led to less 
monocytes and neutrophil infiltration. Furthermore, we provide evidence 
that LPA1/3 blockade enhanced the percentage of non-inflammatory, 
Ly6Clow monocytes and CD4+CD25+FoxP3+ T regulatory cells. Finally, 
we demonstrate that LPA1/3 antagonism mildly reduced plasma LDL 
cholesterol levels. Therefore, pharmacological inhibition of LPA1/3 
receptors may prove a promising approach to diminish atherosclerosis 
development.
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1.   Introduction
Atherosclerosis is a lipid-driven chronic inflammatory syndrome, accountable 
for the majority of acute cardiac episodes and comprising, at present, a principal cause 
of death in Western societies1. The disorder initiates upon damage of the arterial 
endothelium, induced by high shear stress and excessive amounts of cholesterol in the 
form of low-density lipoproteins (LDL). LDL can accumulate within the subendothelial 
space, triggering the immune system to launch an inflammatory cascade2,3. Thereupon, 
circulating monocytes infiltrate and ingest modified LDL particles, differentiating 
into macrophage foam cells; the main components of an atherosclerotic plaque. An 
additional influx of pro-atherogenic innate cells, such as neutrophils4 and mast cells5, 
follows, along with the rise of specific adaptive immune responses through presentation 
of lipid antigens by antigen presenting cells6. This process results in the infiltration of 
various subtypes of T cells, the main one being CD4+ T helper 1 (TH1) cells7-9. Evidently, 
an uncontrollable increase in the atherosclerotic plaque size, or rupture of the plaque, 
may lead to life-threatening clinical events.
Lysophosphatidic acid (LPA) is a bioactive glycerophospholipid found elevated 
in the circulation of patients with acute coronary syndromes8, and directly linked to 
hyperlipidemia9,10. The presence of LPA in the serum has been mainly associated 
with platelet activation11, but has also been described inside human atherosclerotic 
specimens12, as well as in the plaques of LDLr-/- mice, with an increasing concentration 
rate upon disease progression13. Intraplaque LPA is enzymatically formed in situ, upon 
mild modification of the LDL molecule14 and elicits its effects via 9 different G-protein 
coupled receptors (LPA1-6, GPR87, P2Y10 and GPR35) which have been classified into 
different subcategories based on their structural diversity and ligand specificity15,16. 
Of these receptors, LPA1, LPA2 and LPA3 are structurally similar and belong to the 
Endothelial Differentiation Gene (EDG) family of proteins17, with their general mode of 
action leading to gene regulation, chemokine secretion and cell survival18. Interestingly, 
LPA can activate mast cells19,20 and neutrophils21, as well as influence the migration of 
CD4+ T helper cells22; all key cell types that are directly implicated in atherosclerosis. The 
impact of LPA on atherosclerosis has been thoroughly studied in the past, and reviewed 
in detail by Schober & Siess23, with its role extending from increased infiltration 
and activation of monocytes to enhanced foam cell formation and elevated levels of 
endothelial permeability. Specifically, the chemotactic effects induced through LPA are 
linked to upregulation of inflammatory chemokines and adhesion molecules such as 
CCL224, CXCL125 and I-CAM 126. The pro-atherosclerotic effects of LPA have been mainly 
tied to LPA1 and LPA3, which were reported to increase atherosclerosis development 
in apoE-/- mice27. Receptors LPA1 and LPA3 are widely expressed by immune cells28,29, 
as well as endothelial30 and vascular smooth muscle cells31, with LPA3 activation being 
3
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involved in cell migration32, while LPA1 shows both migratory33 and apoptotic effects34. 
In this study, we aimed to examine the development of atherosclerosis upon 
pharmacological blockade of receptors LPA1 and LPA3 (LPA1/3), using the synthetic 
antagonistic compound Ki1642535.
2. Materials & Methods
2.1    Animals 
LDLr-/-mice were initially obtained from the Jackson Laboratories and bred at the Leiden 
University animal facility, with water and food supply ad libitum. All animal work was approved 
by the Leiden University Animal Ethics committee and performed according to the guidelines 
established by the Dutch government and European Union.
2.2    Atherosclerosis 
Atherosclerosis was induced in male LDLr-/- mice (10-11 weeks old) by feeding a Western 
type diet (WTD) (0.25% cholesterol, 15% cocoa butter; Special Diet Services, Essex, UK) for 2 
weeks prior and throughout the course of the treatment. Subsequently, 12-15 mice per group 
were randomized based on age, weight and/or cholesterol levels and injected intraperitoneally 
3 times a week with either a vehicle control or 5mg/kg of the LPA1/3 antagonist, Ki16425; the 
injections were performed for 6 weeks. All mice were monitored for body weight changes every 
week throughout the treatment period; at the experimental endpoint, weight was additionally 
determined in organs such as the spleen and liver.
2.3    Immunohistochemistry
The mice were anaesthetized with a mix of ketamine (100mg/ml), sedazine (25mg/ml) and 
atropine (0.5mg/ml) and perfused with PBS through heart puncture in the ventricles. The hearts 
were dissected below the atria and sectioned perpendicularly to the axis of the aorta, starting 
within the heart and in the direction towards the aortic arch. Upon aortic root identification by 
the appearance of the aortic valve leaflets, 10μm sections were collected and mounted on gelatin-
coated slides. Mean plaque area (in μm2) was calculated for six sequential Oil-Red-O stained 
sections in distal direction, starting at the point where all three aortic valve leaflets first appeared. 
Plaque macrophages were stained using a MOMA-2 antibody at a 1:1000 concentration (rat IgG2b, 
Serotec Ltd.). For the MOMA-2 levels in the plaques, three subsequent sections displaying the 
highest plaque content per mouse were analyzed. Mast cells and neutrophils were visualized by 
staining with a Naphthol AS-D chloro-acetate esterase kit (Sigma Aldrich) and counted manually. 
A mast cell was considered resting when all granules were maintained inside the cell, while mast 
cells were assessed as activated when granules were deposited in the tissue surrounding the 
mast cell. Neutrophils were identified as round cells with a characteristic lobular nucleus and 
pink granular cytoplasm. T cell numbers were determined following a CD3 staining at a 1:150 
concentration (clone S7P, ThermoScientific). All microscopic analyses were performed on a Leica 
DM-RE microscope and ORO, as well as MOMA-2, quantifications were carried out using Leica 
QWin software (Leica, Imaging Systems, UK) and through blinded independent analysis.
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2.4   RT-PCR
Isolation of mRNA was performed on the liver and aortic arch of 8 mice/group, based on the 
guanidium isothiocyanate method58. Subsequently, the M-MuLV reverse transcriptase (RevertAid, 
Leon-Roth) was used for the reverse transcription. The quantitative analysis of specific gene 
expression was executed on a 7500 Fast-real time PCR system (Applied Biosystems, Foster 
City, CA) using SYBR Green Technology. The relative expression was determined based on two 
housekeeping genes; β-actin and ribosomal protein L27 (Rpl27). The complete primer list is 
included in the Supplementary Table S1.
2.5   Serum analysis
Throughout the study, tail blood was collected by a tail-vein cut; serum was obtained by 
centrifugation at 8.000 rpm for 10 minutes. Total cholesterol levels in the serum were measured 
at week 0, 3 and 6 of the treatment by an enzymatic colorimetric assay and in comparison to 
an internal Precipath control (standard serum provided by Roche Diagnostics). At the end of 
the experiment, cholesterol fraction separation for lipoprotein particle analysis was obtained 
after processing 30μL serum/mouse through a Superose 6 column (Smart System, Pharmacia). 
Subsequent measurement of cholesterol levels in the retrieved fractions was performed as 
described above. CCL2 levels in the serum of 13 mice/group were analyzed by ELISA (BD 
Biosciences) according to the manufacturer’s protocol. 
2.6   Flow cytometry
Blood was collected as described above; Red blood cells were lysed using an erythrocyte 
lysis buffer (0.1mM EDTA, 10mM NaHCO3, 1mM NH4Cl, pH=7.2). Subsequently, white blood cells 
were stained with the relevant antibodies for flow cytometry analysis (Supplementary Table 
S2). Spleen tissue was harvested from all mice and processed through a 70μm cell strainer 
to acquire single cell suspensions. Subsequently, cells underwent lysis once, for erythrocyte 
disposal, and were stained for flow cytometry. In approximation, 200.000 cells per sample were 
stained with antibodies against extracellular proteins at a concentration of 0.1 μg/sample for 30 
minutes. For the detection of intracellular antibodies all cells were fixated, permeabilized using 
the transcription factor kit (Ebioscience) and stained at a concentration of 0.3 μg/sample. All flow 
cytometry experiments were executed on a FACS Canto II and data were analyzed using FlowJo 
software.
2.7   Statistics
All data are analyzed using the GraphPad Prism software and presented as mean±SEM. A 
2-tailed Student’s t-test was used to compare individual groups. Non-Gaussian distributed data 
were analyzed using a 2-tailed Mann-Whitney U test. For the analysis of two or more variables a 
two-way ANOVA was used with the Bonferroni post-test for multiple comparisons. The probability 
(alpha) for all tests was set to 0.05 with values lower than this considered significant (P<0.05). 
3.  Results
3.1  LPA1/3 inhibition reduces atherosclerotic plaque size 
To assess the effect of LPA1/3 inhibition on atherosclerosis, LDLr-/- mice were 
injected intraperitoneally with either Ki16425 (5mg/kg) or a vehicle-control for 6 weeks, 
3
(3x/week). Plaque size quantification, using an Oil-Red-O staining showed that mice 
treated with the LPA1/3 inhibitor had significantly smaller plaque size (-40%) compared 
to control mice (Figure 1A, Ki16425: 89*103±9*103 μm2 vs control: 147*103±21*103 
μm2, P=0.023). In fact, plaque size was significantly lower in the treated group at each 
distance measured from the start of the three-valve area up to its end (Figure 1B). A 
MOMA-2 staining was performed to evaluate the intra-plaque macrophage levels. The 
absolute macrophage content of the Ki16425 treated group was significantly lower 
(-45%) compared to the control (Figure 1C, Ki16425: 36*103±8*103 μm2 vs control: 
65*103±6*103 μm2, P=0.006), whereas the relative amount (% macrophage levels of the 
plaque) was not significantly different (Figure 1D, P=0.11). Furthermore, the aortic 
root area was analyzed for mast cell and neutrophil content, since both immune cell 
types express LPA1/3 and are involved in atherosclerosis progression. No differences in 
the number or activation status of mast cells were detected between the two groups 
(Figure 1E, P=0.38 for mast cell # and Fig.1F, P=0.88 for activated mast cell #). 
However, a substantial reduction in the number of infiltrated neutrophils (-31%) upon 
LPA1/3 blockade was observed (Figure 1G, Ki16425:8.5±0.7 neutrophils/μm2 tissue vs. 
control: 12.4±0.9 neutrophils/μm2  tissue, P=0.004).
Figure 1: The LPA1/3 antagonist, Ki16425, reduces atherosclerosis 
development. (a)  Atherosclerotic plaque size in the aortic root of the heart 
was determined by an Oil-Red-O staining on 10µm sections; representative 
pictures are shown. Blockade of receptors LPA1/3 resulted in a 40% reduction 
in atherosclerosis. (b)  The Ki16425 treated mice had significantly lower 
atherosclerotic plaque development throughout the entire three valve area of 
the aortic root. (c) Macrophage expression levels were measured using a MOMA-
2 staining; LPA1/3 antagonism led to 45% less macrophage accumulation within 
the aortic root of the hearts. (d) The relative amount of macrophages in the 
atherosclerotic plaques was not significantly affected by the Ki16425 treatment. 
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(e) Mast cell numbers (#) and (f ) activation state, as well as (g) neutrophil 
numbers were manually quantified using a Naphthol AS-D chloro-acetate esterase 
staining; no difference was observed in the number or degranulation status 
of mast cells in the aortic root. Neutrophil numbers were found significantly 
reduced by 31% in the aortic root of the Ki16425 group as compared to the 
control. All values (n=12/grp) are depicted as mean±SEM (*P<0.05, **P<0.01).
3.2  Treatment with Ki16425 results in decreased serum total cholesterol 
levels
LPA1/3 inhibition with Ki16425 did not alter body weight (Figure 2A) and 
similarly, analysis of the liver weight or spleen weight at the endpoint of the study 
presented no change for the treated versus the control group (Supplementary Figure 
1A,B). Interestingly, total serum cholesterol levels in time upon LPA1/3 inhibition, was 
significantly lower compared to the control group (Figure 2B, w3: -20%, P=0.012; w6: 
-16%, P=0.017). Further analysis of the serum lipoprotein content at the experimental 
endpoint showed a trend towards decreased LDL levels for the Ki16425 treated mice, 
as compared to the control (Figure 2C, P=0.06).
Figure 2: LPA1/3 inhibition 
reduces total cholesterol content 
in the serum. (a)  The animal body 
weight showed no significant 
differences throughout 6 weeks of 
treatment between the groups.  (b) 
Total serum cholesterol remained 
at significantly lower levels in the 
Ki16425 group compared to the 
control. (c) The Ki16425 treated 
animals presented a trend towards 
reduced LDL levels (P=0.06). 
P-values are calculated by the 
fraction sum for each lipoprotein 
per group (n=5/grp). All values are 
depicted as mean±SEM (*P<0.05).
3.3  Pro-inflammatory CCL2 expression and secretion are reduced upon LPA1/3 
inhibition
Considering the lower macrophage and neutrophil content of the atherosclerotic 
plaque, we isolated mRNA from the aortic arch which was subsequently analyzed for the 
expression levels of different chemokines as well as endothelial adhesion molecules. The 
expression of ICAM-1, which is tightly linked to LPA26, did not present any differences 
between the control and Ki16425 group (Figure 3A, P=0.70). The same was observed for 
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chemokine CXCL1 (Figure 3B, P=0.52). The pro-inflammatory chemokine CCL2 showed 
a trend towards reduction in the aortic arch of the Ki16425 treated mice (Figure 3C, 
P=0.067). Similarly, liver mRNA analysis displayed substantially lower CCL2 expression 
upon LPA1/3 antagonism (Figure 3D, P=0.035). In addition, gene expression of the 
macrophage marker CD68 was significantly reduced in the liver of animals treated with 
Ki16425 (Figure 3E, P=0.037). To establish whether the reduction in CCL2 expression 
results in diminished protein levels, CCL2 chemokine secretion in the circulation was 
determined and found considerably lower (-65%) upon LPA1/3 inhibition (Figure 3F, 
Ki16425: 58.9±6.4 pg/mL compared to 165.8±32.8 pg/mL, P=0.003).
Figure 3: Treatment with Ki16425 decreases CCL2 chemokine expression 
and release. Gene profiling in the aortic arch displayed no difference between 
the two groups in (a) ICAM-1 or (b) CXCL1 chemokine expression levels. (c) 
CCL2 expression showed a slight reduction upon LPA1/3 antagonism. (d) Liver 
CCL2 expression was significantly lower in the Ki16425 treated animals 
compared to the control. (e) Macrophage CD68 gene expression in the liver was 
reduced for the Ki16425 mice compared to the controls. (f )  CCL2 chemokine 
secretion was decreased up to 65% in the circulation of the Ki16425 group, 
compared to the control. Gene expression (n=8/grp) is depicted as relative to 
two housekeeping genes (β-actin and Rpl27). Serum CCL2 concentration was 
measured using an ELISA assay (n=13/grp).  All values were calculated as 
mean±SEM. (*P<0.05,**P<0.01).
3.4  CCR2+ neutrophils and monocytes circulate at lower levels upon LPA1/3 
antagonism
Since the reduced CCL2 levels could lower the inflammatory cell infiltration, 
and therefore lower the plaque size, it was particularly intriguing to focus on immune 
cells that respond to this chemokine via its specific receptor, CCR2. For that reason, two 
additional groups of LDLr-/- mice were treated with either Ki16425 or vehicle-control 
for 6 weeks while on WTD. In the blood the overall percentage of circulating neutrophils, 
defined as Ly6G+CD11b+/NK1.1- cells, was not affected by the treatment (Figure 
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4A). However, the relative amount of circulating CCR2+ neutrophils was significantly 
increased over time in the control group (Figure 4B, control: w0 compared to w2, 
P=0.031; w0 compared to w4, P=0.0001), but was found reduced in the treated animals 
after 4 weeks of LPA1/3 inhibition (w4: Ki16425 compared to control, P=0.0060). 
Furthermore, the monocyte population in the circulation, defined as Ly6C+/
CD11b+Ly6G-/NK1.1- cells was found to increase in the control group during 4 weeks of 
treatment (Figure 4C, control: w0 compared to w4, P=0.014). At week 4, the Ki16425 
treated group showed a trend to reduced monocyte percentage when compared to the 
control (Figure 4C, w4: Ki16425 compared to control, P=0.066). Of this population, the 
CCR2+ monocytes, which comprise the inflammatory monocyte subset36 -alternatively 
defined as Ly6Chigh- increased greatly in the control group over time (Figure 4D, 
control: w0 compared to w2, P=0.004; w0 compared to w4, P=0.0002), while the CCR2+ 
monocytes of the treated group were only slightly elevated (Ki16425: w0 compared to 
w2, P=0.64; w0 compared to w4, P=0.054).
Figure 4: LPA1/3 inhibition 
retains circulating CCR2+ 
neutrophils and monocytes at 
low levels while increasing, 
Ly6Clow patrolling monocytes 
over time.  (a)  No difference 
was observed in the circulating 
neutrophil percentage between 
the two groups of animals. (b) 
CCR2+ expressing neutrophils 
were reduced after 4 weeks of 
LPA 1/3 antagonism. (c)  Circulating 
monocytes showed a slight 
reduction upon 4 weeks of Ki16425  
treatment. (d)  CCR2+ monocytes 
remained at lower levels in the 
course of LPA1/3 inhibition. (e) 
Non-inflammatory monocytes 
appeared significantly higher at 2 
and 4 weeks of LPA1/3  inhibition. 
(f )  The ratio of inflammatory/
non-inflammatory monocytes was 
increased in the control group 
compared to the treated. All values 
are calculated as mean±SEM. 
(n=12/grp, *P<0.05, **P<0.01, 
***P<0.001, **** P<0.0001).
On the contrary, Ly6Clow-patrolling monocytes of the control mice showed 
a sharp decline over time (control: w0 compared to w2, P=0.0039; w0 compared to 
w4, P<0.0001), but upon Ki16425 treatment the decrease was only observed after 
4 weeks and was less acute (Ki16425: w0 compared to w4, P=0.0025). Therefore, in 
relation to the control group, LPA1/3 blocked animals presented significantly higher 
non-inflammatory circulating monocytes over time (Figure 4E, Ki16425 compared 
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to control: w2:P=0.048; w4:P=0.040). Therefore, LPA1/3 inhibition retained the 
inflammatory versus non-inflammatory responses at lower levels as shown by the 
relative difference of inflammatory versus the non-inflammatory monocytes per group 
(Figure 4F, Ki16425 w4 compared to control w4: P=0.003).
3.5   LPA1/3 inhibition increases circulating anti-inflammatory CD4+ T regulatory 
cells, while decreasing T helper 1 cells
Flow cytometric analysis of the white blood cell population showed a significant 
reduction in the circulating CD4+ T cell percentage after LPA1/3 inhibition (Figure 5A, 
P=0.036). However, within the CD4+ T cell population, anti-inflammatory FoxP3+/
CD25+/CD4+ TREG percentage was found significantly increased (Figure 5B, Ki16425: 
10.24 ± 0.71% versus control: 7.06 ± 0.41%, P=0.0013). Among the CD4+ TREG 
population, FoxP3+Helios-/CD25+ cells, defined as inducible (i)TREG and generated in 
secondary lymphoid organs37,38, increased significantly in the Ki16425-treated group 
(Figure 5C, P=0.038). The percentage of pro-inflammatory CD4+ TH1 cells in the blood 
was reduced upon LPA1/3 inhibition (Figure 5D, P=0.011). Also in the spleen, CD4+ T 
cells were reduced in the Ki16425 treated mice (Fig.5E, P<0.0001), with no difference 
observed however in the overall FoxP3+/CD25+CD4+ TREG population (Figure 5F, P=0.39). 
Nonetheless, LPA1/3 inhibition resulted in a significant reduction in the inducible CD4+ 
TREG cells (Figure 5G, P=0.025). No significant differences in TH1 cells were observed in 
this compartment (Figure 5H, P=0.09). 
Figure 5: Systemic treatment with Ki16425 for 6 weeks reduces CD4+ T cells 
in the blood and spleen, with a potency to increase anti-inflammatory TREG 
cells.  (a)  Upon 6 weeks of treatment, LPA1/3 antagonism reduced the percentage 
of CD4+ T cells in the blood of LPA1/3 blocked mice, as compared to the control. 
(b)  Anti-inflammatory CD4+ TREG and (c)  inducible FoxP3+Helios- TREG cells were 
detected at higher levels in contrast to (d)  lower inflammatory TH1 cells in the 
blood of the Ki16425 treated mice. (e) In the spleen of Ki16425 treated animals 
CD4+ T cells appeared significantly lower. (f )  No difference was observed within 
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the overall CD4+ TREG cells. (g)  The inducible TREG cells were found substantially 
decreased. (h)  No significant difference was detected in the CD4+ TH1 population. 
All values are calculated as mean±SEM. (n=12/grp, *P<0.05,**P<0.01, 
****P<0.0001).
In addition, no difference was observed within the CD8+ population present in 
the blood or spleen of the two groups (Supplementary Figures 2A,B). Likewise, MHC-
II+CD11chigh dendritic cells (DCs) were not affected by the treatment (Supplementary 
Figure 2C).
3.6  The T cell content of the atherosclerotic plaque is not altered by LPA1/3 
inhibition
 Considering that the systemic differences in the CD4+ T cells upon LPA1/3 
blockade may directly influence the T cell content inside the atherosclerotic plaque, 
a CD3+ immunohistochemical staining was performed in the aortic root. However, no 
significant differences were observed upon manual quantification of the CD3+ cells in 
the three-valve area of both groups (Figure 6, P=0.43).
Figure 6: Total CD3+ T cell numbers in the aortic root show no difference 
between the control and Ki16425-treated groups .  CD3+ cells in the aortic root 
of the hearts were determined upon manual quantification. No difference was 
observed in the CD3+ expressing cells of the aortic root upon LPA1/3  inhibition. 
All values (n=12/grp) are depicted as mean±SEM.
4.   Discussion
In this study we show that pharmacological inhibition of LPA1/3 receptors 
through Ki16425, reduced atherosclerotic plaque development by 40%. Specifically, 
we have found that LPA1/3 antagonism significantly attenuated the macrophage and 
neutrophil content of the plaque. Furthermore, a mild downregulation of total serum 
cholesterol was detected, which may have contributed to the decreased atherosclerotic 
plaque size. We observed a systemic reduction in the expression and secretion of 
chemokine CCL2, which could have resulted in the detected CCR2+ monocyte and 
neutrophil decline in the circulation. This decline in CCR2+ cells in the blood seems 
consistent with the reduction in the absolute amount of macrophages and neutrophils 
inside the atherosclerotic plaques of the Ki16425 mice. Upon lower levels of circulating 
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CCL2, less CCR2+ monocytes and neutrophils are infiltrating the atherosclerotic site 
and subsequently there is a reduction in the absolute number of neutrophils and 
macrophages observed inside the plaque. As the atherosclerotic plaque at this specific 
timepoint consists primarily of macrophages, the absolute amount actually reflected 
the reduction in plaque size, whereas the relative macrophage content did not differ. 
This response is in line with previous evidence supporting that LPA elicits its effects 
through the release of CCL2 by its target cells19. Unlike reports that link the action of 
LPA to endothelial cell activation12,26,39, in this investigation we did not observe any 
differences in the aortic ICAM-1 or CXCL1 expression levels. It is important to mention 
however that in a previously published study by Zhou et al., the atherosclerotic effects 
of LPA were mainly associated with endothelial activation through chemokine CXCL125 
and not with the CCL2-CCR2 axis. Furthermore, in their study no effect was observed 
on cholesterol metabolism, whereas we detected a reduction in LDL cholesterol levels. 
Considering that the above experiments were performed in apoE-/- mice, it is possible 
that strain specific effects are responsible for the different mechanism observed40. In 
the past, numerous studies have examined the differences between the LDLr-/- and 
apoE-/- models. The leading distinction between the two strains is that LDLr-/- mice do 
not develop atherosclerosis unless placed on a high-cholesterol diet41, whereas apoE-/- 
mice have basal plaque formation even on chow diet42. Thereupon, apoE-/- mice develop 
higher plasma cholesterol levels and more pronounced plaques upon WTD, while 
showing lower plaque T cell numbers43. In addition, apoE-/- mice, unlike the LDLr-/-, 
exhibit impaired formation and efflux of HDL particles, an effect which is highly distinct 
from the human case44. With the above in mind, we considered LDLr-/- as a model that 
does not show atherosclerosis-related systemic effects prior to WTD. It is important to 
mention that the presence of apoE can affect monocyte formation and accumulation 
in the plaque45, which could account for the main difference between the two models 
in regard to the role of LPA1/3 receptors. In addition, apoE-/- and LDLr-/- mice have also 
proven to differ in the ABCA1-mediated cholesterol transportation pathway46,47. This 
may explain the reason why LDLr-/- mice show differences in cholesterol regulation 
upon LPA1/3 inhibition, an effect which was absent in apoE-/- mice. Nevertheless, in both 
experimental sets LPA1/3 inhibition substantially reduced plaque development to a 
similar extend despite the fact that the apoE-/- mice were treated with Ki16425 daily for 
3 months while in our study LDLr-/- mice were injected 3x/week for a 6 week period. 
Furthermore, in our study, the patrolling Ly6Clow population was increased 
already after two weeks of Ki16425 treatment, suggesting an additional anti-
inflammatory effect. This anti-inflammatory subtype of mouse monocytes expressing 
the Ly6C protein at low levels, has been previously reported to play a crucial role in the 
control of atherosclerosis development since LDLr-/- mice that lack this subtype showed 
increased plaque formation48. Therefore, the anti-inflammatory effects of patrolling 
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monocytes detected upon LPA1/3 antagonism may have contributed to the reduction 
in atherosclerosis development. Together, it seems that Ki16425 carries out its effects 
primarily by regulating the immune response, since also the CCR2+ monocytes and 
neutrophils are circulating at lower levels compared to the control, already at the second 
week of treatment. This does not exclude the fact that cholesterol lowering mechanisms 
may have been partly responsible for the reduced disease progression. 
In the past, LPA has also been reported to affect the proliferation of T lymphocytes49. 
Here we observe that upon LPA1/3 antagonism, CD4+ T cells are substantially diminished, 
which may have been due to a reduction in LPA induced mitogenesis18. Furthermore, 
LPA can promote the migration of CD4+ T cells33, but not of CD8+ T cells50. This is in line 
with our observations on CD4+ T cells being markedly reduced upon LPA1/3 inhibition, 
while no effects were detectable on the CD8+ T cell population in either the blood or 
spleen. Similarly, no differences were found in the dendritic cell population; however, 
the effects of LPA on DCs seem to depend on their state. For example, mouse DCs were 
previously reported to migrate towards LPA upon LPA3 activation, yet for that to take 
place they had to be in an immature state51. As mentioned above, CD4+ T cells can migrate 
in response to LPA, but this action was previously shown to depend on the expression 
of LPA1 and LPA2. Specifically, these two receptors are considered to have an inverse 
impact on T cell migration, with LPA1 enhancing it while LPA2 hinders it, depending 
though also on whether the cells are in a naive or activated state50. This fact further 
illustrates the complexity behind LPA signaling and how different receptor signaling 
pathways can have entirely opposing actions.
Notably, while CD4+ T cell levels were reduced upon Ki16425 treatment, the anti-
inflammatory TREG cells were strongly enhanced. To our knowledge, there is thus far no 
evidence describing the relationship between LPA1/3 inhibition and TREG induction. The 
observed effects indicate that LPA1/3 inhibition can skew the adaptive immune system 
towards an anti-inflammatory response as demonstrated by the overall lower CD4+ 
levels, with the pro-inflammatory TH1 subset found relatively decreased in the blood 
while the athero-protective52 CD4+ TREG cells were circulating at increased levels.
However, the differences on the CD4+ population in the blood and spleen did not 
reflect the T cell numbers inside the plaques of the treated mice. This suggests that the 
reduced atherosclerotic plaque size observed upon LPA1/3 antagonism was not mediated 
through a difference in local T cell responses, but was rather elicited via a systemic anti-
inflammatory effect of the Ki16425 treatment. Moreover, we found no difference on the 
mast cell counts in the atherosclerotic plaques of the treated mice, despite previous 
evidence that mast cells respond to LPA through LPA1/3 receptors53. Recent studies have 
also implicated additional LPA receptors present on the mast cell surface, which may 
induce mast cell activation in an LPA1/3 independent fashion54. Furthermore, mast cell 
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effects mediated by LPA could also depend on the state of atherosclerosis. For instance, 
our group has previously reported that mast cell activation through LPA leads to 
advanced plaque destabilization19, while in this study we aimed our attention in early 
plaque development.
In conclusion, LPA1/3 receptor inhibition through Ki16425 induced systemic anti-
inflammatory responses via a reduction in CCL2-CCR2 signaling, an enhancement of 
anti-inflammatory innate, as well as adaptive, immune responses and a decrease in 
plasma cholesterol levels, collectively resulting in the reduction of the atherosclerotic 
burden. The anti-inflammatory immune reaction of Ki16425 may span even outside 
atherosclerosis and into other diseases, which are characterized by excessive 
inflammation. For instance, Ki16425 has been found to reduce inflammation in 
experimental models for obesity55, rheumatoid arthritis56, and lung fibrosis57. Thus, 
the importance of singularly targeting the LPA1/3 receptors via pharmacological 
inhibition may grant anti-inflammatory effects without completely shutting down the 
immune response. At the same time it retains possible positive effects that LPA may 
evoke through its additional receptors in other physiological processes inside the body. 
Therefore, LPA1/3 inhibition is an interesting therapy with multiple beneficial effects 
that can be employed in a broad spectrum of diseases, among which atherosclerosis.
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Supplementary Information
Figure 1: Treatment with Ki16425 does not affect the spleen or liver weight of mice. 
(a) The spleen weight between the control and Ki16425 treated group showed no significant 
difference (P=0.63) at the end of the study. (b) Similarly, the liver weight between the control 
and Ki16425 groups was not substantially different (P=0.38). All values (n=13/grp; spleen 
and n=6/grp; liver) are depicted as mean±SEM.
Figure 2: LPA1/3 inhibition did not affect the amount of CD8+ T lymphocytes or dendritic 
cells. The amount of CD8+ T cells in the (a) circulation and (b) spleen was not affected by 
treatment with Ki16425 (P=0.50) and (P=0.78). (c) The overall percentage of dendritic cells 
present in the spleen showed no differences among the control and treated mice (P=0.60). 
All values (n=12/grp) are depicted as mean±SEM.
Gene Forward primer (5’-3’) Reverse primer (3’-5’)
CCL2 GCATCT GCCCTAAGGTCT TCA TTCACTGTCACACTGGTCACTCCTA
CD68 TGCCTGACAAGGGACACTTCGGG GCGGGTGATGCAGAAGGCGATG
CXCL1 TTGACCCTGAAGCTCCCTTG AGGTGCCATCAGAGCAGTC
I-CAM 1 GTCCGCTTCCGCTACCATCA GGTCCTTGCCTACTTGCTGCC
Rpl27 CGCCAAGCGATCCAAGATCAAGTCC AGCTGGGTCCCTGAACACATCCTTG
β-actin AACCGTGAAAAGATGACCCAGAT CACAGCCTGGATGGCTACGTA
Supplementary Table 1: qPCR gene primer sequences. All gene expression analysis was 
performed using two housekeeping genes (β-actin and Rpl27). Abbreviations: Chemokine 
C-C motif ligand 2 (CCL2); cluster of differentiation 68 (CD68); chemokine C-X-C motif ligand 
1 (CXCL1); Intercellular adhesion molecule-1 (ICAM-1); 60s ribosomal protein ligand 27 
(Rpl27).
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Antibody Fluorochrome Clone Company
CD11b eFluor 450 M1/70 Ebioscience
Ly6C PercP Cy5.5 HK1.4 Ebioscience
Ly6G PE 1A8 BD Biosciences
CCR2 APC #475301 R&D Systems
CD4 PercP Rm4-5 BD Biosciences
CD25 FITC PC61.5 Ebioscience
NK1.1 FITC PK136 Ebioscience
CD8a PercP 53-6.7 BD Biosciences
MHC-II eFluor 450 AF6-120.1 Ebioscience
CD11c APC N418 Ebioscience
FoxP3 eFluor 450 FJK-16s Ebioscience
T-bet Alexa -Fluor 660 eBio4B10 Ebioscience
Helios Alexa-Fluor 647 22F6 Ebioscience
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Abstract
Mast cells are potent innate immune cells that aggravate 
atherosclerosis through the release of pro-inflammatory mediators inside 
atherosclerotic plaques. Similarly, CD4+ T cells are constituents of the 
adaptive immune response and accumulate within the plaques following 
lipid-specific activation by antigen presenting cells. Lately it is being 
proposed that these two cell types can interact, upon request, in a direct 
manner. However, no indication of such an interaction has been previously 
investigated in atherosclerosis. In our study, we aimed to examine 
whether mast cells can act as non-classical antigen presenting cells in 
atherosclerosis, thereby shaping the CD4+ T cell response. We observed 
that mast cells can increase their MHC-II expression under hyperlipidemic 
conditions both in vivo and in vitro. Furthermore, we showed that mast 
cells can present antigens in vivo via their MHC-II molecules. High-fat 
diet serum enhanced the expression of the co-stimulatory molecule 
CD86 on the mast cell surface in vitro, while co-culture of OVA-peptide 
loaded mast cells shifted the OT-II CD4+ T cell response towards a TH1 
cell subset. In accordance, the aortic TH1 cell content of atherosclerotic 
mice that lack mast cells was found reduced as compared to their wild-
type counterparts. Importantly, we here established that mast cells in 
advanced human atherosclerotic plaques express HLA-DR, indicating that 
they are capable of antigen presentation inside human atherosclerotic 
tissues. Therefore, we are the first to show that mast cells may function 
as non-classical antigen presenting cells and directly modulate adaptive 
immunity in atherosclerosis.
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1.  Introduction
Atherosclerosis is a chronic, lipid-mediated, autoimmune disease of the medium 
and large arteries, which involves both innate and adaptive immune reactions1. The 
communication between the innate and adaptive immune response is achieved through 
professional antigen presenting cells, such as dendritic cells, that can specifically 
activate T lymphocytes with antigens taken up from the atherosclerotic plaque2. It has 
previously been established that during the progression of atherosclerosis, antigens 
from the oxidized low-density lipoprotein (oxLDL) molecules can elicit immune 
responses by activating an array of T cell subtypes, like the TH1 and TH2 cell types3,4. This 
happens inside secondary lymphoid tissues, such as the spleen and the local draining 
lymph nodes and requires three key-signals that involve presentation of the antigenic 
fragments. Antigen presentation is triggered by major histocompatibility complex I or II 
(MHC-I/II) and followed by a strong co-stimulatory response, in the form of proteins like 
CD86, along with secreted cytokines priming the T cell activation process5. In response, 
activated T cells subsets translocate to the atherosclerotic plaque and influence the 
disease outcome locally6. The differential T cell subset effect is partially attributed to 
the different cytokine milieu secreted by the two cell types. Specifically, TH1 cells, which 
are the most abundant type inside progressing atherosclerotic plaques, secrete large 
amounts of interferon-γ (IFNγ) while TH2 cells are found at lower numbers and release 
mainly interleukin-4 (IL-4), interleukin-5 (IL-5) and interleukin-13 (IL-13)7,8. CD4+ TH1 
cells have been proven to be proatherogenic9, while TH2 cells appear to counteract for the 
TH1-mediated effects10 and through secretion of IL-5 show an atheroprotective function. 
On the other hand, IL-4 cytokine is reported to have a pro-atherogenic function with 
lower plaques developing upon its absence11 making thus the exact role of TH2 cells in 
atherosclerosis hard to define12. Therefore, the diversity, in terms of quality and quantity 
of the T cell subsets, can exert differential effects and inversely affect the progression 
of atherosclerosis. Still, although activated T cells have in principle a pre-established 
fate upon entering the vessel wall, local costimulation in the plaques13,14 may alter their 
behaviour.
Mast cells are tissue resident innate immune cells that have long been 
established to contribute to atherosclerosis progression15. These cells accumulate in the 
atherosclerotic tissue upon plaque development and, according to their classical mode 
of action, release pro-inflammatory mediators such as proteases and cytokines16,17. 
Yet, increasing evidence suggests that mast cells can also adopt an inducible antigen 
presenting phenotype that may influence the immune response inside tissues18. While 
mast cells are not classical antigen presenting cells like dendritic cells, peritoneal mast 
cells have been found to upregulate MHC-II in the presence of cytokines IL-4 and IFNγ19, or 
inside the lymph nodes of mice that have been injected with lipopolysaccharide (LPS)20. 
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Importantly, mouse bone marrow derived mast cells have been reported to present 
peptides of the model-antigen ovalbumin (OVA) to CD4+ T cells21. Likewise, human 
cultured mast cells can directly present antigens to CD4+ T cells through the human 
MHC-II equivalent protein HLA-DR22,23. However, up to date it is not known whether 
mast cells can directly influence the adaptive immune response during atherosclerotic 
plaque progression. Therefore, we aimed to study the antigen presentation capacity of 
mast cells to CD4+ T cells in atherosclerosis.
2.  Materials & Methods
2.1   Animals
 All animal work was performed in compliance with the guidelines directed by the European 
Union Directive 2010/63EU and the Dutch Government. The experimental work was approved 
by the Animal Ethics committee of Leiden University. The animals were originally obtained by the 
Jackson Laboratories and subsequently bred in the local animal facility, while provided with food 
and water ad libitum. At experimental endpoint, mice were subcutaneously anesthetized with an 
injection mix of ketamine (100mg/mL), sedazine (25mg/mL) and atropine (0.5mg/mL) and their 
vascular system was perfused with PBS upon heart puncture in the left ventricle. 
2.2   WTD-timecourse experiment 
 In order to examine the effect of WTD on the antigen presentation capacity of mast cells we 
performed a timecourse experiment (Supplemental Figure 1A). Male LDLr-/- mice (n=10/grp) 
of an average age 8-10 weeks old were placed on a Western-type diet (WTD) (0.25% cholesterol, 
15% cocoa butter; Special Diet Services, Essex, UK) for either 4 or 8 weeks, or kept on a chow 
diet until the experimental endpoint. Mouse peritoneal cells were collected by peritoneal lavage, 
using 10mL PBS, to study the mast cell peritoneal population according to their characteristic 
expression of markers FcεRIα and CD117. Notably, the peritoneal mast cell population was also 
examined for the expression of the myeloid cell marker CD11c, to ensure that the observed 
population was not MHC-II+ dendritic cells or macrophage foam cells, as these cells have been 
previously reported to express inducible Fcε-receptors in atopic dermatitis, allergy and inside 
atherosclerotic plaques24,25. The para-aortic lymph nodes of these mice were isolated at the 
experimental endpoint and fixated in formalin for 24 hours. Subsequently, all lymph nodes were 
embedded in OCT medium (Sakura) and 6μm cryosections were collected. Mast cell detection 
was performed using a Naphthol AS-D chloro-acetate esterase kit (Sigma Aldrich). The T cell 
population in the para-aortic lymph nodes was detected through antibody staining against CD3 
at a 1:150 concentration (clone SP7, Thermoscientific). Determination of all mast cell and CD3+ 
T cell numbers was performed by blinded and independent manual quantification of 2 collected 
sections per mouse. Representative pictures were obtained using a Leica DM-RE microscope 
(Leica Systems, UK). 
2.3   Eα-presentation experiment
 In order to study the ability of mast cells to present antigens through their MHC-II molecule 
we made use of the Eα-peptide presentation system whereupon an Eα-GFP peptide, after 
internalization and degradation, can be presented by the MHC-II molecules on the surface of 
APCs and is detected by specifically designed antibodies against Eα-fragments26 we performed 
an Eα-peptide presentation experiment (Supplemental Figure 1B). Male LDLr-/- mice (n=14/
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grp, average age:13 weeks) were placed on a WTD for 4 weeks. 24 hours prior to the end of the 
experiment one group was injected intraperitoneally with Eα-GFP27, (100μg/mouse) while an 
additional group was administered sterile PBS as a control. Peritoneal cells isolated from Eα-
treated mice were further stimulated ex vivo with Eα-GFP (200μg/mL) for either 3 or 24 hours 
and compared with peritoneal cells isolated from the PBS injected mice. The expression levels of 
an Y-Ae-Streptavidin antibody against Eα were determined by flow cytometry in comparison to 
the control-PBS expression.
2.4   Bone marrow derived mast cell stimulation
 To investigate the antigen presentation function of mast cells in vitro, bone marrow derived 
mast cells (BMMCs) were cultured from isolated bone marrow cells in RPMI 1640 medium 
containing 25mM HEPES (Lonza) supplemented with 10% fetal calf serum (FCS), (1x) minimal 
essential medium non-essential amino-acids (MEM NEAA; Gibco), 60μM β-mercaptoethanol 
(Sigma), 1% mix of penicillin/streptomycin (PAA), 1% sodium pyruvate (Sigma) and 2% 
L-glutamine (Lonza) for 4 weeks with cytokine IL-3 (5 ng/mL; Immunotools). Mast cell purity was 
assessed by the expression of FcεRIα and CD117 and routinely found to be above 98%. Mature 
mast cells kept in culture for weeks 4 - 6 were used for all experiments. MHC-II induced mast cells 
(iMCs) were obtained by a mix of cytokines IL-4 (20ng/mL) and IFNγ (50ng/mL). Subsequently, to 
study the effect of hyperlipidemic serum, iMCs were stimulated for 24h with 10% serum isolated 
from either chow fed or 4 weeks WTD fed LDLr-/- mice and all conditions were renewed for an 
additional period of 24h. iMCs were additionally stimulated with 40% peritoneal fluid which was 
obtained by peritoneal lavage with 10ml PBS and after centrifugation at 1.600 RPM for 5 minutes. 
After a period of 24h all conditions were renewed accordingly. Cytokines IL-12p70, IFN-γ and IL-4 
secretion was measured by ELISA (BD Biosciences) according to the manufacturer’s protocol. 
2.5   Mast cell-OT-II CD4+ T cell co-culture
 To study the direct presentation of antigens by mast cells to CD4+ T cells in vitro we made use 
of the OVA presentation system. In a co-culture experiment, iMCs were repeatedly treated with 
10% chow/WTD serum, as described above, in the presence of an OVA-peptide (10μg/mL) that 
can directly bind the MHC-II surface molecules and is directly presented to the T cell receptor 
(TCR) without requiring internalization. CD4+ T cells were isolated from genetically modified OT-
II mice28 using a magnetic-bead isolation kit (Miltenyi) and activated with αCD3 (1μg/mL) and 
αCD28 (0.5μg/mL) for 24h. Subsequently, after washing off the stimulants, mast cells and T cells 
were placed together in a co-culture system. Cells were seeded in quintuplicate per condition 
at a 1:1 ratio for 72 hours. At the end of the experiment, all samples were prepared for flow 
cytometry. For the proliferation assay radioactive 3H-Thymidine (0.5μCi/well; PerkinElmer) was 
added to the samples after 48h and the incorporation rate was measured 15h later using a liquid 
scintillation analyzer (Tri-Carb 2900R). The levels of cytokines IL-4 and IFNγ were determined by 
ELISA (BD Biosciences) according to the manufacturer’s protocol. 
2.6   Mast cell deficiency experiment
To investigate the effect of mast cells on the T cell population in atherosclerosis, male mast 
cell deficient apoE-/-/KitW-sh/W-sh mice as well as control apoE-/- mice (Supplemental Figure 1C) 
of (n=16/grp, average age 16 weeks), were fed a WTD for 6 weeks. The intraplaque cell content 
was obtained through enzymatic digestion of the aortic tissue for 30 minutes at 37oC, with a 
mix of collagenase I (450u/mL; Sigma) and XI (250U/mL Sigma) and DNase (120U/mL; Sigma), 
hyaluronidase (120 U/mL; Sigma) and samples were further processed using flow cytometry.
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2.7   Human specimens 
 To explore the ability of human intraplaque mast cells to present antigens, 20 anonymous 
atherosclerotic plaques were collected post-operatively from carotid or femoral artery 
endarterectomy surgeries, performed between July 2016 and December 2016 at the Haaglanden 
Medical Center (HMC), Westeinde, The Hague, The Netherlands. The handling of all human 
samples was performed in accordance with the “Code for Proper Secondary Use of Human Tissue”. 
All atherosclerotic samples were processed in single cell suspensions, as described previously29. 
In short, cell suspensions from human atherosclerotic plaques were obtained upon digestion 
with collagenase IV (Gibco) and DNase (Sigma) for 2 hours at 37oC prior to single-cell separation 
through a 70μm cell strainer. All human white blood cell populations were characterized by 
flow cytometry, based on the expression of the pan-leukocyte marker CD45. The mast cells were 
further defined by the FcεRIα and CD117 antibodies. 
2.8   Flow cytometry
All cell populations are depicted as the percentage of viable cells, determined according 
to a fixable viability dye solution (eBioscience). Gating strategies and controls are shown in 
Supplemental Figure 2. Cells were stained with antibodies against extracellular proteins or 
fixated and permeabilized using a transcription factor kit (eBioscience) for intracellular stainings 
(Table 1). Flow cytometry measurements were performed on a FACS Canto II and data were 
analysed using FlowJo software.
Targeted 




Viability Dye eFluor 780 - 0.1 μg/sample eBioscience
Mouse FcεRIα PercP Cy5.5 MAR-1 0.1 μg/sample Biolegend
Mouse CD117 APC/PE Cy7/ PE 2B8 0.1 μg/sample eBioscience
Mouse MHC-II FITC/PE M5/ 114.15.2 0.1 μg/sample eBioscience
Mouse CD11c PE N418 0.1 μg/sample eBioscience
Mouse CD86 PE/APC GL1 0.1 μg/sample eBioscience
Mouse Ea52-68 Biotin EBioY-Ae 0.5 μg/sample eBioscience
Mouse Streptavidin APC - 0.3 μg/sample eBioscience
Mouse Thy1.2 PE Cy7 53-2.1 0.1 μg/sample eBioscience
Mouse CD4 PercP RM4-5 0.1 μg/sample BD Biosciences
Mouse CD8 eFluor 450 53-6.7 0.1 μg/sample eBioscience
Mouse T-bet Alexa-Fluor 660 eBio4B10 0.3 μg/sample eBioscience
Mouse Ki-67 FITC SoIA15 0.3 μg/sample eBioscience
Human CD45 PE Cy7 2D1 0.3μg/sample eBioscience
Human FcεRIα APC AER-37 0.1μg/sample eBioscience
Human CD117 PercP Cy5.5 104D2 0.1μg/sample BD Biosciences
Human HLA-DR PE L243 0.3μg/sample eBioscience
Human CD63 PE H5C6 0.1μg/sample eBioscience
Table 1: List of extracellular and intracellular antibodies used in all flow cytometry 
experiments
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2.9   Statistics
 All data are presented as mean±SEM. Values within groups were tested for normal 
distribution and corrected with a Bonferroni post-test for multiple comparisons. In the event of 
one-variable analysis among two groups a 2-tailed Student’s t-test was used, while among more 
than two groups a one-way ANOVA was performed. For the analysis of two variables between 
groups, a two-way ANOVA test was used. Non-Gaussian distributed data were analyzed with a 
Mann-Whitney U test. Pearson’s correlation was used to estimate the association between two 
variables in human mast cells. The probability (alpha) value for all tests was set to 0.05, with 
differences lower than this considered significant (P<0.05). 
3.  Results
3.1 Western-type diet increases the MHC-II expression on peritoneal mast cells
To determine the effects of high lipid diet on the mast cells, we fed LDLr-/- mice a 
WTD for a period of 4 to 8 weeks and compared the peritoneal mast cell population with 
LDLr-/- mice fed a chow diet. Upon increasing periods of WTD, the relative amount of 
peritoneal mast cells increased significantly (Figure 1A, chow: 0.39±0.1% vs WTD 4wk: 
1.97±0.4%, P=0.014; chow vs WTD 8wk: 2.02±0.3%, P=0.011). Likewise, the absolute 
number of peritoneal mast cells increased after 4 weeks of WTD (Figure 1B, P=0.060), 
however this number returned to chow-levels upon 8 weeks of WTD. Interestingly, 
we observed that during 4 weeks of WTD the peritoneal mast cell population showed 
an enhancement in expression of the antigen presenting protein MHC-II (Figure 1C, 
chow-MCs:30.38±1.7% vs WTD 4wk-MCs:52.48±5.9%, P=0.014). The absolute number 
of mast cells that express MHC-II upon 4 weeks of WTD showed a 4-fold increase as 
compared to the number of MHC-II+ MCs in chow diet (Figure 1D, chow: 3677±367 
mast cells vs WTD 4wk: 21561±5071 mast cells, P=0.009). Also here, 8 weeks of WTD 
restored the amount of MHC-II+ expressing mast cells to chow-levels. Furthermore, 
the para-aortic lymph nodes of these mice showed a slight increase in the number of 
mast cells after 4 weeks of WTD, as compared to the chow-fed mice. The mast cells 
accumulated particularly in the subcapsular sinuses of the lymph nodes (Supplemental 
Figures 3A,B), an area where soluble antigens meet professional antigen presenting 
cells30. However, no difference was observed between the groups in the number of T 
cells in the area (Supplemental Figure 3C).
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Figure 1: Peritoneal mast cells of LDLr-/- mice increase in amount and MHC-II 
expression after 4 weeks of WTD. Representative flow cytometry plots are shown, with 
the mast cell population defined by the expression of receptors FcεRIα and CD117. The mast 
cell percentage in the peritoneal cavity of LDLr-/- mice increased after 4 and 8 weeks of WTD 
(A). The mast cell numbers peaked after 4 weeks of WTD and were restored to normal levels 
after 8 weeks of WTD (B). Characteristic dot plots of the MHC-II expression on the mast 
cell population show the peritoneal mast cells that express protein MHC-II (C). The MHC-
II-expressing mast cells increased significantly in percentage and numbers after 4 weeks 
of WTD, while returning to normal after 8 weeks (D). All values (n=5/gr) are depicted as 
mean±SEM; *p<0.05, **p=0.01
3.2 The MHC-II molecules on the peritoneal mast cells can present antigens in 
vivo
We next sought to examine whether the MHC-II molecules on the peritoneal 
mast cell surface are functional and capable of presenting antigens in vivo by using 
the Eα-peptide system26. We therefore injected the Eα-peptide or PBS-control in the 
peritoneum of WTD-fed LDLr-/- mice. After a period of 24 hours we observed that 
the MHC-II expression was enhanced in the Eα-injected mast cells as compared to 
control (Figure 2A, PBS:16.3±4.9% Eα:29.75±6.1% P=0.052). Importantly, Eα-peptide 
fragments were detected on the mast cell surface of the Eα-injected group (Figure 
2B, PBS:2.73±0.3% vs Eα:7.07±1.5%, P=0.009). We further examined the capacity of 
peritoneal mast cells to present the Eα-peptide ex vivo. Upon 3h of peptide addition, 
Eα-GFP+ signal was detected in the peritoneal mast cells, indicating that the peptide 
is internalized but not yet processed by the lysosomal compartment (Figure 2C, PBS: 
3.41±1.9% vs Eα(3h): 27.7±6.2%, P=0.008). No Eα-GFP+ cells were observed after 24 
hours. However, at this timepoint Eα-peptide fragments were detected on the peritoneal 
mast cell surface, indicating that during this period the Eα-peptide was fully processed 
by the lysosomes and its fragments were presented on the mast cell surface through 
the MHC-II molecule (Figure 2D, PBS: 4.46±1.2% vs Eα(24h): 22.08±9.1%, P=0.062). 
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As expected, no fragment presentation by mast cells was detected in the first 3h of Eα-
addition.
Figure 2: The MHC-II protein on the 
peritoneal mast cell surface is able 
to present antigenic fragments of the 
Eα-peptide, upon WTD. LDLr-/- mice, 
fed a WTD for 4 weeks, increase their 
MHC-II expression levels 24h after i/p 
injection of Eα-GFP, as compared to 
the PBS mice (n=10/grp) (A). The Eα-
peptide fragments are detected in vivo 
on the surface of peritoneal mast cells, 
24h after administration (n=11/grp) 
(B). Peritoneal cells isolated from the 
PBS and Eα-administered mice (n=6/
grp) were further treated ex vivo with 
Eα-GFP peptide. Eα-GFP uptake by 
peritoneal mast cells was detected 3h 
after addition, while 24h later there 
was no detectable Eα-GFP signal (C). 
Eα-peptide fragments were observed 
24h later, on the peritoneal mast cell 
surface (D). All values are depicted as 
mean±SEM (n=10/grp); **p<0.01.
3.3  WTD serum enhances the presentation capacity of bone marrow derived 
mast cells in vitro
Since WTD-induced hypercholesterolemia seemed to enhance the presentation 
machinery of mast cells, we aimed to further investigate the direct effect of hyperlipidemic 
serum on the non-classical MHC-II expression of mast cells. We therefore used bone-
marrow derived mast cells (BMMCs) to examine the effects of atherogenic serum 
isolated from mice fed a WTD for 4 weeks or chow diet serum. It is worth mentioning 
here that, unlike peritoneal mast cells31, bone marrow derived mast cells are not able to 
constitutively express MHC-II32 unless induced with specific factors19,20. For that reason, 
in our BMMC experiments we induced MHC-II expression on the mast cells (iMCs) using 
IL-4 and IFNγ (Supplemental Figure 4A). This does not seem to be necessary in vivo 
because hyperlipidemic serum already contains these cytokines (Supplemental Figure 
4B,C). We observed that upon repeated treatment of iMCs, for 48h with WTD (4wk) 
serum, mast cells increased their MHC-II expression levels by 2-fold as compared to 
chow serum (Figure 3A, chow-iMC: 3.12±0.3% vs WTD-iMC: 10.25±0.1%; P<0.0001). 
Furthermore, the costimulatory protein CD86, which is necessary for the strengthening 
of the antigen presentation process33, was also found to increase in a WTD specific 
manner on the surface of the WTD-iMCs, as compared to chow-iMCs. (Figure 3B, chow-
iMC: 1.73±0.1% vs WTD-iMC: 2.53±0.1%, P=0.0012). Finally, for antigen presentation 
to be efficient, cytokine signals are also needed. Therefore, we measured the levels of 
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cytokine IL-12, which is one of the most potent cytokines for TH1 subset skewing34. We 
did not observe any differences between the WTD and chow treated iMCs (Figure 3C), 
however it was certain that mast cells, in the presence of serum are able to provide the 
third signal needed for CD4+ TH1 cell skewing. Interestingly, when iMCs were treated 
with fluid collected from the peritoneal cavity of LDL-/- mice fed either chow or WTD 
(4 weeks) they showed a marked increase in their MHC-II expression (Supplemental 
Figure 4D). We therefore measured the IL-4 and IFNγ levels in the peritoneal cell fluid 
and observed that both cytokines are present (Supplemental Figure 4E,F), indicating 
that peritoneal mast cells seem to have the necessary signals needed for MHC-II 
induction in vivo. 
Figure 3: Inducible bone marrow derived mast cells repeatedly treated with WTD 
serum possess all three signals required for antigen presentation. The expression of 
MHC-II on the surface of bone marrow mast cells increased upon repeated (48h) in vitro 
treatment with 10% serum isolated from LDLr-/- mice that were fed a WTD for 4 weeks, as 
compared to chow serum (A). Co-stimulatory molecule CD86 was enhanced on the surface of 
mast cells after repeated treatment with 10% WTD (4wk) serum from LDLr-/- in comparison 
to chow-serum (B). Bone marrow mast cells were capable of secreting cytokine IL-12 after 
repeated serum treatment, with no significant difference detected between chow or WTD 
samples (C). All values are shown as mean±SEM; *p<0.05, **p<0.01.
3.4  OVA-peptide specific CD4+ T cell proliferation is enhanced upon co-culture 
with WTD-treated mast cells
Thereafter, we aimed to unravel the direct effect of mast cell mediated antigen 
presentation to CD4+ T cells. We isolated CD4+ T cells from genetically modified 
OT-II mice, that specifically recognize ovalbumin antigens28, and after 24h of pre-
activation with αCD3/CD28 we placed them in a coculture with iMCs loaded with an 
OVA-peptide (OVAp) in the presence of either chow or WTD diet. OVAp-loaded iMCs 
showed a significant increase on their MHC-II expression in the presence of CD4+ T 
cells, regardless of the type of serum (Figure 4A, P<0.001). Furthermore, the OVAp-
iMC population pretreated with WTD-serum showed an increase in their CD86 
expression when co-cultured with CD4+ T cells (Figure 4B). CD4+ T cells increased 
their proliferation rate in an OVAp specific manner with significant enhancement in 
the proliferation rate when co-cultured with WTD-pretreated iMCs, as detected by 
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the incorporation rate of 3H-Thymidine (Figure 4C, chow-iMCs:9033±2558 dpm vs 
WTD-iMCs: 25331±2889 dpm, P<0.0001). The WTD effect of OVAp-carrying iMCs on 
the proliferation rate of CD4+ T cells was further confirmed by flow cytometry after 
detection of the intracellular proliferation marker Ki-67 on the CD4+ T cell population 
(Figure 4D, chow-iMCs:17.76±0.09% vs WTD-iMCs:25.56±1.7%, P=0.004). Finally, we 
measured the secretion of IFNγ and IL-4 in the co-culture since, aside from inducing 
MHC-II on the mast cells, they are the most important cytokine “fingerprints” of the 
CD4+ TH1 or TH2 subsets respectively. The secretion of IFNγ was slightly increased in 
the WTD-iMC conditions upon the presence of CD4+ T cells; however, no difference was 
observed between the OVAp-induced IFNγ secretion by CD4+ T cells (Figure 4E). In 
contrast, IL-4 secretion was significantly increased in the chow iMC conditions, effect 
which was not observed in the WTD iMC-CD4+ samples, resulting thus in a significant 
difference in the IL-4 levels between chow and WTD conditions (Figure 4F, chow-
iMC:14.16±2.3 pg/ml vs WTD-iMC:5.85±1.9 pg/ml, P=0.002) suggesting that mast cell 
induced antigen presentation in hyperlipidemic conditions favors the secretion of IFNγ 
over IL-4 and therefore TH1 cell skewing over TH2.
Figure 4: Bone marrow iMCs, repeatedly treated with WTD-serum and loaded with 
an OVA-peptide, enhance the proliferation rate of pre-activated OT-II CD4+ T cells. The 
expression of MHC-II on the mast cell surface was increased in OVAp-loaded mast cells at 
the presence of CD4+ T cells (A). The percentage of costimulatory molecule CD86 was found 
increased only WTD-treated mast cells that were loaded with OVAp and in the presence of 
CD4+ T cells (B). The proliferation rate of pre-activated OT-II CD4+ T cells increases upon 
presentation of OVAp by mast cells treated with WTD as compared to chow-treated MCs, 
as measured by both radioactive thymidine incorporation and expression of proliferation 
marker ki-67+ with flow cytometry (C and D). The IFNγ secretion by CD4+ T cells was 
increased upon presentation of the OVAp by WTD-treated mast cells as compared (E). The 
secretion of IL-4 by CD4+ T cells was increased upon presentation of OVAp by the chow-
treated mast cells (F). All values (n=5/grp) are shown as mean±SEM; *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001.
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3.5  Aortic CD4 + T cells show reduced proliferation in mast cell deficient mice
To verify whether mast cells affect the CD4+ T cell population in the atherosclerotic 
plaque we placed mast cell deficient apoE-/-/KitW-sh/W-sh mice on a WTD and compared the 
intraplaque CD4+ T cell content in their aortas with that from WTD-fed control apoE-/- 
mice. Using flow cytometry, we observed a reduction in the percentage of Ki-67+ CD4+ 
T cells in the aortas of atherosclerotic mast cell deficient mice as compared to controls 
(Figure 5A, apoE-/-: 30.91±5.2 % vs apoE-/-/KitW-sh/W-sh:13.7±1.2, P=0.013). This reduction 
was also apparent when comparing the absolute number or proliferating CD4+ T cells 
(Figure 5B, apoE-/-: 1725±567 #cells vs apoE-/-/KitW-sh/W-sh: 389±59 #cells, P=0.037). 
Interestingly, a decline in the number of TH1 cells was also detected in the aortas of 
mast cell deficient apoE-/- mice as compared to the control apoE-/- mice (Figure 5C, 
apoE-/-: 148±25 #cells vs apoE-/-/KitW-sh/W-sh: 45±16 #cells, P=0.056). Of note, the total 
T cell percentage is found slightly reduced in the aortas of the mast cell deficient apoE-
/- (Figure 5D). This reduction is not due to the CD8+ T cell population which remains 
unchanged (Figure 5E) but rather due to the reduction of the CD4+ T cells (Figure 5F, 
apoE-/-: 4.72±0.8 % vs apoE-/-/KitW-sh/W-sh: 2.37±0.7 #cells, P=0.028). 
Figure 5: Mast cell deficient apoE-/-/KitW-sh/W-sh mice show a reduction in the proliferation 
of CD4+ TH1 cells in the aortic arch. The percentage and absolute numbers of proliferating 
ki-67+/CD4+ T cells were reduced in the aortic arch of apoE-/-/KitW-sh/W-sh mice, fed a WTD for 6 
weeks, as compared to apoE-/- mice (A and B).  The numbers of TH1 cells in the aorta of mast 
cell deficient apoE-/- mice were decreased, as measured by the expression of transcription 
factor T-bet on the aortic CD4+ T cell population (C). Mast cell deficient apoE-/- mice fed a 
WTD show a slight reduction in their aortic T cell percentage (D). The aortic CD8+ T cell 
content of apoE-/- mice was not affected by the absence of mast cells (E). The aortic CD4+ 
T cell content was significantly decreased in of apoE-/- mice fed a WTD upon the absence of 
mast cells (F). All values (n=8/group) are depicted as mean±SEM; *p<0.05, **p<0.01.
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3.6  Human intraplaque mast cells express HLA-DR
Finally, to establish whether our data can be translated to the human disease 
setting, we analyzed the mast cell content of 20 endarterectomy plaques collected from 
carotid or femoral arteries. We are the first to use flow cytometry for the detection of 
human intraplaque mast cells, in femoral as well as carotid arteries as measured by 
the expression of receptors FcεRIα and CD117(Figure 6A, carotid hMCs: 0.81±0.1%, 
femoral hMCs: 1.26±0.2%). Focusing on the antigen presentation capacity of mast 
cells inside the atherosclerotic plaques, we further stained them for the expression of 
protein HLA-DR. We observed that mast cells inside human atherosclerotic plaques can 
express HLA-DR in both the femoral and the carotid arteries (Figure 6B, carotid hMCs: 
9.30±4.3% vs femoral hMCs: 23.8±6.9%). Interestingly, the HLA-DR expressing cells 
showed a negative association with the activated mast cell population, as detected by 
marker CD6335, which comprises the majority of mast cells within the atherosclerotic 
plaque (Figure 6C, P=0.024). 
Figure 6: Human mast cells from 
carotid and femoral atherosclerotic 
plaques express HLA-DR. The mast 
cell population in the plaques of 
human subjects (n=20), obtained from 
endarterectomy surgery, are detected 
based on the high expression of FcεRΙα 
and CD117. Representative flow 
cytometry plots of human mast cells, 
gated according to the expression of 
receptors FcεRIα and CD117 (A). Human 
intraplaque mast cells express HLA-DR, 
in the femoral artery and carotid artery 
samples (B). The HLA-DRhi mast cells 
show a negative correlation with the 
activated CD63+ mast cell population in 
the atherosclerotic arteries (C).
4.   Discussion
In this project, we sought to examine whether mast cells can act as non-professional 
antigen presenting cells in atherosclerosis. We observed that hyperlipidemic conditions 
induce the expression of MHC-II on the peritoneal mast cell surface and furthermore, 
that mast cells are able to process and present antigens in vivo. Within the atherosclerotic 
tissue, mast cells appear to augment the TH1 response in a manner that seems to 
partially involve a direct interaction between these two cell types. Importantly, we show 
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that antigen presentation by mast cells may even take place within the atherosclerotic 
plaques of human subjects, a process that appears to associate in a negative manner 
with the classical mast cell activation taking place within the plaque.
The capacity of mast cells to directly shape T cell responses, upon request by 
certain signals in their microenvironment, is a process that has recently gained attention 
in the field36.  However, the question was posed long ago in a study reporting that rat 
mast cells incubated with IFNγ showed increased MHC-II expression; thus arguing 
that mast cells, aside from their classical degranulating nature may also be capable 
of presenting antigens37. The regulation of the MHC-II molecule expression by IFNγ 
has previously been established in professional antigen presenting cells38, but also in 
human mast cells39. Additionally, peritoneal mast cells, in the presence of IFNγ/IL-419, 
have been shown to increase their MHC-II expression levels. This effect may explain 
why mast cells increase their MHC-II levels in an atherosclerotic environment, since 
it is known that patients with coronary heart disease show increased levels of IFNγ in 
their serum40. Moreover, human plaque tissue contains high amounts of IFNγ41. Here 
we observed that mast cells increase their MHC-II levels both in vivo and in vitro in 
a WTD-specific manner in accordance to detecting high levels of IFNγ, in the serum 
and peritoneal fluid of hyperlipidemic mice. We also saw that the absence of mast cells 
significantly reduced the number of TH1 cells, the main producers of IFNγ, inside the 
atherosclerotic plaques. Furthermore, antigen presentation through WTD-treated mast 
cells increased the IFNγ secretion by T cells, which, when combined with the reduced 
IL-4 secretion, supports the generation of TH1 cells. Mast cells have also been found to 
enhance plaque progression in an IFNγ dependent manner16, with mast cell deficient 
mice developing smaller atherosclerotic plaques42 which suggests that IFNγ may also 
function as a regulator of the direct interaction between mast cells and TH1 cells within 
the atherosclerotic plaque. It is worth noting that while WTD-treated mast cells seem 
to support a TH1 response, chow-treated mast cells tend to favor the TH2 phenotype. 
Interestingly, allergic asthma is a classic TH2 mediated condition where mast cells are 
famously known for their adverse effects43. In contrast, atherosclerosis is shaped by the 
action of TH1 cells, as mentioned before. Therefore, it seems that mast cells can act on the 
adaptive immune system in situ and according to the local inflammatory status.
Our study also shows that mast cells can express, upon request, all three signals 
required for antigen presentation. The presence of multiple costimulatory molecules 
on the mast cell surface, such as OX40L, CD80 and CD86, has been previously stated 
to be a main assistant in their direct communication with CD4+ T cells20,44. Here we 
observed that WTD conditions increase CD86, however we cannot exclude that other 
costimulatory molecules may participate in the described interaction with CD4+ T 
cells. Furthermore, mast cells are known for their potent cytokine secretion, and TNFα 
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release has also been reported to enhance local antigen presentation32. In the case of 
atherosclerosis, signal 3 could be provided by the mast cells, for instance in the form of 
IL-12 which skews T cells towards a TH1 subset, but also by the inflammatory cytokine 
content of the hypercholesterolemic serum.
In addition, we here establish that the MHC-II protein on the surface of mast 
cells is a fully functional molecule that can bind antigens processed by the lysosomal 
machinery of the cell and successfully transport them to the cell surface where they 
can be introduced to CD4+ T cells. However, while the Eα and OVA peptides are model 
antigens that serve in exploring the presentation capacity of a cell, the WTD-specific 
induction of MHC-II implies that lipid specific antigens may be presented by mast cells. 
Although it is still unclear which peptide fragments elicit an adaptive immune response 
in atherosclerosis it is worth mentioning that oxLDL has been previously reported 
to regulate the expression of MHC-II on macrophages in an autophagy mediated 
pathway45. It would therefore be intriguing to see if such a pathway is shaping also 
the lipid-specific mast cell presentation capacity that we observe here. Overall, it is 
interesting to investigate the means through which mast cells take up antigens from 
their surrounding atherosclerotic environment since, to our knowledge, mast cells are 
not capable of ingesting lipid proteins through the classic scavenger receptors such as 
those that mediate macrophage foam cell formation. 
The way by which mast cells are activated within the atherosclerotic tissue has 
not yet been fully deciphered. While the classical FcεR-pathway is the most plausible 
manner, it is known that oxLDL can activate human mast cells in a Toll-like receptor 
(TLR)4-dependent mode46. This is of importance considering that TLR4 signaling on 
APCs enhances antigen presentation47. In line with the above, CD63 is an activation 
marker linked to the FcεR-mediated degranulation35. Notably, this study is the first to use 
flow cytometry as a method to detect human mast cells within atherosclerotic plaques. 
While we saw that intraplaque mast cells express high levels of CD63, their expression 
was negatively correlated to the HLA-DR expressing population. Even though this 
does not indicate a causal relationship, it seems that mast cells that are engaged with 
the presentation of antigens are not at that current moment activated. Furthermore, 
HLA-DR expression by human mast cells has also been previously reported in human 
tonsils22, a common centre of inflammation in the body. Importantly, a very recent study 
investigating the presentation capacity of human skin mast cells provides additional 
evidence that these cells express HLA-DM in an IFNγ-specific manner and directly 
present antigens to CD4+ T cells further shaping thus not only the TH1 response48, but 
also prompting T cells to act back on the mast cells. Likewise, we saw that CD4+ T cells 
act on the mast cell MHC-II expression in a positive way. It therefore seems that T cells 
can in turn affect the mast cells in a manner that favors the induced antigen presentation 
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ability of the latter.
Lastly, it is worth to mention that in vitro examination of the mast cell antigen 
presentation capacity in different studies shows slight discrepancies. This diversity 
probably lies on the in vitro generation of mast cells from bone marrow progenitors 
and the stimuli used. It is however important to remember that mast cells are found 
only within tissues, whereupon they undergo the last step of differentiation according 
to local stimuli.  
In conclusion, this study showed that mast cells are capable of presenting 
antigens in a hypercholesterolemic manner and this effect is potently intensifying the 
proatherogenic TH1 cell type within atherosclerotic plaques. Importantly, mast cells 
seem capable of antigen presentation within human plaques, indicating that these 
cells can also shape the adaptive immune response apart from exacerbating the innate 
inflammatory pathways. Further research on how to modulate this interaction may 
induce novel ways to limit atherosclerosis development.
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Supplementary Information
Supplemental Figure 1: Experimental set-up for the in vivo experiments. Time-course 
experiment using LDLr-/- mice fed 4 to 8 weeks Western-type diet or chow diet fed mice 
to compare their peritoneal mast cell populations (A). Eα-peptide presentation experiment 
performed on LDLr-/- mice fed a WTD for 4 weeks. Eα-peptide or sterile PBS was injected 24 
hours prior sacrifice, in order to analyze the presentation capacity of peritoneal mast cells 
(B). Analysis of the aortic CD4+ T cell content in mast cell deficient apoE-/- mice, as compared 
to their wild-type counterparts, upon WTD feeding (C).
Supplemental Figure 2: Gating strategies & controls of flow cytometry experiments. 
Representative ancestry gating of mouse peritoneal mast cells and human intraplaque mast 
cells discriminated for their singularity based on cell height (FSC-H) or width (FSC-W) and 
area (FSC-A) as well as size (FSC) and granularity (SSC). The cells were further separated 
from the dead population which stained positive for a viability marker (FVD) (A) and human 
cells were further stained for the pan-leukocyte marker (CD45) (B). Peritoneal mast cell 
population did not show any CD11c expression in comparison to peritoneal myeloid cells 
(C). Isotype control for MHC-II antibody clone (I-A/I-E) and HLA-DR antibody clone used 
in flow cytometry experiments (D and E). Eα-peptide expression on Eα-injected mice as 
compared to their PBS counterparts (F).
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Supplemental Figure 3: Mast cells increase 
in numbers inside the para-aortic draining 
lymph nodes of LDLr-/- upon 4 weeks of 
Western-type diet. Representative pictures of 
para-aortic lymph nodes of LDLr-/- mice stained 
with Naphthol-chloroacetate esterase for mast 
cells (red) and with αCD3+ for T cells (brown) (A). 
The mast cell numbers were found increased in 
the para-aortic lymph nodes of LDLr-/- mice upon 
4 weeks of WTD (B). The T cell numbers within 
the para-aortic lymph nodes of LDLr-/- were not 
altered upon 4 weeks of WTD as compared to 
control chow diet (C). All values (n=3/grp) are 
depicted as mean±SEM.
Supplemental Figure 4: Cytokine mediated induction of MHC-II on the mast cell 
surface: Bone marrow mast cells express MHC-II only upon induction by cytokines IL-4 
(10ng/ml) and IFNγ (20ng/ml) (A). WTD serum isolated by LDLr-/- mice after being fed a 
WTD for 4 weeks contains a combination of both IFNγ and IL-4 cytokines as compared to 
chow serum (B and C). Bone marrow derived mast cells repeatedly incubated with fluid 
isolated from the PC-cavity of mice under 4 weeks of WTD increase their MHC-II expression 
as compared to chow PC-fluid (D). IFNγ and IL-4 cytokines are present in the peritoneal 
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Abstract 
The development of atherosclerosis is tightly regulated by the 
innate and adaptive immune system. Communication between these 
two compartments occurs, among others, also through lipid-antigen 
presentation by CD1d, a protein found on antigen presenting cells, to 
the NKT cell population. Recent evidence states that also mast cells 
express CD1d and directly communicate with NKT cells. However, no 
such relationship has been reported in atherosclerosis. Here, we aimed 
to elucidate the CD1d-mediated interaction between mast cells and NKT 
cells upon atherosclerosis progression in vivo. We adoptively transferred 
CD1d-/- or control mast cells to mast cell deficient apoE-/-/KitW-sh/W-sh mice 
and subsequently placed these animals on a Western-type diet for 10 
weeks. In the course of the study, CD1d-/- mast cell restoration resulted 
in a mild increase in total serum cholesterol levels. At the endpoint, the 
aortic root of the CD1d-/- mast cell reconstituted mice showed increased 
plaque size with less collagen deposition and more intimal CD4+ T cells, 
as compared to control mice. The T cell population in the spleen and 
circulation had higher T-bet expression and elevated pro-inflammatory 
cytokine production inside the aortic arch, in the form of IFNγ, TNFα 
and IL-17. This study is the first to illustrate that disruption of the CD1d 
communication pathway between mast cells and NKT cells aggravates 
atherosclerosis through a shift towards inflammatory T cell responses. 
This newly found ability of mast cell action during plaque progression 
sheds new light on their role in atherosclerosis.
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1. Introduction
The accumulation and modification of lipids within large arteries is the 
essential step for the onset of atherosclerosis1. Yet, it is the activation of the innate 
and adaptive immune system that establishes the disease development, in the form of 
macrophage foam cells taking up these modified lipids and forming an atherosclerotic 
plaque2. Along with foam cell formation, macrophages process and present digested 
lipoprotein antigens to various T cell populations, through their MHC-machinery3. 
However, lipid fragments can also be presented through an MHC-I like protein named 
CD1d4. Presentation through CD1d is designed to specifically target and activate NKT 
cells, an adaptive cell population with unique T cell receptor (TCR) chains, tailored for 
endogenous and exogenous lipids5. In addition, these cells carry various markers of 
the innate NK cell population, therefore being the bridge between innate and adaptive 
immunity. Upon activation, NKT cells secrete vast amounts of TH1 and TH2 cytokines, such 
as IFNγ, TNFα or IL-4 and IL-13, respectively, depending on the quality and prevalence 
of their activating ligand6,7. Furthermore, their activation can be differentially shaped by 
co-stimulatory molecules, such as CD40L8 and OX409. However, it can also be cytokine-
induced, independently of CD1d mediation10,11. NKT cells reside at high numbers in the 
liver12, but have also been reported inside the atherosclerotic plaques of experimental 
models13 and human atheromata14, where they are thought to act in a proatherogenic 
manner15. NKT cells appear crucial mostly in the initial phase of the disease where they 
exacerbate plaque progression13, until the adaptive response develops, whereupon 
primarily IFNγ producing CD4+ TH1 cells16 take over. However, NKT cells have also 
been described to influence advanced atherosclerosis, mainly by inducing plaque 
destabilization and necrotic core formation17.  Previous studies have established that 
NKT cell activation through its most potent known activator, α-galactosylceramide 
(α-GalCer), increases atherosclerotic plaque progression in apoE-/- mice17,18, whereas 
CD1d deficiency impairs neointima formation19. In addition, CD1d protein expression 
was elevated inside human atherosclerotic tissues in comparison to normal intima20 
and its role has been further confirmed in CD1d-/-LDLr-/- mice, which upon high fat diet 
develop smaller plaques17. In fact, CD1d-/- mice completely lack NKT cells, indicating how 
essential CD1d molecules are for the thymic development of the NKT cell population21. 
NKT cells undergo maturation in the thymus and upon reaching stage 2, can migrate to 
the periphery22. Subsequently, these cells, whether in the periphery or in the thymus, 
may advance to stage 3 after glycolipid presentation through CD1d23. 
CD1d is expressed in various immune cells aside from macrophages. Professional 
antigen presenting cells such as dendritic cells and B cells are known activators of 
NKT cells through this receptor24,25. CD1d has also been reported to appear on the 
membrane of non-antigen presenting cell populations, such as the mast cells26. A recent 
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study suggested that CD1d expression on peritoneal mast cells can lead to NKT cell 
proliferation and cytokine release in vitro27. An indication of how this interaction may 
shape the immune response in vivo is given in allergic asthma where the CD1d-mediated 
action of mast cells on NKT cells aggravates airway inflammation by leading to more IgE 
production26, a pathway known to trigger mast cell activation28. Mast cells are classical 
pro-inflammatory intermediaries in atherosclerosis29, detected at an activated state 
inside atherosclerotic plaques30. Under the influence of modified lipids, mast cells 
secrete cytokines exacerbating disease progression31, a characteristic that they share 
with  NKT cells. 
However, no direct interaction between these two cell types has been described 
in atherosclerosis before. Therefore, we aimed to examine whether an established 
communication, mediated by CD1d,  between mast cells and NKT cells would affect 
disease progression in vivo. We adoptively transferred CD1d-/- or control mast cells 
into mast cell deficient apoE-/-/KitW-sh/W-sh mice and examined the progression of 
atherosclerosis in hyperlipidemic conditions.
2. Materials & Methods
2.1 Cell culture
Bone marrow isolated from female control LDLr-/- or from CD1d-/-/LDLr-/- mice was cultured 
for 4 weeks at 37oC and 5% CO2, in RPMI 1640 medium containing 25mM HEPES (Lonza) 
supplemented with 10% fetal calf serum (FCS), 60μM β-mercaptoethanol (Sigma), 100U/mL 
mix of penicillin/streptomycin (PAA), 1% non-essential amino-acids (NEAA; Gibco), 1% sodium 
pyruvate (Sigma) and 2% L-glutamine (Lonza) in the presence of cytokine IL-3 (5 ng/mL; 
Immunotools), to obtain mature mast cells. CD1d expression and mast cell purity, based on the 
expression of FcεRIα and CD117, were assessed at the adoptive transfer point (Supplementary 
Figures 1A,B).
2.2 Animals
All animal handling was executed in conformation with the guidelines of Directive 
2010/63EU, as stated by the European Parliament and the experimental line was approved by 
the Leiden University Animal Ethics committee. Mice were bred and housed in the local facility 
with water and food supply ad libitum.
2.3 Atherosclerosis
Atherosclerosis-prone, mast cell deficient female apoE-/-/KitW-sh/W-sh mice with an average 
age of 15 weeks (n=10/grp) were adoptively transferred i.v. with 10*106 fully maturated 
bone marrow derived mast cells, isolated from either LDLr-/- or CD1d-/-LDLr-/- mice, hereafter 
referred to as control or CD1d-/- mast cells, respectively. After 4 weeks, mice were placed on a 
Western-Type diet (WTD) containing 0.25% cholesterol and 15% cocoa butter (SDS, Essex, UK) 
for a period of 10 weeks. The experimental set-up is described in Supplementary Figure 1C. 
During the study, tail blood was collected through the tail-vein, and serum was obtained upon 
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centrifugation at 8.000 rpm for 10 minutes. Total cholesterol levels were assessed for weeks 0, 
3, 6 and 9 of the experiment, using an enzymatic colorimetric assay and compared to an internal 
Precipath control (Roche Diagnostics). Serum collected at the experimental endpoint was used 
for lipoprotein fraction separation (n=9 mice/grp). Samples were separated through a Superose 
6 column (Smart Systems, Pharmacia) and the retrieved fractions were subsequently analysed 
for cholesterol levels. At the experimental end-point all animals were subcutaneous anesthetized 
with a mix of ketamine (40mg/mL), sedazine (6.25mg/mL) and atropine (0.05mg/mL).
2.4 Immunohistochemistry
The hearts of all mice were dissected below the atria and freshly frozen in OCT compound 
(Sakura). Hearts were sectioned, horizontally and towards the aortic arch. Upon identification 
of the trivalve leaflets of the aortic root, 10μm sections were collected. Mean plaque size was 
calculated for 7-8 sequential sections using an Oil-Red-O (ORO) staining (Sigma Aldrich). 
Macrophage content was assessed upon staining with a MOMA-2 antibody (1:1000, rat IgG2b, 
Serotec Ltd.). Intraplaque collagen was quantified using a Masson’s Trichrome staining kit 
(Sigma Aldrich). The CD4+ (1:90, clone RM4-5, BD Biosciences) and CD8+ (1:100, clone Ly-2, BD 
Biosciences) T cell content in the aortic root was manually quantified. All morphometric analyses 
were performed in a blinded independent fashion on a Leica DM-RE microscope using a Leica 
QWin software (Leica Imaging Systems, UK).
2.5 Aortic arch cytokine stimulation
Aortic arches were digested in a mix of collagenase I (450u/mL; Sigma) and XI (250U/
mL Sigma) and DNase (120U/mL; Sigma) and hyaluronidase (120 U/mL; Sigma). Single cells 
were obtained with a 70μm cell strainer. Subsequently cells were stimulated with a mix of 
PMA/Ionomycin (Sigma) in the presence of Brefeldin A (eBioscience) for 30 minutes. Cytokine 
production was measured using flow cytometry, after cell fixation and permeabilization (BD 
Bioscience).
2.6 Flow Cytometry
All blood and spleen samples were lysed with an erythrocyte lysis buffer (0.1mM EDTA, 
10mM NaHCO3, 1mM NH4Cl, pH=7.2) to obtain white blood cells. Spleen and thymus samples 
were processed through a 70μm cell strainer for single cell selection. Single white blood (WB), 
thymus and spleen cells were stained with a viability dye solution as well as fluorescently labeled 
antibodies for extracellular proteins or permeabilized (Ebioscience) and subsequently stained 
with intracellular antibodies for transcription factor and cytokine determination (Supplementary 
Table 1). Measurements were performed on a FACS Canto II (Becton Dickinson, Mountain View, 
CA) and analysed using FlowJo software.
2.7 Statistics
All data are depicted as mean±SEM and analysed in GraphPad Prism 7. A 2-tailed Student 
t-test was used to compare between groups. Data were tested for normal distribution and Non-
Gaussian distributed values were compared with a Mann-Whitney U test. Probability P<0.05 was 
considered significant.
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3. Results
3.1 NKT cell levels are elevated upon CD1d-/- mast cell reconstitution
In this project, we aimed to examine the CD1d-mediated interaction between 
mast cells and NKT cells in atherosclerosis. We adoptively transferred CD1d-/- or control 
mast cells into mast cell deficient mice and subsequently fed both groups a WTD for 
10 weeks. Upon 3 weeks of WTD, circulating CD1d-tetramer+ NKT cell levels were 
elevated in the CD1d-/- mast cell reconstituted group as compared to the control mast 
cell group (Figure 1A., w3: CD1d-/-: 3.04±0.5% vs control: 1.77±0.2%, P=0.0006). 
However, no difference was detected in the activated CD69+ circulating NKT cells 
(Figure 1B). At the experimental end-point the NKT cell population in the thymus was 
found increased upon CD1d-/- mast cell reconstitution, as compared to control mast 
cells (Figure 1C, CD1d-/-: 0.65±0.05% vs control: 0.48±0.04%, P=0.014). Among the 
thymic NKT cells, particularly stage 2 CD24-CD44+NK1.1- migrating NKT cells appeared 
elevated (Figure 1D, CD1d-/-: 69.9±3.2% vs control: 59.2±2.8%, P=0.024) while stage 
3, CD24-CD44+NK1.1+ NKT cells were slightly reduced in the CD1d-/- mast cell group, 
in comparison to control (Figure 1E, P=0.075). The liver NKT cell population did not 
differ between the groups (Figure 1F). However, the NKT cells of the CD1d-/- mast 
cell group were significantly less activated as compared to the control mast cell group 
(Figure 1G, CD1d-/-: 55.9±1.8% vs control: 63.5±2.3%, P=0.018). It is worth noting that 
at the experimental endpoint we were able to detect a similar level of mast cells inside 
the peritoneal cavity in both groups of mice (Supplementary Figure 2A), whereas the 
CD40L levels on the NKT population of CD1d-/- reconstituted mice was found reduced 
as compared to control (Supplementary Figure 2B). The above findings indicate that 
lack of CD1d expression by the mast cells results in the migration of more stage 2 NKT 
cells from the thymus to the periphery, yet, in the liver these cells do not appear to get 
activated. 
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Figure 1: NKT cell levels are elevated but cells appear less active upon reconstitution 
of mast cell deficient mice with CD1d-/- mast cells. (A) Circulating levels of NKT cells 
increased at 3 weeks of WTD in the CD1d-/- reconstituted mice as compared to control. 
(B) No difference was detected on the NKT cell activation in the blood over time, between 
the groups. (C) Total thymic NKT cells as well as (D) migrating stage 2 NKT cells of mice 
carrying CD1d-/- mast cells were elevated, in comparison to NKT cells in mice reconstituted 
with control mast cells. (E) CD1d-dependent stage 3 NKT cells in the thymus, were slightly 
reduced in CD1d-/- reconstituted mice, as compared to control. (F) No difference in the total 
NKT cell populations of the liver between the two groups. (G) The NKT cells in the liver of 
CD1d-/- reconstituted mice showed decreased activation as compared to control mice. All 
values are depicted as mean±SEM. *P<0.05, ***P<0.001
3.2 Serum cholesterol levels are elevated in the CD1d-/- mast cell reconstituted 
mice
In the course of the experiment, we analysed the total cholesterol levels in the 
serum of both groups of mice. We observed that after 3 weeks of WTD, total cholesterol 
was elevated in the circulation of CD1d-/- mast cell reconstituted mice, as compared to 
control mast cell repopulated mice (Figure 2A, w3: CD1d-/-: 1258±74 mg/dL vs control: 
1066±46 mg/dL, P=0.02). At the experimental endpoint, we further examined the 
lipoprotein fractions carried in the circulating cholesterol levels. We did not observe 
any difference among the (V)LDL and HDL fractions between the groups (Figure 2B). 
Figure 2: Cholesterol levels in the 
circulation show a mild increase in CD1d-
/- mice at week 3. (A) Total cholesterol 
levels in the serum of CD1d-/- mast cell 
reconstituted mice showed a slight increase 
over time of WTD, as compared to control 
mast cell reconstituted mice. (B) No 
difference was observed in the lipoprotein 
fractions between the two groups of mice. 
*P<0.05 
3.3 CD1d-disruption on the mast cells increases atherosclerotic plaque size in 
the aortic root
After 10 weeks of WTD, the aortic root was analysed to determine atherosclerotic 
plaque size and morphology. Specifically, the atherosclerotic plaque size was analysed 
using an ORO staining (Figure 3A), the macrophage content in the area was detected 
using a MOMA-2 staining (Figure 3B) while the collagen composition of the plaque 
was established using a Masson’s trichrome staining (Figure 3C). The atherosclerotic 
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plaque of the aortic root in CD1d-/- mast cell reconstituted mice was increased by 15% as 
compared to the plaque size of control mast cell reconstituted mice (Figure 3D, CD1d-
/-: 95*104±3.7*104 μm2 vs control: 83*104±3.8*104 μm2, P=0.033). Of note, the plaque 
development was elevated across the entire aortic root of the heart, measured from the 
start of the three-valve area up to the receding of the valves (Supplementary Figure 
3A). Furthermore, the macrophage deposition in the plaque area of these mice was 
slightly elevated (Figure 3E, CD1d-/-: 37*104±1.4*104 μm2 vs control: 32*104±2.5*104 
μm2, P=0.066). In contrast, the plaques of the CD1d-/- mast cell reconstituted group 
showed reduced collagen content, as compared to control (Figure 3F, CD1d-/-: 55.7±2% 
vs control: 61.1±1%, P=0.038).
Figure 3: Mice reconstituted with CD1d-/- mast cells develop increased atherosclerosis 
in the aortic root, as compared to mice reconstituted with control mast cells. 
Representative pictures per group of mice for (A) ORO staining, (B) MOMA-2 staining and 
(C) Masson’s trichrome staining (n=9/grp). The aortic root of mice reconstituted with CD1d-
/- mast cells show (D) higher atherosclerotic plaques, (E) higher macrophage area and (F) 
lower collagen deposition, as compared to mice reconstituted with control mast cells. All 
values are depicted as mean±SEM. *P<0.05 
3.4 T cells within the atherosclerotic site produce pro-inflammatory cytokines 
Upon further characterization of the aortic root area, we manually quantified the 
CD4+ and CD8+ T cell content. The number of CD4+ T cells in the CD1d-/- mast cell mice 
showed a slight increase as compared to control (Figure 4A, CD1d-/-: 14.9±4.2 cells/μm2 
vs control: 5.6±1.3 cells/μm2, P=0.060). No difference was observed in the intimal CD8+ 
T cells between the groups (Figure 4B). In addition, we analysed, using flow cytometry, 
the T cell content –as defined by Thy1.2+ expression- in the aortic arch of these mice. The 
CD1d-/- mast cell bearing mice showed a mild reduction in the percentage of T cells in 
the area, in relation to control mice (Figure 4C, P=0.060). This was mainly attributed to 
a slight reduction in the CD8+ T cell percentage (Supplementary Figure 3B). Therefore, 
the total T cell population present in the aortic arch of CD1d-/- mast cell reconstituted 
mice is characterized mainly by CD4+ T cells (Figure 4D, CD1d-/-: 32.2±2.8% vs control: 
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24.6±2.1%, P=0.041). Importantly, the T cells present in the aortic arch of these mice 
showed a substantial increase in pro-inflammatory cytokine production. Specifically, 
the aortic T cells of the CD1d-/- reconstituted group presented a significant increase in 
the production of cytokines IFNγ (Figure 4E, P=0.012), IL-17 (Figure 4F, P=0.025) and 
TNFα (P=0.0016) as opposed to the control group.
Figure 4: CD4+ T cells are increased inside atherosclerotic sites of CD1d-/- mast cell 
reconstituted mice and produce higher amounts of pro-inflammatory cytokines. (A) 
CD4+ T cells in the plaque intima of the aortic root appeared increased upon CD1d-/- mast cell 
reconstitution, as compared to control. (B) No difference was observed in the intimal CD8+ 
T cell numbers between the groups. (C) Aortic T cells appear reduced in the aorta of the 
CD1d-/- reconstituted group as compared to control reconstituted mice. (D) The CD4+ T cell 
levels of the total T cell population are elevated in the CD1d-/- mast cell group as compared 
to control. (E) IFNγ-producing, (F) IL-17-producing and (G) TNFα-producing T cells in the 
aorta of CD1d-/-reconstituted mice are increased, in comparison to control mice. All values 
are depicted as mean±SEM. *P<0.05, **P<0.01
3.5 T-bet expression is higher in the CD4+ and CD8+ T cell populations
Having in mind the close relation between NKT and TH1 cells, and upon observing 
the T cell responses in the atherosclerotic tissue, we aimed to analyse the systemic 
T cell response. We examined circulating and splenic T cells for the expression of 
transcription factor T-bet, which controls the secretion of pro-inflammatory cytokine 
IFNγ and CD4 TH1 cells 32. In the blood of the CD1d-/- mast cell reconstituted mice we 
detected a substantial increase in T-bet expressing CD8+ T cells, as compared to control 
(Figure 5A, CD1d-/-: 8.2±0.9% vs control: 4.7±0.5%, P=0.004). Furthermore, while 
there was no difference in the percentage of TH1 cells (Figure 5B), the T-bet expression 
levels of the total CD4+ T cell population were elevated in the CD1d-/- mast cell group 
in relation to control (Figure 5C, P=0.034). On the same line, T-bet expressing CD8+ 
T cells were mildly elevated in the spleen of the CD1d-/- group (Figure 5D, P=0.077). 
The CD1d-/- mast cell carrying mice showed higher TH1 levels in their spleen, in relation 
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to the control group (Figure 5E, P=0.010). No difference was detected between the 
groups in the levels of T-bet expression within the entire CD4+ T cell population of the 
spleen (Figure 5F). Of note, both groups showed a similar percentage of total CD8+ 
and CD4+ T cells in the blood (Supplemental Figure 3C,D) and spleen (Supplemental 
Figure 3E,F).
Figure 5: T-bet expression is increased in the circulating and splenic T cells of CD1d-
/- mast cell reconstituted mice. (A) The percentage of T-bet expressing CD8+ T cells in the 
blood was elevated upon CD1d-/- mast cell reconstitution as compared to control mast cell 
reconstitution (n=9/grp). (B) No difference was observed in the circulating CD4+ TH1 cells 
between the groups; however (C) T-bet expressing CD4+ T cells were elevated in the blood 
of CD1d-/- reconstituted mice as compared to control reconstituted mice. (D) Splenic T-bet 
expressing CD8+ T cells (n=9/grp) as well as (E) CD4+ TH1 cells are elevated in the spleen of 
CD1d-/- reconstituted mice in comparison to control reconstitution. (F) No difference was 
detected in the T-bet expression levels of the total CD4+ T cell population between the two 
groups. All values are depicted as mean±SEM. *P<0.05, **P<0.01
4. Discussion
In this study, we examined the CD1d-mediated effect of mast cells on NKT cells 
during atherosclerosis progression. We discovered that disruption of this axis aggravates 
atherosclerotic plaque development and destabilization through increased infiltration 
of CD4+ T cells in the plaque intima. The T cell population in the plaques of mice which 
lacked CD1d-expressing mast cells showed high pro-inflammatory cytokine production, 
in the form of IFNγ, TNFα and IL-17. This may have caused the increased macrophage 
accumulation in the plaque. Furthermore, after 3 weeks of WTD, these animals showed 
a slight increase in serum cholesterol levels, and although temporary, it might have 
contributed to the observed plaque progression. The above results suggest that mast 
cell CD1d expression, influences the function of NKT cells and the subsequent control of 
CD4+ T cell infiltration in a protective manner, which is previously unreported.
Early through WTD, following the adoptive transfer of CD1d-/- mast cells, we 
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detected an increase in the circulating levels of NKT cells. This increase was also 
apparent in the thymus of CD1d-/- mast cell reconstituted mice and could be explained 
by the elevated stage 2 NKT cells. As mentioned, thymic NKT cells of this stage migrate 
into peripheral tissues33, which may thus explain their enhanced abundance in the 
circulation. However, while stage 2 are migrators and potent cytokine secretors, 
transition to stage 3 requires glycolipid presentation through CD1d34. Interestingly, 
we observed a reduction in the stage 3 thymic population of NKT cells, indicating that 
signal through CD1d is partially absent in the CD1d-/- mast cell reconstituted mice, as 
it was expected. This is implied also by the reduced activation and co-stimulation of 
the NKT population in the liver. These data suggest that the proatherogenic phenotype 
observed does not arise from a possible positive feedback signaling of other CD1d-
expressing cells on the NKT population. It rather seems that NKT cells, generated in the 
thymus progress to stage 2 and migrate to the periphery at higher frequencies, perhaps 
to counteract for the absence in the CD1d signaling cascade initiated by the mast cells.
As stated before, NKT cells can potently activate T cells35 and, in atherosclerosis, 
NKT cells are suggested to act prior to and pave the way for T cell infiltration in the 
plaque. In contrast to the existing concept on the proatherogenic role of NKT cells in 
atherosclerosis, and despite the reduced NKT cell activation, in this study we observed 
increased CD4+ T cells within the plaque intima of the aortic root and an elevated cytokine 
production mainly by CD4+ T cells of the aortic arch. While this seems surprising, 
particularly since CD1d signaling is known to induce a proatherogenic response on the 
NKT cells18, a previously published study demonstrated that NKT cells in mice fed a 
high-fat diet, control TH1 cell responses specifically via a reduced IFNγ secretion in the 
serum upon α-GalCer injection36. Other reports have also stated that CD1d-mediated 
effects on the NKT cells can subsequently control TH1 cells. For example, in arthritis 
an autoimmune condition characterized by the presence of mast cells, loss of CD1d-
mediated NKT activation exacerbated the TH1 responses, again in an IFNγ mediated 
manner37. In our study the pro-inflammatory IFNγ production of both the CD4+ and 
CD8+ T cell subsets seemed to be under the control of transcription factor T-bet, which 
showed elevated expression in T cells of both the spleen and the circulation. T-bet 
directly induces the production of IFNγ38, whereas ΤΗ1 cells can also secrete TNFα39. In 
addition, NKT cells have been previously reported to inhibit TH17 cell differentiation40, 
the main CD4+ T cell subset secreting cytokine IL-1741 that increases in proatherogenic 
conditions42. Therefore, it seems that loss of CD1d expression by the mast cells, and 
subsequent partial loss of NKT cell activation, led to an increase in TH1 cells, which in 
turn augmented atherosclerotic plaque progression. Hence, there is a tight balance 
between NKT and TH1 cells with mast cells playing a fundamental role in it. 
The increase in pro-inflammatory CD4+ T cells observed within the atherosclerotic 
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plaques of CD1d-/- mast cell reconstituted mice may have influenced the collagen 
deposition in the area. Specifically, the atherosclerotic plaques of these mice contained 
less collagen, signifying reduced plaque stability43. Cytokine IFNγ, has been accounted for 
its destabilizing manner43,44. Pro-inflammatory cytokine secretion by T cells could also 
explain the enhanced macrophage infiltration observed in the plaque, particularly since 
these cells inflict damage on the endothelium45 and induce macrophage accumulation in 
the area46. Macrophages in turn produce a vast array of matrix metalloproteinases and 
are greatly implicated in plaque destabilization47. Therefore the increased macrophage 
content may have contributed to the destabilizing phenotype observed. It is also 
important to mention that the slight increase detected in circulating cholesterol levels 
may have contributed to the enhanced plaque development. 
Up to date there are limited reports on the CD1d mediated action of mast cells 
on NKT cells. Mast cells on their own are potent cytokine secretors in organs where 
NKT cells reside, such as the thymus48, the atherosclerotic plaque29 and the liver49. 
Mast cell activation results in the release of proteases and cytokines, with IFNγ and 
TNFα considered among the typical cytokines excreted in their microenvironment. 
Furthermore, CD1d expression on the mast cell surface has been associated with 
mast cell activation via their classical receptor, FcεR26. Therefore, CD1d on the mast 
cell surface could also partly affect the activation of mast cells and, through that, the 
local response inside the plaque. The above study examining the function of mast cells 
and NKT cells, indicated that mast cells express also the costimulatory protein CD40; 
albeit not in a manner that influenced the NKT cell response in their experimental 
setup. Our results however showed that CD1d-/- mast cells seem to negatively affect the 
CD40L expression on liver NKT cells, thus supporting this mode of action. Additional 
co-stimulatory pathways may also participate in the observed mast cell-NKT cell 
interaction since ox40L and CD48 expression on the mast cells are reported to regulate 
cytokine secretion by NKT cells27 . 
To conclude, here we describe for the first time an in vivo interaction through 
mast cell-CD1d and NKT cells in atherosclerosis. This relationship seems to be 
protective, since its interruption increases atherosclerotic plaques, showing a highly 
pro-inflammatory CD4+ T cell content. A reduction in the mast cell-mediated CD1d 
activation of the NKT cells may therefore result in a compensatory operation of their 
close relatives, the T cells. While we have no further evidence of the exact lipid antigen 
presented by mast cell-CD1d to NKT cells, or why disruption of a classical proatherogenic 
pathway would enhance instead of hamper atherosclerosis, it is important to remember 
that NKT cells are also involved in many tolerogenic responses with presentation of 
endogenous lipids as to control autoimmune reactions50. Additionally, in the past it was 
shown that activation of NKT cells protects against autoimmune conditions, such as 
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diabetes51 or arthritis52. In atherosclerosis, mast cells via the expression of CD1d and 
subsequent lipid presentation, appear to be fine-tuning the NKT cell actions, leading 
thus to a newly described mechanism of action in this disease.
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Supplementary Information
Supplemental Figure 1: Experimental set-up and controls. (A) Flow cytometry purity 
check, 1 day prior to mast cell reconstitution. (B) Isotype controls for CD117, FcεRIα and 
CD1d expression on the transferred BMMCs. (C) Mast cell deficient apoE/KitW-sh/W-sh mice 
were adoptively transferred through i.v. injections with 10*106 mature bone marrow derived 
mast cells of either CD1d-/- mice or control control mice. After a 4 week-recovery period, the 
mice were placed on a WTD for an additional 10 weeks. 
Antibody Clone Concentration Fluorochrome Company
Fixable Viability 
Dye - 0.05 μg/sample eFluor 780 eBioscience
FcεRIα MAR-1 0.1 μg/sample PercP Cy5.5 Biolegend
FcεRIα MAR-1 0.1 μg/sample APC eBioscience
CD117 2B8 0.1 μg/sample APC/PE Cy7 eBioscience
CD1d 1B1 0.1 μg/sample PE eBioscience
CD1d-tetramer - 0.125 μg/sample BV 420 -
CD69 H1.2F3 0.1 μg/sample PE eBioscience
CD24 M1/69 0.1 μg/sample PercP Cy5.5 BD Biosciences
CD44 IM7 0.1 μg/sample PE Cy7 eBioscience
NK1.1 PK136 0.1 μg/sample FITC eBioscience
CD40L MR1 0.1 μg/sample APC eBioscience
CD4 GK1.5 0.1 μg/sample FITC/eFluor 450 eBioscience
CD8a 53-6.7 0.1 μg/sample PercP BD Biosciences
CD8a 53-6.7 0.1 μg/sample APC eBioscience
Thy1.2 53-2.1 0.1 μg/sample PE Cy7 eBioscience
IFNγ XMG1.2 0.3 μg/sample BV650 BD Biosciences
IL-17 eBio17B7 0.3 μg/sample Alexa Fluor 488 eBioscience
TNFα MP6-XT22 0.3 μg/sample PE eBioscience
T-bet eBio4B10 0.3 μg/sample Alexa Fluor 660 eBioscience
Supplementary Table 1. Flow cytometry antibodies: List of extracellular and intracellular 
antibodies
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Supplemental Figure 2: Mast cells are detected in the peritoneum of mast cell deficient 
apoE-/-/KitW-sh/W-sh mice in both groups at the experimental endpoint. (A) Mast cell levels 
in the peritoneum of apoE-/-/KitW-sh/W-sh mice reconstituted with either control or CD1d-/- 
BMMCs show no difference between the two groups. (B) The percentage of liver NKT cells that 
express the costimulatory molecule CD40L is decreased upon CD1d-/- BMMC reconstitution, 
as compared to control BMMC reconstitution. All values are depicted as mean±SEM. *P<0.05 
Supplemental Figure 3: Atherosclerotic plaques in the heart of the CD1d-/- 
reconstituted mice develop at a higher rate across the aortic root area. (A) CD1d-/- mast 
cell reconstitution results in increased atherosclerosis development through the aortic root, 
as compared to reconstitution of mice with control mast cells (n=9/grp). (B) The CD8+ T 
cell content in the aortas of CD1d-/- reconstituted mice is slightly reduced in comparison to 
control mice. No difference was detected in the total (C) circulating CD8+ (D) splenic CD8+ or 
(E) circulating CD4+ T cell levels and (F) spleen CD4+ T cells between the two groups of mice. 
All values are depicted as mean±SEM. *P<0.05
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Abstract
Human mast cells have previously been associated with adverse 
cardiovascular events. Mast cell activation, through the classical antigen 
sensitized-IgE binding to their characteristic Fcε-receptor, causes the 
release of their cytoplasmic granules. These granules are filled with 
neutral proteases, such as chymase and tryptase, histamine and pro-
inflammatory mediators. Mast cells accumulate at high numbers within 
the human atherosclerotic tissue, particularly in the shoulder region of the 
plaque. However, their activation mechanisms, as well as their protease 
content, locally in the plaque, are still largely unclear. This is the first study 
to use flow cytometry for the analysis of the mast cell content in 22 human 
plaque samples, collected after femoral and carotid endarterectomy 
surgery. We observed that most intraplaque mast cells are activated, based 
on their CD63 protein expression. Furthermore, we detected that most of 
the activated mast cells had IgE fragments bound on their surface, while a 
fraction showed IgE-independent activation. Finally, we confirm previous 
reports stating that, while the majority of mast cells contain both chymase 
and tryptase, there is remarkable heterogeneity in the distribution of these 
proteases within the mast cell population per individual. In conclusion, 
this project establishes the strong relation between the presence of IgE 
and the activation of mast cells, which leads to the subsequent secretion 
of their protease content inside atherosclerotic plaques. Our data pave the 
way for potential therapeutic intervention through targeting IgE-mediated 
actions in human atherosclerosis.
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Report
Up to the present day, atherosclerosis, the main underlying pathology of acute 
cardiovascular syndromes like stroke or myocardial infarction, is the major cause of 
human mortality1. As in most pathological conditions, the response of the immune 
system is crucial in the advancement of atherosclerosis, with the mast cells being key 
mediators in this process2. Mast cells are innate immune cells, mainly characterized 
by their notorious granular load release, upon activation with antigen-sensitized 
IgE fragments in allergy3. Aside from allergic inflammation, mast cells have long 
been established to play an important pro-inflammatory role in the development of 
atherosclerosis, as detected by both experimental studies as well as in human subjects4. 
Mast cells reside at low numbers in normal arterial tissue, however they are found to 
accumulate in arteries where a lipid-rich atherosclerotic plaque is formed5. In fact, as 
human atherosclerosis progresses, mast cells become increasingly activated whereupon 
they excrete their granules in the surrounding tissue6. The degranulated material 
consists mainly of proinflammatory cytokines, histamine and neutral proteases, such as 
chymase and tryptase7. Mast cell activation is reported to augment plaque progression8, 
enhance plaque destabilization9 and increase the levels of intraplaque hemorrhage 
incidence10. Previous attempts to characterize mast cells and their protease content 
in human atheromata, by the means of immunohistochemistry, has revealed that they 
comprise a very heterogeneous population; the majority contain only tryptase, while 
a smaller but significant proportion contains chymase as well11. This heterogeneity is 
particularly interesting considering that diversity in the quality and quantity of the 
mast cell degranulating material may exert differential effects inside the atherosclerotic 
plaque. For example, while mast cell chymase seems to impede tissue repair after a 
myocardial infarction episode12, tryptase has been reported to participate in the 
healing process13. Furthermore, mast cells inside human plaques have been found to 
correlate with typical atherogenic immune populations like dendritic cells and T cells14. 
Importantly, in a human study of 270 patients, intraplaque mast cells emerge as the 
primary immune cell type to positively associate with future cardiovascular events15. 
Until this day, the means by which mast cells get activated inside the atherosclerotic 
plaque have not been elucidated in full detail. However, it is suggested that the 
classical IgE-sensitized pathway16,17 is involved up to a certain extent. Nevertheless, 
there is increasing evidence that additional atherosclerosis-specific mechanisms can 
trigger mast cell activation, independently of IgE-binding18,19 such as through TLRs20, 
complement21 or neuropeptide22 receptors. Thus far, the proportional effect of these 
distinct pathways involved in atherosclerosis, as well as the exact phenotype of mast 
cells inside human plaques, have not been clarified. 
In this technical report of an ongoing cohort study, we made use of the flow 
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cytometry method to phenotypically characterize human intraplaque mast cells. The 
atherosclerotic plaque material of 22 human subjects was collected post-operatively 
from carotid and femoral arteries. Specifically, anonymous individuals, for whom we 
did not receive any patient details, underwent endarterectomy surgery in a period 
between July and December 2016 at the Haaglanden Medical Center (HMC), Westeinde, 
The Hague, NL, after which the atherosclerotic plaque was collected. The handling of all 
human samples complied with the “Code for Proper Secondary Use of Human Tissue”. 
Human plaques were processed into single cell suspensions by a 2-hour digestion round 
at 37oC, with an enzyme mix consisting of collagenase IV (Gibco) and DNase (Sigma) 
as previously described23. Subsequently, the samples were filtered through a 70μm 
cell strainer to obtain single cells. The cells were further stained with extracellular 
antibodies containing a fluorescent label or fixated and permeabilized (BD Biosciences) 
for intracellular staining (Table 1). Fluorescently labeled samples were measured on 
a FACS Canto II (BD Biosciences) or Cytoflex (Beckman Coulter) and analyzed using 
FlowJo software. All data are depicted using GraphPad Prism 7. Values were tested 
for normalcy. Upon non-Gaussian distribution, an unpaired Mann Whitney U-test was 
performed. In the case of more than two groups a one way-ANOVA analysis was used. 
Differences lower than P<0.05 were considered statistically significant.
Antibody Fluorochrome Clone Concentration Company
Fixable Viability 
Dye eFluor 780 - 0.1μg/sample eBioscience
CD45 PB 2D1 0.25μg/sample eBioscience
FcεRIα APC/PE Cy7 AER-37 0.12 μg/sample eBioscience
CD117 PercP Cy5.5 104D2 0.1μg/sample eBioscience
CD63 PE H5C6 0.1μg/sample eBioscience
IgE PE Cy7/FITC Ige21 0.25μg/sample eBioscience
Chymase/CMA1 Alexa Fluor 647 - 0.1μg/sample Bioss Antibodies
Tryptase/TPSAB1 PE - 0.1μg/sample LSBio 
Table 1: List of extracellular and intracellular antibodies used.
In Figure 1A we demonstrate the gating strategy that we followed to detect 
human intraplaque mast cells. Specifically, we pre-selected all cells from the debris 
present in the human plaques, based on their size (FSC) and granularity (SSC). Of these, 
single cells were further separated according to their width (FSC-W) and area (FSC-A). 
In addition, viability was detected according to the negative binding of a fluorescent 
viability dye (FVD-). Viable white blood cells were separated based on the expression of 
the panleukocyte marker CD45. Of these cells, we were able to detect the population of 
intraplaque mast cells according to the high expression of their characteristic markers 
FcεRIα, the ligand for IgE24 and of CD117, the receptor for stem cell factor, a growth factor 
that is required for the end-stage maturation of mast cells25. Accordingly, we observed 
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that the percentage of mast cells, out of all leukocytes present inside atherosclerotic 
plaques, is 1.19±0.31% for carotid arteries (n=9) and 1.32±0.21% for femoral arteries 
(n=13) (Figure 1B). Of note, a number of leukocytes may be contained in the excluded 
debris material. Nonetheless we enumerated the viable cells after manual quantification 
using both Trypan Blue and in relation to the percentage of viable, CD45+ cells observed 
according to our gating strategy. We detected that carotid plaques consisted of a 
mean 12.386±4.961 mast cells while femoral plaques contained 94.273±37.420 mast 
cells. We were able to isolate more inflammatory cells from femoral as compared to 
carotid arteries, and thus we identified increased mast cell numbers in femoral plaques 
(P=0.081; Figure 1C). Indeed, femoral plaque samples overall tended to show higher 
total leukocyte content as compared to carotid plaques (carotid: 12*105±4.7*105 
leukocytes vs femoral:76*105±27*105 leukocytes, P=0.081; Figure 1D).
Figure 1: Mast cell content in human plaques. (A) Human mast cell gating strategy 
using flow cytometry. Human intraplaque cells were selected based on their size and area. 
Viable cells were further separated according to the negative incorporation of fluorescent 
viability dye (FVD-). Immune cells were detected using the pan-leukocyte marker CD45+ 
and the human mast cell population was further classified using antibodies against their 
characteristic markers FcεRIα+ and CD117+. (B) Mast cell percentage inside human plaques 
isolated upon endarterectomy surgeries in carotid and femoral arteries. (C) Mast cell 
absolute numbers inside human carotid and femoral artery samples. The femoral arteries 
show a slight increase in mast cell content. (D) Femoral artery plaques show an increased 
number of white blood cells as compared to the carotid artery plaques, based on the 
expression of marker CD45. Percentages are depicted in a Tukey box plot. Cell numbers are 
depicted as mean±SEM; (n=10-12/grp).
 We proceeded to characterize the status of the detected human intraplaque cells. 
Specifically, we stained them for the levels of IgE bound on their surface and observed 
that inside carotid arteries: 7.779±3.419 intraplaque mast cells, or approximately 
63% of the total mast cell population, contained IgE, whereas in the femoral plaques 
6
77.493±35.927 mast cells, or 82% of all mast cells had IgE on their surface (P=0.058; 
Figure 2A). Because IgE binding usually implies mast cell degranulation, we also 
screened our cells for the expression of CD63, a lysosomal protein that fuses with the 
membrane upon release of cellular content and therefore marks mast cell activation26. 
We detected 6.998±3.530 CD63+ mast cells in carotid plaques, which indicates 
about 56% of these cells being in an activated state, while femoral plaques showed 
57.417±23.152 activated mast cells, at a total percentage of 61% (Figure 2B). We were 
particularly interested to determine the proportion of IgE mediated activation per 
patient. For that reason, we analyzed within each arterial plaque sample the population 
of mast cells that showed IgE bound and also expressed CD63 (IgE+CD63+), as opposed 
to only IgE-binding (IgE+CD63-) and only CD63 expression (IgE-CD63+) (Figure 2C). We 
discovered that 23.81±3.7% of all human plaque mast cells have IgE bound on their 
surface without being activated, whereas the majority of mast cells, with 40.01±3.9%, 
appeared to have IgE bound on their surface and had also undergone degranulation. 
Interestingly, a proportion of mast cells, namely 19.6±2.9%, appeared to be activated 
without showing any IgE-fragments bound on their surface, suggesting that this mast 
cell fraction had been activated via alternative mast cell activation pathways. The 
IgE-activated population was, however, significantly higher than the cells that were 
subjected to non-IgE mediated activation (P=0.0005), but also higher than the mast cell 
population that showed binding of IgE without being activated (P=0.0067).
Figure 2: Basic characterization of human intraplaque mast cells. (A) IgE-antigen 
bound mast cells within the atherosclerotic plaques of human carotid and femoral arteries. 
(B) Number of activated mast cells, as defined by marker CD63, inside carotid and femoral 
artery human plaques. (C) Percentage of IgE-bound, IgE-activated and non-IgE activated 
mast cells per artery sample (n=22). (D) Chymase-containing mast cell numbers in human 
carotid and femoral plaques.(E) Number of mast cells containing tryptase in human carotid 
and femoral arteries. (F) Chymase-only, chymase and tryptase-containing and, tryptase-
only mast cell percentages per artery sample (n=7). All values are depicted as mean±SEM. 
**P<0.01, ***P<0.001
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In a smaller sample of the same patients (n=7) we quantified the mast cell 
populations that contained chymase and tryptase. Regarding chymase expression, we 
detected 3.769±1.847 mast cells (30%) inside carotid plaques, and 86.805±28.025 
mast cells (92%) inside femoral plaques containing this protease (Figure 2D). On the 
other hand, 6.807±1.439 (54%) of carotid intraplaque mast cells, and 70.627±27.340 
(75%) of femoral intraplaque mast cells contained tryptase (Figure 2E). Aiming 
to assess the distribution of chymase and tryptase contents within the mast cell 
population of the same patients, we analyzed the mast cells consisting of only chymase 
(Chymase+Tryptase-) or only tryptase (Chymase-Tryptase+), as compared to the mast 
cells containing both proteases (Chymase+Tryptase+) (Figure 2F). We observed that 
the majority of mast cells, namely 42.0±14.4% were positive for both proteases, while 
27.7±13% contained only chymase and 16.4±12.5% only tryptase.
Overall, in this report we are the first to characterize intraplaque mast cells in 
human atherosclerosis. We provide evidence that the majority of mast cells present 
in arteries with advanced atherosclerosis are activated through IgE binding, while 
a smaller fraction can undergo non-IgE dependent activation. We also show that, as 
mentioned previously11, human intraplaque mast cells mainly contain both chymase 
and tryptase, while we detected smaller percentages of either chymase-only, or 
tryptase-only carrying mast cells; thus confirming the concept of high heterogeneity in 
the protease content of mast cells in atherosclerotic disease. 
Interestingly, while IgE levels in the circulation17 have been linked to an increased 
incidence of acute cardiovascular events and IgE fragments have been previously 
reported inside human atheromatic tissue16, up to now it was not clear to which 
extent this pathway affects the activation of mast cells in the area. Our data confirm 
that most mast cells present in atherosclerotic plaques are activated5,10, as it has been 
shown previously specifically for the shoulder region. Yet, what we show here is that 
the main activating mechanism is through classical antigen-sensitized IgE binding 
on their surface Fcε-receptors. Nonetheless, this does not seem to be the only way by 
which mast cells are activated in human atherosclerosis. It is still unclear what this 
implies in terms of mediator release. It would be interesting to further characterize 
the intracellular content of these cells to examine if different activation pathways lead 
to the release of different proteases and cytokines, and how this may possibly affect 
the surrounding environment. In addition, we show that a small proportion of cells 
bind IgE without undergoing activation. Circulating IgE can thus bind on the surface of 
intraplaque mast cells and sensitize them prior to antigen binding. The exact antigenic 
fragment that may cause intraplaque mast cell activation has not yet been identified but 
binding of lipid specific antigenic fragments is the most plausible idea20. Furthermore, 
the detection of IgE fragments inside the plaque tissue confirms that these fragments 
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can surpass the endothelial wall barrier and accumulate in the plaque area, which may 
explain the reason why circulating IgE levels correlate with end-stage cardiovascular 
events like atherothrombosis27 and myocardial infarction28. It is thus reasonable to 
acknowledge IgE as an important risk factor in cardiovascular episodes, even though 
it still remains to be elucidated whether it is a causative element29. In addition, our 
data raise an interesting question regarding patients who suffer from other syndromes 
with increased circulating IgE levels. The development of atherosclerosis is a chronic 
process, which spans from the formation of a fatty streak, during an individual’s teenage 
years and may result in an unfortunate acute event of an end-stage plaque rupture and 
vessel occlusion30. In the course of those years a fraction of humans may be diagnosed 
with allergic inflammatory conditions, associating with high levels of circulating IgE31. 
This may mean that IgE has an increased chance to migrate through the endothelium 
and bind intraplaque mast cells, raising thus the likelihood for a future cardiovascular 
event. In fact, there is compiling evidence that allergic asthma and atherosclerosis are 
linked32, and mast cells are seemingly paramount in this32. In addition, patients with 
a genetic condition called hyper-IgE syndrome have been very recently demonstrated 
to show signs of coronary subclinical atherosclerosis33. Interestingly, our group has 
demonstrated that the mast cell stabilizer cromolyn acts in a protective manner in 
atherosclerosis experimental studies34. Therefore, a mast cell stabilization approach 
may be an interesting preventive strategy in individuals who show high circulating IgE 
levels, but who have not yet been diagnosed with cardiovascular disease syndromes.
As mentioned before, mast cell activation implies release of their granular 
material. When it comes to their protease secretome, chymase and tryptase are widely 
acclaimed as the most abundant as well as the most characteristic components of mast 
cell granules35. In our study, human atherosclerotic tissue mast cells show remarkable 
diversity in their chymase and tryptase content. Experimental mouse models and human 
observations have previously disclosed the adverse effects exerted by each individual 
protease in cardiovascular syndromes and suggest specific protease inhibition as a 
beneficial strategy36. One must keep in mind however, that chymase and tryptase can 
act differentially in the surrounding microenvironment, and that the balance between 
the two may differently affect plaque characteristics. It seems that while they appear 
to enhance inflammation at a full-blown or chronic degranulation scale, they can 
also, under circumstances, promote wound healing37. It is important to also note here 
that the number of patient samples in this analysis was limited as to draw any firm 
conclusions on the exact protease content and release. Nevertheless, we confirmed that 
most intraplaque mast cells in humans contain both tryptase and chymase, with an 
opening for additional studies on human intraplaque mast cells and their secretome. A 
possible analysis in the concentration of chymase and tryptase levels within the plaque 
or in the blood of these patients may shed more light into the degranulating material of 
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these cells.
In conclusion, in this brief human analysis we made use of flow cytometry or the 
first time, to characterize mast cells finside the atherosclerotic plaques of humans. We 
confirm that the major pathway for the activation of mast cells inside the plaque tissue 
is IgE-mediated and that intraplaque mast cells are highly activated and vary in their 
protease content. This is particularly important since it suggests that already available 
modes of therapy like mast cell stabilization agents38, or anti-IgE treatment39, may prove 
beneficial in patients suffering from atherosclerosis. In the future, it would be intriguing 
to assess the plaque stage of these human samples, to gain more information on the 
exact function of this interesting cell type. We hope that bigger scale patient studies and 
analysis of more characterization markers, for instance through mass spectrometry, 
will reveal new pathways via which mast cells may act in atherosclerosis, opening thus 
new ways to interfere in cardiovascular disease.
147Phenotypic characterization of human intraplaque mast cells using flow cytometry | 
6
Reference list:
1. Benjamin, E. J. et al. Heart Disease and Stroke Statistics-2017 Update: A Report From the 
American Heart Association. Circulation 135, e146–e603 (2017).
2. Bot, I., Shi, G.-P. & Kovanen, P. T. Mast cells as effectors in atherosclerosis. Arterioscler. 
Thromb. Vasc. Biol. 35, 265–271 (2015).
3. Amin, K. The role of mast cells in allergic inflammation. Respir. Med. 106, 9–14 (2012).
4. Shi, G.-P., Bot, I. & Kovanen, P. T. Mast cells in human and experimental cardiometabolic 
diseases. Nat. Rev. Cardiol. 12, 643–658 (2015).
5. Kaartinen, M., Penttila,  a. & Kovanen, P. T. Accumulation of activated mast cells in the 
shoulder region of human coronary atheroma, the predilection site of atheromatous 
rupture. Circulation 90, 1669–1678 (1994).
6. Kovanen, P. T., Kaartinen, M. & Paavonen, T. Infiltrates of activated mast cells at the site 
of coronary atheromatous erosion or rupture in myocardial infarction. Circulation 92, 
1084–1088 (1995).
7. Bot, I. & Biessen, E. A. L. Mast cells in atherosclerosis. Thromb. Haemost. 106, 820–826 
(2011).
8. Ramalho, L. S. et al. Role of mast cell chymase and tryptase in the progression of 
atherosclerosis: study in 44 autopsied cases. Ann. Diagn. Pathol. 17, 28–31 (2013).
9. Mayranpaa, M. I., Heikkila, H. M., Lindstedt, K. A., Walls, A. F. & Kovanen, P. T. Desquamation 
of human coronary artery endothelium by human mast cell proteases: implications for 
plaque erosion. Coron. Artery Dis. 17, 611–621 (2006).
10. Kaartinen, M., Penttila, A. & Kovanen, P. T. Mast cells accompany microvessels in human 
coronary atheromas: implications for intimal neovascularization and hemorrhage. 
Atherosclerosis 123, 123–131 (1996).
11. Kaartinen, M., Penttila, A. & Kovanen, P. T. Mast cells of two types differing in neutral 
protease composition in the human aortic intima. Demonstration of tryptase- and 
tryptase/chymase-containing mast cells in normal intimas, fatty streaks, and the 
shoulder region of atheromas. Arterioscler. Thromb.  a J. Vasc. Biol. 14, 966–972 (1994).
12. Wei, C.-C. et al. Mast cell chymase limits the cardiac efficacy of Ang I-converting enzyme 
inhibitor therapy in rodents. J. Clin. Invest. 120, 1229–1239 (2010).
13. Somasundaram, P. et al. Mast cell tryptase may modulate endothelial cell phenotype in 
healing myocardial  infarcts. J. Pathol. 205, 102–111 (2005).
14. Rohm, I. et al. Increased Number of Mast Cells in Atherosclerotic Lesions Correlates with 
the Presence of Myeloid but not Plasmacytoid Dendritic Cells as well as Pro-inflammatory 
T Cells. Clin. Lab. 62, 2293–2303 (2016).
15. Willems, S. et al. Mast cells in human carotid atherosclerotic plaques are associated with 
intraplaque microvessel density and the occurrence of future cardiovascular events. Eur. 
Heart J. 34, 3699–3706 (2013).
16. Wang, J. et al. IgE stimulates human and mouse arterial cell apoptosis and cytokine 
expression and promotes atherogenesis in Apoe-/- mice. J. Clin. Invest. 121, 3564–3577 
(2011).
17. Guo, X. et al. Serum IgE levels are associated with coronary artery disease severity. 
Atherosclerosis 251, 355–360 (2016).
18. Kelley, J. et al. Mast cell activation by lipoproteins. Methods Mol. Biol. 315, 341–348 
(2006).
19. Yu, Y., Blokhuis, B. R., Garssen, J. & Redegeld, F. A. Non-IgE mediated mast cell activation. 
Eur. J. Pharmacol. 778, 33–43 (2016).
20. Meng, Z. et al. Oxidized low-density lipoprotein induces inflammatory responses in 
148 | Chapter 6
| Chapter 6
cultured human mast cells via Toll-like receptor 4. Cell. Physiol. Biochem. 31, 842–53 
(2013).
21. de Vries, M. R. et al. Complement factor C5a as mast cell activator mediates vascular 
remodelling in vein graft disease. Cardiovasc. Res. 97, 311–320 (2013).
22. Bot, I. et al. The neuropeptide substance P mediates adventitial mast cell activation and 
induces intraplaque hemorrhage in advanced atherosclerosis. Circ. Res. 106, 89–92 
(2010).
23. Van Brussel, I. et al. Fluorescent activated cell sorting: an effective approach to study 
dendritic cell subsets in human atherosclerotic plaques. J. Immunol. Methods 417, 76–85 
(2015).
24. Burd, P. R. et al. Interleukin 3-dependent and -independent mast cells stimulated with IgE 
and antigen express multiple cytokines. J. Exp. Med. 170, 245–257 (1989).
25. Tsai, M. et al. Induction of mast cell proliferation, maturation, and heparin synthesis by 
the rat c-kit ligand, stem cell factor. Proc. Natl. Acad. Sci. U. S. A. 88, 6382–6386 (1991).
26. Kraft, S. et al. The tetraspanin CD63 is required for efficient IgE-mediated mast cell 
degranulation and anaphylaxis. J. Immunol. 191, 2871–2878 (2013).
27. Sinkiewicz, W. et al. Immunoglobulin E as a marker of the atherothrombotic process in 
patients with acute myocardial infarction. Cardiol. J. 14, 266–273 (2007).
28. Langer, R. D., Criqui, M. H., Feigelson, H. S., McCann, T. J. & Hamburger, R. N. IgE predicts 
future nonfatal myocardial infarction in men. J. Clin. Epidemiol. 49, 203–209 (1996).
29. Lippi, G., Cervellin, G. & Sanchis-Gomar, F. Immunoglobulin E (IgE) and ischemic heart 
disease. Which came first, the chicken  or the egg? Ann. Med. 46, 456–463 (2014).
30. Insull, W. J. The pathology of atherosclerosis: plaque development and plaque responses 
to medical treatment. Am. J. Med. 122, S3–S14 (2009).
31. Laske, N., Bunikowski, R. & Niggemann, B. Extraordinarily high serum IgE levels and 
consequences for atopic phenotypes. Ann. Allergy. Asthma Immunol. 91, 202–204 (2003).
32. Wang, L. et al. Allergic asthma accelerates atherosclerosis dependent on Th2 and Th17 in 
apolipoprotein E deficient mice. J. Mol. Cell. Cardiol. 72, 20–27 (2014).
33. Abd-Elmoniem, K. Z. et al. Coronary atherosclerosis and dilation in hyper IgE syndrome 
patients: Depiction by magnetic resonance vessel wall imaging and pathological 
correlation. Atherosclerosis 258, 20–25 (2017).
34. Bot, I. et al. Perivascular mast cells promote atherogenesis and induce plaque 
destabilization in apolipoprotein E-deficient mice. Circulation 115, 2516–2525 (2007).
35. Caughey, G. H. Mast cell proteases as pharmacological targets. Eur. J. Pharmacol. 778, 
44–55 (2016).
36. He, A. & Shi, G.-P. Mast cell chymase and tryptase as targets for cardiovascular and 
metabolic diseases. Curr. Pharm. Des. 19, 1114–1125 (2013).
37. Douaiher, J. et al. Development of mast cells and importance of their tryptase and 
chymase serine proteases in inflammation and wound healing. Adv. Immunol. 122, 211–
252 (2014).
38. Finn, D. F. & Walsh, J. J. Twenty-first century mast cell stabilizers. Br. J. Pharmacol. 170, 
23–37 (2013).
39. Logsdon, S. L. & Oettgen, H. C. Anti-IgE therapy: clinical utility and mechanistic insights. 
Curr. Top. Microbiol. Immunol. 388, 39–61 (2015).




Mast cell depletion in 
advanced atherosclerosis 
does not induce plaque regression
Manuscript in preparation
1Eva Kritikou
1Thomas van der Heijden





1 Division of Biopharmaceutics, Leiden Academic Centre for Drug Research, 
Leiden University, Leiden, The Netherlands
Abstract 
Regression of atherosclerotic plaques is a continuous challenge 
in the prevention of acute cardiovascular syndromes. While many 
pharmacological approaches have proven successful in arresting 
progressing atherosclerosis, it is still complicated to reverse the process of 
plaque formation and reduce pre-formed stenotic tissue in arteries. Mast 
cells are plaque components, known for their pro-inflammatory role during 
atherosclerosis progression. Numerous studies have shown that this cell 
type accumulates inside atherosclerotic plaques and their activation, and 
subsequent degranulation, can enhance plaque development, while their 
stabilization hampers plaque progression. However, mast cells have also 
been implicated in atherosclerosis regression and in this project, we aimed 
to determine whether mast cell depletion can induce plaque regression. We 
made use of the DTR-conditional depletion model, to abolish the presence 
of mast cells in RMB-LDLr-/- mice while simultaneously altering the food 
content from high-fat to lipid-low diet. We did not observe any differences 
in atherosclerotic plaque size, as well as macrophage or smooth muscle 
cell content, indicating that mast cell depletion in this setup did not induce 
plaque regression. The absence of mast cells however, did markedly reduce 
the amount of infiltrating neutrophils and collagen content in the plaque 
area. In conclusion, depletion of mast cells is not an optimal therapeutic 
target for the reversion of pre-established atherosclerosis.
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1.   Introduction
Acute cardiovascular events, generally caused by atherosclerotic plaque 
progression in large arteries, are identified as the major cause of death in Western 
societies1. Atherosclerosis progresses at a chronic, yet silent, fashion that can remain 
undetected for years; until the plaque reaches an advanced stage, where it may 
either destabilize, or rupture, leading to a myocardial infarction or a stroke2. Up to 
date, the only therapeutic method available to eradicate an atherosclerotic plaque, 
is surgical intervention, for instance through coronary angioplasty with or without 
stent-placement, which can however lead to secondary (re)stenosis3. A possible 
reduction of the atherosclerotic plaque size, upon induction of plaque regression 
via non-invasive therapy, would help in the struggle against unwanted side-effects. 
From a pharmacological perspective, statin use can decrease the (very) low density-
lipoprotein content, providing plaque stability. Still, lipoprotein fraction modulation 
alone, without taking the inflammatory context into account, is not able to induce 
plaque regression4,5. Previously, it has been shown in mice, that lowering of the lipid 
diet content in combination with anti-inflammatory treatment, can induce regression 
of atherosclerotic plaques6,7. However, until now no such method has been successfully 
applied on human subjects8. In a recent experimental model study, successful plaque 
regression was achieved in LDL-receptor-/- mice by targeting the adaptive immune 
response, through the inhibition of the co-stimulatory pathway triggered by OX40 
and OX40-ligand7. Interestingly, this intervention affected also the mast cell content of 
the atherosclerotic plaque, which appeared reduced in number and activation status. 
This event was of particular importance, considering the role that mast cells play in 
atherosclerosis.
Mast cells accumulate within the plaque tissue in the intima and adventitia9 
and promote disease progression and plaque destabilization10. The adverse effect of 
mast cells is mainly attributed to their degranulating nature, which leads to the release 
of pro-inflammatory mediators11 such as cytokines and proteases. Our group has 
previously found that apoE-/- mice develop increased plaques upon systemic mast cell 
activation, an effect which was reversed by using a mast cell stabilizer12. Furthermore, 
mast cell deficient LDLr-/-/KitW-sh/W-sh mice show lower plaque size and lipid deposition, 
as compared to control LDLr-/- mice13. Importantly, in a clinical study where human 
plaque specimens from carotid arteries were analysed, mast cells were found to be 
the only inflammatory cell type that positively correlated with increased intra-plaque 
haemorrhage and future cardiovascular events14. For these reasons, mast cell targeting 
appears to be significantly interesting as a possible method to control atherosclerosis.
Therefore, in this study we aimed to assess the therapeutic potential that mast 
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cell deficiency may exert, in combination with a lipid lowering diet. 
2.   Materials & Methods
2.1  Animals 
All animal work was performed according to the guidelines of the European Parliament 
Directive 2010/63EU and all experimental work was approved by the Animal Ethics committee of 
Leiden University. The mice were bred and housed in the facility under ad libitum water and food 
supplies. The red mast cell and basophil mouse strain (RMB mice, official name: B6.Ms4a2tm1Mal) 
was provided by the laboratory of dr. P. Launay INSERM U1149, Paris, France15. These mice 
express the simian diphtheria toxin receptor (DTR)16 under control of the FcεR1β gene promoter, 
a receptor which is specifically expressed by mast cells17. Injection of diphtheria toxin (DT) will 
therefore induce apoptosis of all FcεR1β expressing cells. RMB mice were subsequently crossed 
with LDLr-/- mice (Jackson Laboratories, USA) to obtain atherosclerosis-prone RMB-LDLr-/- mice. 
LDLr-/- mice were included in the study as a control group (control-LDLr-/-) for DT-mediated side 
effects18. 
2.2   Atherosclerosis 
Male RMB-LDLr-/- (n=12/group), and control-LDLr-/- (n=6) of average age 19-20 weeks were 
fed a Western type diet (WTD) [0.25% cholesterol, 15% cocoa butter; Special Diet Services, Essex, 
UK] for 10 weeks, to develop atherosclerosis. After the 10-week WTD period, a baseline group of 
mice was sacrificed for assessment of the high-lipid diet effects. The remaining groups of mice 
were placed on a low-lipid (chow) diet for a subsequent period of 6 weeks. Simultaneously the 
DT/PBS injection scheme was initiated. Diphtheria toxin was injected intraperitoneally (0.5mg/
mL) in order to achieve specific depletion of all FcεR1β-expressing cells. DT was injected 3 times 
within the first week of the depletion period, for optimal cell clearance (boost period). After the 
first week, DT was injected at a maintenance fashion every 13 days. Before the baseline sacrifice 
and DT-administration period, all mice were randomized according to their age, weight and total 
serum cholesterol levels. All remaining mice were monitored for body weight changes throughout 
the compound administration period and until the endpoint of the experiment. After the 6-week 
chow period all mice were anesthetized by subcutaneous injections using ketamine (100mg/mL), 
sedazine (25mg/mL) and atropine (0.5mg/mL) and their vascular system was perfused by PBS 
administration at a continuous low flow via heart puncture in the left ventricle.
2.3   Total cholesterol analysis 
 Serum was obtained upon separation of blood, collected through the tail-vein. At the 
experimental endpoint, serum was collected from blood collected via the eye vein. Serum 
separation was achieved by centrifugation at 8.000 rpm for 10 minutes. Total cholesterol levels 
in the serum were assessed using an enzymatic colorimetric assay with Precipath as an internal 
control (Roche Diagnostics).
2.4  Immunohistochemistry 
The hearts of all mice were fixed in formalin for 24 hours and subsequently dissected below 
the atria. All hearts were embedded in O.C.T. compound (Sakura) and sectioned horizontally to 
the aortic axis and towards the aortic arch. Upon identification of the aortic root, defined by the 
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trivalve leaflets, 10μm sections were collected. Mean plaque size (in μm2) was calculated for three 
sequential sections, displaying the highest plaque content, using an Oil-red-O staining (Sigma 
Aldrich), which is specific for neutral lipid marking. Mast cell and neutrophil content was manually 
quantified following a Naphthol AS-D chloro-acetate esterase kit (Sigma Aldrich). The distinction 
of neutrophils from mast cells was performed according to their cellular characteristics, 
specifically the pink granular cytoplasm and lobular nucleus. Plaque macrophages were stained 
with a MOMA-2 antibody at a 1:1000 concentration (rat IgG2b, Serotec Ltd.). Smooth muscle 
cell quantification was performed following a staining with α-smooth muscle actin (αSMA) at a 
concentration of 1:1000 (Abcam). Intraplaque collagen was assessed using a Masson’s trichrome 
staining kit (Sigma Aldrich). T cell content in the aortic root was determined after a CD3 staining 
at a 1:150 concentration (clone SP7, ThermoScientific). All analyses were performed on a Leica 
DM-RE microscope and staining quantification levels were measured using a Leica QWin software 
(Leica, Imaging Systems, UK) and through blinded independent analysis.
2.5   Flow cytometry
 Blood, spleen and heart lymph node tissues were harvested for further analysis of their 
immune cell populations. To obtain blood leukocytes, red blood cell lysis was performed with a 
solution of 0.1mM EDTA, 10mM NaHCO3, 1mM NH4Cl, pH=7.2. Splenocytes as well as cells from 
the draining heart lymph nodes were obtained upon organ grinding through a 70μm filter and 
subsequent erythrocyte lysis. All cells were stained with fluorescently labeled antibodies against 
the markers of interest (Table 1). All antibodies were used at a concentration of 0.1μg/sample. 
The flow cytometry experiments were performed with a FACS Canto II and data were analyzed 
using a FlowJo software. 
Antibody Fluorochrome Clone Company
CD11b eFluor 450 M1/70 Ebioscience
Ly6G PE 1A8 BD Biosciences
NK1.1 FITC PK136 Ebioscience
FcεR1α PercP Cy5.5 MAR-1 Biolegend
CD117 APC 2B8 Ebioscience
CD4 eFluor 450 GK1.5 Ebioscience
CD8a PercP 53-6.7 BD Biosciences
Table 1: Flow cytometry antibodies
2.6   Statistics
Data collected were analyzed for normal distribution and are presented as mean±SEM. For 
the analysis of one variable between more than two groups a one-way ANOVA was performed, 
with a Bonferroni post-test for multiple comparisons. For the analysis of one variable between 
two individual groups, a 2-tailed Student’s t-test was used, with the Bonferroni post-test for 
multiple comparisons. The probability for all tests was set to 0.05 with lower values considered 
significant (P<0.05).
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3.   Results
3.1 Conditional depletion of mast cells using the Diphtheria toxin mouse 
model 
In this study, we aimed to evaluate effects of mast cell depletion on atherosclerosis, 
in combination with a lipid-lowering diet. After a 10-week period of WTD, a baseline 
group of RMB-LDLr-/- mice was sacrificed, to determine baseline plaque characteristics. 
The remaining groups of mice were switched to a chow diet while injected with DT 
or PBS for a period of 6 weeks. An additional group of LDLr-/- mice served as controls 
to estimate possible toxic effects of diphtheria toxin. Through the injection period 
we monitored all three groups of mice (PBS, DT & control) for possible changes in 
body weight. However, we did not observe any substantial differences in body weight 
development between the control group and the PBS or DT groups (Figure 1A). This 
indicated that administration of DT in such fashion does not elicit any toxic side effects 
and hence we proceeded with comparing the baseline, PBS and DT groups. To ensure 
that the diet-reversal indeed reduced the circulating lipid content, we measured the 
total cholesterol levels in the serum at the end of the study. While the baseline group 
showed high total serum cholesterol, the PBS and DT groups displayed a significant 
reduction in their circulating cholesterol levels, as expected upon diet switch (Figure 
1B, P<0.0001). We next aimed to assess the efficiency of DT to deplete mast cells, by 
specifically examining the presence of mast cells in the perivascular tissue of the aortic 
root in the mouse hearts; an area prone to develop atherosclerosis. Upon manual 
quantification of cell numbers, we observed that mast cells were absent in the DT group, 
as compared to the baseline and PBS groups of mice (Figure 1C, DT: 0.77±0.29 cells 
per section vs PBS: 12.83±1.94 cells per section, P<0.0001; vs baseline: 9.52±1.65 cells 
per section, P=0.0005). Representative pictures of the Naphthol AS D-chloroacetate 
esterase staining performed in the aortic root of the hearts demonstrated that in the DT 
group all mast cells were virtually absent (Figure 1D).
Figure 1: RMB-LDLr-/- conditional depletion using diphtheria toxin resulted in the 
abolishment of mast cells in the aortic root of the hearts. (A) Diphtheria toxin (DT) 
i/p injections (0.5mg/mL) did not evoke unspecific effects on the body weight of the DT 
or control group of mice, as compared to the PBS group. (B) Reversal from WTD to chow 
diet significantly reduced total cholesterol levels in the serum in both groups of mice (PBS 
& DT) as compared to the baseline group. (C) The number of mast cells in the aortic root of 
the heart after 6 weeks of DT-specific mast cell depletion was diminished, in comparison 
to the PBS group. (D) The number of mast cells was quantified with the use of a Naphthol 
AS-D chloro-acetate esterase staining; representative pictures of 10μm sections in the aortic 
root of the heart are shown. All values (n=12/grp) are depicted as mean±SEM. ***P<0.001, 
****P<0.0001 compared to the baseline group; ####P<0.0001 compared to the PBS-treated 
group.
3.2   Mast cell depletion does not alter plaque size upon chow diet
 Upon establishing the successful depletion of mast cells inside the 
atherosclerotic tissue, we moved on to characterize the impact of their absence in 
atherosclerotic plaque size. We used an ORO staining to visualize the lipid content of 
the plaque (Figure 2A) in the aortic root. However, quantification of the plaque size 
did not display any significant differences among the three groups of mice (Figure 2B, 
DT: 26*104 ± 3*104 μm2, PBS: 30*104 ± 2*104 μm2 baseline: 29*104 ± 5*104 μm2, P>0.05). 
Subsequently, we assessed the macrophage content of the plaque with a MOMA-2 
staining (Figure 2C). Diet reversal from WTD to chow revealed a sharp reduction in the 
intraplaque macrophage content of both the PBS and DT groups (Figure 2D, P<0.0001). 
Additionally, analysis of the plaque T cell content in the hearts was performed by an 
immunohistochemical staining against membrane protein CD3 (Figure 2E). We 
observed a significant decrease in T cell numbers in the plaques of the DT group as 
compared to the baseline; yet no difference was observed among DT and PBS mice 
(Figure 2F, DT: 12.2±1.4 cells vs baseline: 39.9±10.3 cells, P=0.012). 
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Figure 2: Conditional depletion of mast cells upon chow diet did not affect 
atherosclerotic plaque size, macrophage content or T cell number in the aortic root 
of the heart. (A) An Oil-Red-O staining in the aortic root was performed to determine the 
atherosclerotic plaque size among the groups; representative pictures are shown. (B) No 
significant difference was observed between the Baseline, PBS and DT groups. (C) The 
macrophage content of the atherosclerotic plaques was quantified using a MOMA-2 staining; 
example pictures of the staining are depicted for each group. (D) Diet reversal from WTD 
to chow, resulted in a substantial reduction in the macrophage plaque content, with no 
difference observed between the PBS and DT groups. (E) The number of T cells was assessed 
using a staining against CD3; representative pictures are shown. (F) The number of T cells 
present in the aortic root of DT mice was significantly reduced as compared to the baseline 
group, however no significant changes were observed between the DT and PBS groups. 
All values (n=12/grp) are depicted as mean±SEM. *P<0.05, ****P<0.0001 compared to the 
baseline group. 
3.3  Atherosclerotic plaques appear less stable upon mast cell depletion
 The collagen deposition, as measured by a Masson’s Trichrome staining, in the 
plaques of the DT mice was found significantly reduced in comparison to the PBS group 
of mice (Figure 3A,3B, DT: 88*104 ± 13*104 μm2 vs PBS: 136*104 ± 17*104 μm2, P=0.044). 
No significant changes were detected when comparing the baseline and DT mice. Of 
note, no difference was observed in the necrotic core area of the plaques between the 
different groups of mice (DT:53*104 ± 11*104 μm2, PBS: 68*104 ± 9*104 μm2, baseline: 
58*104 ± 15*104 μm2). We also determined the smooth muscle cell (SMC) content of 
all groups (Figure 3C), however, this did not differ between the three groups of mice 
(Figure 3D). 
Figure 3: Collagen deposition in the aortic root of the hearts was reduced upon mast 
cell depletion. (A) The collagen content of the aortic root was quantified using a Masson’s 
Trichrome staining; representative pictures are presented. (B) The deposition of collagen 
inside the atherosclerotic plaques of DT mice was found significantly reduced as compared 
to the PBS group of mice. (C) Quantification of the smooth muscle cell content in the plaque 
area of the heart was performed using an αSMA staining; representative pictures per group 
are shown. (D) No difference was observed between the PBS and DT groups in the total 
smooth muscle cell area of the aortic root. All values (n=12/grp) are depicted as mean±SEM. 
#P<0.05 compared to the PBS treated group.
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3.4   The neutrophil content is negatively affected by the absence of mast cells 
in the plaque
As mast cells were previously established to induce neutrophil chemotaxis19, we 
analysed the neutrophil content in the circulation and the atherosclerotic plaque of all 
mice. We did not observe any differences in the percentage of circulating neutrophils, 
defined as Ly6C+/CD11b+Ly6G-/NK1.1- cells (Figure 4A). However, in line with previous 
data from our group19, we observed a significant reduction in the intraplaque neutrophil 
numbers upon mast cell depletion, as compared to both the PBS and baseline groups 
(Figure  4B, DT: 5.4±1.1 cells vs PBS: 17.7±2.3 cells, P<0.0001; vs baseline: 16.3±1.9 
cells, P=0.0005).
Figure 4: The neutrophil content 
of the aortic root was significantly 
diminished following the depletion 
of mast cells upon chow diet. (A) 
The proportion of neutrophils present 
in the circulation was not altered 
among the PBS and DT groups. (B) The 
number of neutrophils accumulating 
in the aortic root of DT treated mice 
was highly reduced during mast cell 
depletion, as compared to the PBS and 
baseline groups. All values (n=12/grp) 
are depicted as mean±SEM. ***P<0.001 
compared to the baseline group; 
####P<0.0001 compared to the PBS-
treated group.
3.5 Mast cell absence reduces the levels of CD4+ and CD8+ T cells in the heart 
lymph nodes
Since the inflammatory cell content of the atherosclerotic plaque is in direct 
communication with the proximal heart lymph nodes (hLN)20, an area rich in T cells, we 
aimed to analyze the local CD4+ and CD8+ T cell content using flow cytometry. The CD4+ 
percentage in the draining hLNs was significantly reduced in the DT as compared to the 
PBS group (Figure 5A, DT: 17.75±0.59 % as compared to PBS: 20.69±0.63 %, P=0.003). 
However, no difference was observed among the percentages of CD4+ T cells circulating 
in the blood (Figure 5B). Along the same line, CD8+ T cells appeared at a substantially 
lower percentage in the hLNs of the DT mice as compared to the PBS mice (Figure 5C, 
DT: 15.6±0.9 % compared to PBS: 18.9±0.9 %, P=0.020). Finally, no differences were 
observed among the three groups in the levels of circulating CD8+ T cells (Figure 5D).
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Figure 5: CD4+ and CD8+ T cell levels were 
reduced in the heart lymph nodes of mast 
cell depleted mice. (A) The percentage of CD4+ 
T cells in the heart lymph nodes was significantly 
reduced in the DT group as compared to the PBS. 
(B) The amount of circulating CD4+ T cells did 
not differ between the groups of mice. (C) The 
CD8+ T cell percentage in the heart lymph nodes 
was decreased in the DT group as compared to 
the PBS. (D) Blood CD8+ T cells were not altered 
upon DT treatment, in comparison to the other 
two groups of mice. All values (n=12/grp) are 
depicted as mean±SEM. #P<0.05 compared to the 
PBS-treated group.
4.   Discussion 
In the present study, we aimed to assess the possible therapeutic effect of mast 
cell depletion on pre-existing atherosclerotic plaques, in the presence of a lipid lowering 
diet. We confirmed that the switch from WTD to chow diet reduced the total cholesterol 
levels in the circulation and furthermore, that DT treatment depleted the mast cell 
content from the tissues, including the aortic root of the heart. Despite the successful 
depletion of mast cells, we did not detect regression in the atherosclerotic plaque size 
of the aortic root; indicating that mast cell depletion in this context is not relevant as 
therapeutic means for the regression of atherosclerosis.
Macrophages were markedly affected by the diet reversal in both chow-fed 
groups of mice, similarly as described previously7; but the absence of mast cells did not 
have any additional effect on the plaque macrophage content. 
In contrast, collagen deposition in the plaques was found reduced in the mast 
cell depleted mice. At first glance this seems surprising, considering that mast cell 
chymase inhibition has been reported to increase the intraplaque collagen content in 
apoE-/- mice21. In addition, mast cell degranulation products have been implicated in 
the degradation of extracellular matrix components11, with mast cell deficient LDLr-
/-/KitW-sh/W-sh mice showing higher collagen levels as compared to their wild-type 
counterparts13. In line with the above, mast cell stabilization with tranilast was reported 
to increase collagen deposition in a diabetes study22. However, mast cell tryptase has 
been noted to increase collagen synthesis in renal fibrosis23. This suggests that the level 
and quality of degranulating mast cell products can have a substantially different effect 
on the collagen deposition process. Furthermore, mast cells have been proven to have a 
regenerative capacity under tissue repair conditions. For instance, mast cell infiltration 
and degranulation mediators in the myocardium has been proven crucial in extracellular 
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matrix remodelling24, during the healing phase following an infarct episode. In contrast 
to the observed collagen reduction, the smooth muscle cell content of the plaques was 
not altered upon mast cell depletion. While this result may seem inexplicable, smooth 
muscle cell α-actin is a cytoskeletal protein expressed in terminally differentiated 
arterial smooth muscle cells, and not in the SMCs undergoing proliferation25. However, 
it is the proliferative state of SMCs that is characterized by collagen production inside 
the atherosclerotic plaques26. The collagen reduction observed here may, thus, be linked 
primarily to proliferative smooth muscle cells and, therefore, not directly determined 
by α-SMA.
The neutrophil intraplaque content was also found highly reduced upon mast 
cell depletion. Mast cell tryptase has been previously reported to attract neutrophils in 
the surrounding tissue, through endothelial mediated cytokine release27. Furthermore, 
recently our group has observed that neutrophil infiltration within atherosclerotic 
plaques is greatly affected by mast cells and particularly through their release of 
chemokine CXCL1 that can direct neutrophils inside the plaques by acting on their 
CXCR2 receptor19. Moreover, a close relationship between mast cells and neutrophils 
was also reported in rheumatoid arthritis28. 
In addition, the total T cell population appeared significantly reduced in the 
hearts of chow-fed mice that did not contain mast cells, as compared to WTD-fed mice 
with mast cells. Lately it is being proposed that mast cells can interact with T cells in 
a direct fashion29. In the case of atherosclerosis, stabilization of mast cells in LDLr-/- 
mice has been reported to reduce CD4+ T cell numbers in the plaques30, whereas the 
intraplaque amount of mast cells was positively associated with the number of CD8+ 
T cells in human atherosclerotic specimens31. Therefore, it could be that the physical 
presence of mast cells is needed, to a certain extend, for T cells to infiltrate or survive 
within the atherosclerotic plaques. Interestingly, in the draining heart lymph nodes, 
both CD4+ and CD8+ T cell populations appeared markedly reduced in the absence of 
mast cells, suggesting that mast cells may shape the immune response of secondary 
lymphoid organs. However, no effect was observed in the circulating rate of both CD4+ 
and CD8+ T cells. The fact that the absence of mast cells seems to affect mainly the lymph 
node population that is adjacent to the atherosclerotic site, and less the systemic T cell 
response, indicates that the observed effects are local and atherosclerosis specific. 
Overall, the atherosclerotic plaques of mice upon lipid lowering appeared to 
contain similar amounts of macrophages, T cells and smooth muscle cells, regardless of 
whether mast cells were present or not. However, the absence of mast cells significantly 
affected the amount of collagen deposited in the atherosclerotic area as well as the 
local neutrophil infiltration. In this experimental setup, mast cell depletion did not 
induce atherosclerosis regression upon a lipid-lowering diet. It is worth mentioning 
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that intervention on the CD3+ axis has been previously shown to induce atherosclerosis 
regression6. Be that as it may, in regressing plaques it is equally crucial for foam cells to 
emigrate in the draining lymph nodes32, where they can act on the local T cell response. 
In this study, we saw that while mast cells were able to shape the CD4+/CD8+ lymph 
node content they did not regulate macrophage emigration from the plaques, and 
therefore plaque regression. Ultimately, even though mast cells seem to firmly assist 
atherosclerosis regression7 they do not seem able to trigger it. Nevertheless, the above 
data indicate that although mast cells are regarded as classical pro-inflammatory 
effectors, they may also have protective effects that favour plaque stabilization. 
Therefore, in atherosclerosis it may be optimal to refine individual pathways of mast cell 
action and selectively intervene on the adverse ones in order to successfully interfere in 
disease progression. 
162 | Chapter 7
Reference list:
1. Benjamin, E. J. et al. Heart Disease and Stroke Statistics-2017 Update: A Report From the 
American Heart Association. Circulation 135, e146–e603 (2017).
2. Hansson, G. K., Libby, P. & Tabas, I. Inflammation and plaque vulnerability. J. Intern. Med. 
278, 483–493 (2015).
3. Kim, M. S. & Dean, L. S. In-stent restenosis. Cardiovasc. Ther. 29, 190–198 (2011).
4. Nissen, S. E. et al. Effect of very high-intensity statin therapy on regression of coronary 
atherosclerosis: the ASTEROID trial. JAMA 295, 1556–1565 (2006).
5. Hewing, B. & Fisher, E. A. Preclinical mouse models and methods for the discovery of the 
causes and treatments of atherosclerosis. Expert Opin. Drug Discov. 7, 207–216 (2012).
6. Kita, T. et al. Regression of atherosclerosis with anti-CD3 antibody via augmenting a 
regulatory  T-cell response in mice. Cardiovasc. Res. 102, 107–117 (2014).
7. Foks, A. C. et al. Interruption of the OX40-OX40 ligand pathway in LDL receptor-deficient 
mice causes regression of atherosclerosis. J. Immunol. 191, 4573–4580 (2013).
8. Feig, J. E. Regression of atherosclerosis: insights from animal and clinical studies. Ann. 
Glob. Heal. 80, 13–23 (2014).
9. Laine, P. et al. Association Between Myocardial Infarction and the Mast Cells in the 
Adventitia of the Infarct-Related Coronary Artery. Circulation 99, 361–369 (1999).
10. Bot, I., Shi, G.-P. & Kovanen, P. T. Mast cells as effectors in atherosclerosis. Arterioscler. 
Thromb. Vasc. Biol. 35, 265–271 (2015).
11. Kovanen, P. T., Kaartinen, M. & Paavonen, T. Infiltrates of activated mast cells at the site 
of coronary atheromatous erosion or rupture in myocardial infarction. Circulation 92, 
1084–1088 (1995).
12. Bot, I. et al. Perivascular mast cells promote atherogenesis and induce plaque 
destabilization in apolipoprotein E-deficient mice. Circulation 115, 2516–2525 (2007).
13. Sun, J. et al. Mast cells promote atherosclerosis by releasing proinflammatory cytokines. 
Nat. Med. 13, 719–724 (2007).
14. Willems, S. et al. Mast cells in human carotid atherosclerotic plaques are associated with 
intraplaque microvessel density and the occurrence of future cardiovascular events. Eur. 
Heart J. 34, 3699–3706 (2013).
15. Dahdah, A. et al. Mast cells aggravate sepsis by inhibiting peritoneal macrophage 
phagocytosis. J. Clin. Invest. 124, 4577–4589 (2014).
16. Saito, M. et al. Diphtheria toxin receptor-mediated conditional and targeted cell ablation 
in transgenic mice. Nat. Biotechnol. 19, 746–750 (2001).
17. Beaven, M. A. & Baumgartner, R. A. Downstream signals initiated in mast cells by Fc 
epsilon RI and other receptors. Curr. Opin. Immunol. 8, 766–772 (1996).
18. Christiaansen, A. F., Boggiatto, P. M. & Varga, S. M. Limitations of Foxp3(+) Treg depletion 
following viral infection in DEREG mice. J. Immunol. Methods 406, 58–65 (2014).
19. Wezel, A. et al. Mast cells mediate neutrophil recruitment during atherosclerotic plaque 
progression. Atherosclerosis 241, 289–296 (2015).
20. Randolph, G. J. Emigration of monocyte-derived cells to lymph nodes during resolution of 
inflammation and its failure in atherosclerosis. Curr. Opin. Lipidol. 19, 462–468 (2008).
21. Bot, I. et al. Mast cell chymase inhibition reduces atherosclerotic plaque progression and 
improves plaque stability in ApoE-/- mice. Cardiovasc. Res. 89, 244–252 (2011).
22. Jones, S. E., Gilbert, R. E. & Kelly, D. J. Tranilast reduces mesenteric vascular collagen 
deposition and chymase-positive mast cells in experimental diabetes. J. Diabetes 
Complications 18, 309–315 (2004).
23. Kondo, S. et al. Role of mast cell tryptase in renal interstitial fibrosis. J. Am. Soc. Nephrol. 
| Chapter 7 163Mast cell depletion in advanced atherosclerosis does not induce plaque regression | 
7
12, 1668–1676 (2001).
24. Somasundaram, P. et al. Mast cell tryptase may modulate endothelial cell phenotype in 
healing myocardial  infarcts. J. Pathol. 205, 102–111 (2005).
25. Thyberg, J. Differentiated properties and proliferation of arterial smooth muscle cells in 
culture. Int. Rev. Cytol. 169, 183–265 (1996).
26. Adiguzel, E., Ahmad, P. J., Franco, C. & Bendeck, M. P. Collagens in the progression and 
complications of atherosclerosis. Vasc. Med. 14, 73–89 (2009).
27. Compton, S. J., Cairns, J. A., Holgate, S. T. & Walls, A. F. Human mast cell tryptase stimulates 
the release of an IL-8-dependent neutrophil chemotactic activity from human umbilical 
vein endothelial cells (HUVEC). Clin. Exp. Immunol. 121, 31–36 (2000).
28. Pimentel, T. A., Sampaio, A. L. F., D’Acquisto, F., Perretti, M. & Oliani, S. M. An essential role 
for mast cells as modulators of neutrophils influx in collagen-induced arthritis in the 
mouse. Lab. Invest. 91, 33–42 (2011).
29. Bulfone-Paus, S. & Bahri, R. Mast Cells as Regulators of T Cell Responses. Front. Immunol. 
6, 394 (2015).
30. Wang, J. et al. Pharmaceutical stabilization of mast cells attenuates experimental 
atherogenesis  in low-density lipoprotein receptor-deficient mice. Atherosclerosis 229, 
304–309 (2013).
31. Rohm, I. et al. Increased Number of Mast Cells in Atherosclerotic Lesions Correlates with 
the Presence of Myeloid but not Plasmacytoid Dendritic Cells as well as Pro-inflammatory 
T Cells. Clin. Lab. 62, 2293–2303 (2016).
32. Trogan, E. et al. Gene expression changes in foam cells and the role of chemokine receptor 
CCR7 during atherosclerosis regression in ApoE-deficient mice. Proc. Natl. Acad. Sci. U. S. 
A. 103, 3781–3786 (2006).
164 | Chapter 7




General discussion -  Future perspectives
168 | Chapter 8
Synopsis
Atherosclerosis is the most prevailing underlying pathology responsible for 
the increased mortality rates due to acute cardiovascular syndromes1. Cardiovascular 
disease (CVD) was accounted for 1 in 3 deaths in US adults over the year 2014, with 
approximately 1 death incidence occurring every 40 seconds2. In Europe, CVD is 
the cause of 45% of all deaths, according to the 2017 statistics rates3. Despite the 
misconception that cancer is the leading cause of death nowadays, mortality due to 
CVD is actually higher than the sum of deaths by cancer and chronic lower respiratory 
disease1. Therefore, research aiming at identifying new therapeutic strategies to battle 
atherosclerosis pathology from an early stage is mandatory. 
Atherosclerotic plaque formation is a chronic process which develops as a 
result of disturbed cholesterol regulation and immune system dysfunction4. Mast cells 
are immune components that have been described as important contributors in the 
progression of experimental mouse and human atherosclerosis5. The presence of mast 
cells within the plaques of human carotid arteries, was found to be a predictor of future 
cardiovascular events and furthermore, was associated with intraplaque hemorrhage 
levels, a characteristic of end-stage atherosclerosis6. Activation of mast cells in the 
plaque is suggested to lead to plaque destabilization7, increasing thus the chances for an 
acute episode. However, the exact mechanism by which these cells get activated inside 
the plaque tissue has not been studied in detail. 
In the work described throughout this thesis, we aimed to decipher the action of 
mast cells in experimental and human atherosclerosis. In chapter 3 we determined the 
therapeutic potential of the LPA1/3 antagonist, Ki16425, which was hypothesized to lead 
to inhibition of a recently described mast cell activator, termed lysophosphatidic acid8. 
Chapters 4 and 5 examined the novel role of mast cell mediated antigen presentation 
in atherosclerosis. In chapter 6, by applying a translational approach, we determined 
the abundance and function of mast cells in human atherosclerotic plaques. Finally, in 
chapter 7 we explored the influence of mast cells in atherosclerosis regression.
Mast cells act on multiple cardiovascular syndromes
The contribution of mast cells in the pathology of atherosclerosis is a subject 
that has gained considerable attention over the years. Upon contemplating the adverse 
effects that mast cell activation can elicit in other autoimmune pathologies, such as 
allergy9 or rheumatoid arthritis10, it is necessary to gain more information regarding 
their exact function in atherosclerotic disease. Therefore, during this thesis we aimed to 
unravel their mechanisms of action in atherosclerosis. 
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Chapter 2 offered a general overview on the implication of mast cells in various 
cardiovascular diseases (CVD). Even though the field of atherosclerosis has been actively 
investigating their function for the past 20 years, not much is known regarding other 
cardiovascular pathologies. 
We reviewed the role of mast cells in diet induced obesity. Mast cells have been 
shown to infiltrate white adipose tissue11 and contribute to local adipogenesis12 and 
probably obesity. However, recently it was revealed that mast cells, through their 
secretion of leptin, can actually protect against obesity and diabetes, highlighting their 
dual-face actions13. This notion was strengthened by a report stating that mast cells 
can promote the formation of brown fat cells14, which comprise the protective kind of 
adipocytes responsible for body temperature retention15.
This double-edged nature of mast cells was also discussed in the case of 
myocardial infarction (MI). We conferred on their detrimental role in end-stage plaque 
rupture16. Their adverse nature in plaque destabilization was suggested in a new paper 
stating that mast cells are found at increased numbers in patients with stable and 
unstable coronary plaques, as well as in individuals who suffered from either an acute or 
chronic MI episode17. However, it seems that mast cells do not exert only harmful effects, 
since they are linked to neo-angiogenesis and healing of the myocardium after an acute 
MI episode18,19. Interestingly, a very recent report stated that following an MI incident, 
mast cells deriving from white adipose tissue can communicate with cardiomyocytes, 
increase their contractility and improve heart function20.
The effect of mast cells on the pace of the myocardium may be particularly 
important in arrhythmia, as we also discussed in the second chapter. Indeed, the 
presence of mast cells has also been reported a few years ago in arrhythmic atrial 
fibrillation21. Heart rhythm-related dysfunctions are linked to atherosclerosis22 and 
atrial fibrillation in particular shows an increasing predominance at present1. In fact, 
arrhythmia is widely understudied with respect to the contribution of the immune 
system. Interestingly, mast cells are a population that is fundamentally populating the 
heart at a normal state23. Although information available on the role of mast cells in 
arrhythmia is scarce, it seems that they act in a negative way24,25. Furthermore, a novel 
paradigm-shifting study revealed that also macrophages can influence the regulation 
of heart rhythm26. Mast cells are reported to interact with macrophages in other 
cardiovascular diseases such as atherosclerosis27 and aortic aneurysms28. While this 
does not imply a causative relationship, it would be interesting to investigate in the 
future a possible interaction between tissue resident macrophages and cardiac mast 
cells in heart rhythm disorders.
It is therefore apparent that mast cells do not compose a cell type that is clear-
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cut pro-inflammatory in cardiovascular syndromes. Examination of their function 
should be approached in a delicate fashion.
Modulation of immune responses in atherosclerosis through mast cells
Having in mind the above mentioned diverse abilities of mast cells, as well as the 
fact that atherosclerosis is the underlying pathology for the majority of CVDs, we aimed 
to experimentally elucidate their effects in atherosclerosis.
In chapter 3 we examined the downstream effects of the established mast cell 
activator, lysophosphatidic acid (LPA)29. LPA is a bioactive lipid produced inside the 
atherosclerotic plaques where it has been shown to act in a proatherogenic manner30,31. 
LPA acts via its specific receptors LPA1/332 on an array of immune cells33 among which the 
mast cells29,34. For that reason, we inhibited the action of LPA by blocking the downstream 
signaling of receptors LPA1/3, with the use of the small molecule Ki16425. LPA1/3 
inhibition had a significant impact on the systemic immune response, which resulted in 
a 40% reduction of the plaque burden, caused by a reduced macrophage content. The 
protective effect of Ki16425 was mainly attributed to the disruption of the CCR2-CCL2 
infiltration axis, but we also observed an increase in the non-inflammatory monocyte 
content and the anti-inflammatory TREG population.  These effects were accompanied by 
a mild reduction in the LDL cholesterol levels. Overall, inhibition of LPA1/3 appears to be 
an appealing therapeutic method to limit the progression of established atherosclerosis. 
Furthermore, our observations show that a shift of the systemic immune response, 
from pro-inflammatory to anti-inflammatory, in atherosclerosis can not only halt 
plaque progression, but can also influence cholesterol regulation. However, in this study 
we did not observe any significant mast cell contribution. Nonetheless, we still have 
strong indications that mast cells may also be affected by the LPA-signaling cascade. For 
example, mast cells have been reported to act also through additional LPA receptors, 
such as LPA5, which in our study were still fully-functional35. Be that as it may, this did 
not seem to have any effect on the mast cell response we observed. The previously 
reported LPA action on the mast cells was introduced at advanced atherosclerosis 
stages29, which was not the case in our experimental setup. The beneficial effects that 
we reported on the adaptive immune response suggest that LPA1/3 inhibition may also 
be therapeutically relevant for a prolonged period. It would therefore be interesting to 
investigate this agent throughout a longer timeframe. In addition, the induction of TREG 
cells opens the pathway to investigating this agent in atherosclerosis regression since 
TREG cells are themselves an attractive therapeutic target36,37.
The overall importance of the adaptive immune response, and particularly the 
one evoked by T cells is a known fact38. CD4+ T cells, predominantly those of the TH1 
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phenotype, are the most frequent inside atherosclerotic plaques39. In chapter 4 we 
discussed a newly found direct interaction between mast cells and CD4+ T cells in 
atherosclerosis. Knowing that mast cells are in close cross-talk with T cells in other 
inflammatory diseases40,41, and based on novel reports on the role of mast cells as 
inducible antigen presenting cells42,43, we aimed to study whether they interact with 
CD4+ T cells in atherosclerosis. We reported that mast cells increase their antigen 
presentation capacity upon hyperlipidemia, by increasing their MHC-II expression 
in both experimental atherosclerosis, as well as inside human plaques. Through this 
crosstalk mast cells can present antigens directly to CD4+ T cells, which, under the 
influence of a high-fat diet, are skewed towards a pro-atherogenic TH1 subtype. This 
is interesting, considering the fact that mast cells in allergies seem to favor a TH2 
response instead44. It therefore seems that mast cells exert differential effects on T 
cells according to the local inflammatory milieu. Atherosclerosis, being a TH1 mediated 
disease, is probably favoring presentation of antigenic fragments that are affecting the 
TH1 subset. On the contrary, in allergies, which are mediated by TH2 cells, mast cells seem 
to enhance the TH2 response. It would be interesting to see if this mast cell-CD4+ T cell 
crosstalk results in antibody production by the B cells. Screening for TH1-linked antibody 
fragments is an attractive concept to explore further. Furthermore, we do not know 
what is the exact contribution of this pathway in atherosclerosis. It would be intriguing 
to see if abolishment of MHC-II, specifically from the surface of mast cells, can affect 
atherosclerosis progression in vivo. Also, we do not yet know which antigenic fragments 
are presented by mast cells to CD4+ T-cells via MHC-II, in atherosclerosis. In the future, 
it may be appealing to scan the MHC-II epitopes of mast cells for lipid-specific antigenic 
presentation, as well as explore the pathway via which mast cells take up antigens from 
their surroundings. For instance, their uptake capacity could be investigated through 
differentially charged nanoparticles. Finally, a crucial question arises, on whether mast 
cells can take up lipids in a “foam-cell” fashion.  Although we do not have indications 
that they possess classical uptake receptors, present on macrophages or dendritic cells, 
mast cells may take up lipids by other means and store them in forms other than neutral 
lipid accumulation.
The existence of a direct crosstalk between mast cells and the adaptive immune 
system was investigated also in chapter 5, where we observed a direct interaction 
with the NKT cell population, through CD1d-mediated lipid-specific presentation. 
Surprisingly, this pathway showed a protective effect in atherosclerosis development. 
This was an unexpected finding, considering that NKT cells, which in our study showed 
reduced activation, are reported to be proatherogenic, particularly upon engagement 
with CD1d45. However, we must remember that NKT cells can function as activators as 
well as inhibitors of the immune response, depending on the glycolipid that is presented 
to them46,47. In fact, it has been previously reported that NKT cells can negatively regulate 
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CD4+ cells in atherosclerosis, in a fashion that matches our observations48. Furthermore, 
a protective role of NKT cells was also observed in other autoimmune syndromes 
where mast cells are known mediators, such as obesity49 and rheumatoid arthritis50. 
Therefore, it seems that, while classical presentation of lipid antigens through CD1d 
present on APCs exacerbates atherosclerosis51,52, antigen presentation through CD1d 
on the mast cell surface, exerts a protective effect. It is also interesting to observe that, 
although indirectly, mast cells again affect the CD4+ TH1 cell response, as in the case of 
MHC-II mediated presentation. This interaction seems to be tightly balanced, and of 
importance, in atherosclerosis development; therefore, it requires further exploration.
The presentation capacity of human mast cells mentioned in the fourth chapter, 
was accompanied by a general phenotypic characterization of human mast cells as 
stated in chapter 6. While human intraplaque mast cells are the only immune cell type 
that was found to positively associate with future cardiovascular events6, it is still not 
fully understood how these cells become activated within the atherosclerotic plaque. 
In this study we screened human intraplaque mast cells obtained from 22 carotid and 
femoral arteries, using for the first time the flow cytometry method. We confirmed 
immunohistochemical data from previous reports, which stated that the protease 
secretome of mast cells is highly heterogeneous53, showing a differential cellular 
content of tryptase and chymase. Importantly, we detected high levels of activation by 
human intraplaque mast cells, based on their expression of protein CD6354. Of note, the 
majority of activated mast cells were IgE-sensitized, indicating that this pathway is the 
main activation mode of the human intraplaque mast cell population. This does not 
come as a surprise, since mast cells are mostly known for their classical degranulation 
potency upon antigen-sensitized IgE binding on their Fcε-receptor55. However, it may 
explain why serum IgE levels correlate in a positive manner with coronary artery 
disease56. This observation as mentioned above, has also been attributed to mast 
cells6,17. In addition, we noted that a minor fraction of these cells was activated in a non-
IgE specific manner, thus strengthening the case of non-classical Fcε-receptor mediated 
activation of mast cells. It has been proven that mast cells in cardiovascular diseases can 
get activated by means other than FcεR, such as through TLRs57, complement receptors57 
or neuropeptide receptors58. However, we did not have an indication on the proportion 
of these alternative activation pathways within the atherosclerotic plaque. The adverse 
effects that this seemingly small fraction of mast cells can exert in atherosclerosis 
progression, like in the case of substance P which is linked to intraplaque hemorrhage 
levels59, indicates the magnitude of power that these cells possess in atherosclerosis. 
The above, therefore, states how important it is to consider therapeutic possibilities 
that target mast cells.
In chapter 7, we explored the therapeutic potential that arises from the 
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sheer absence of mast cells in atherosclerosis regression conditions. Specifically, we 
conditionally depleted mast cells, at a systemic level, upon altering the diet content from 
high-fat to normal chow. In our experimental setup we did not observe any reduction 
in the atherosclerotic plaque size; which indicates that depletion of mast cells after 
an ongoing inflammatory cascade, does not have the intensity to reduce the plaque 
volume. We did detect, however, a reduced neutrophil intraplaque influx, in the absence 
of mast cells. This effect can be explained by the fact that mast cells induce neutrophil 
infiltration into the plaque60. Interestingly, even though there was no effect detected in 
overall plaque burden, mast cell depletion affected the collagen content of the plaque 
in a negative manner. This was unexpected, since mast cells are negatively associated 
with collagen deposition inside atherosclerotic plaques, in a chymase specific action61. 
Yet, tryptase release has been reported to induce collagen synthesis in a renal fibrosis 
model62, indicating again the complex manner by which these cells act. 
Overall, the observations stated in this thesis suggest that when it comes to 
intervention of the mast cell action, we should not aim solely on their abolition as they 
do not appear to possess only harmful effects, but are rather fine tuners of the overall 
immune response.
Future perspectives
The research described in this thesis paves the way for exploring the therapeutic 
potential of targeting mast cells in atherosclerosis. Evidently, this cell type, as most 
immune cells, shows remarkable plasticity. As such, mast cells require refined targeting 
of specific pathways that would inhibit their negative actions, while retaining or even 
enhancing their positive effects. 
In the case of atherosclerosis, mast cells are, for the most part damaging, when 
it comes to disease progression; particularly, through their FcεR mediated activation. 
This specific response is a promising therapeutic point, mainly due to the already 
commercially available agents that target its ligand, IgE63. Specifically, IgE has been found 
to circulate at high levels in the serum of patients suffering from an acute cardiovascular 
syndrome64. In addition, IgE levels independently correlate with the severity of coronary 
syndromes56. Here we reported that IgE can penetrate the endothelial barrier, accumulate 
inside the atherosclerotic plaque and bind on the surface of mast cells, thus sensitizing 
them. The accumulation of IgE within the atherosclerotic plaque does not necessarily 
require the participation of an antigen. However, most of the intraplaque mast cells 
we examined were found to have IgE bound on their surface and to be at an activated 
state. It therefore seems, that they have undergone at least one cycle of degranulation in 
the area. A previous study has stated that, IgE is elevated upon myocardial infarction65 
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and the authors detected IgE fragments inside human atherosclerosis specimens. 
However, this intraplaque IgE was argued to act mainly on the inducible FcεRI of the 
macrophages, and not on intraplaque mast cells. Here we have provided proof that 
the intraplaque IgE is also activating mast cells in the plaque area. For this process to 
take place, the presence of an antigen is also necessary. As mentioned above, we do 
not know which antigenic fragment may bind on IgE. It may however be speculated 
that the antigen derives directly from the atherosclerotic plaque environment. Further 
research is needed on the antigen-mediated activation of mast cells within the plaques. 
Yet, upon considering the harmful effects linked to intraplaque mast cell activation7,66, 
it is obvious that intervention on this pathway may prove beneficial for end-stage CVD 
related events. The IgE-antibody blocking agent omalizumab67, which is already on the 
market and prescribed for allergic asthma cases68,69, as well as for patients suffering 
from urticaria70 and mastocytosis71, could prove beneficial also in atherosclerosis. 
Indeed, we are eager to report that we have gained permission to study the effects of 
omalizumab in atherosclerosis patients.
A more crude method to battle the adverse effects of mast cell activation could be 
through the use of mast cell stabilizers72, such as cromolyn73 or tranilast74. These agents 
act on the mast cell mediated degranulation pathway, mainly by affecting ion exchange 
between the cell and its microenvironment75,76. Mast cell stabilization via this method 
has been proven in the past to be beneficial in experimental atherosclerosis studies7,77. 
Since in our experimental work we showed that human intraplaque mast cells are highly 
activated, using a mast cell stabilizer to eliminate their degranulation sounds appealing. 
However, there are two important aspects to keep in mind. The first one is that the 
mode of action that stabilizers exert is not strictly specific for mast cells. For example, 
tranilast is known to influence also vascular smooth muscle cells78, an effect which could 
risk adverse effects. The second aspect that needs to be noted is that inhibition of the 
mast cell degranulation machinery exclusively will alter also the release of mediators 
that are not necessarily pro-inflammatory. For example, mast cells are a source of the 
anti-inflammatory cytokine IL-1078, which is known to be athero-protective79,80. In fact, 
mast cells have been recently reported to act in an immunoregulatory manner in bone 
marrow81 as well as in solid organ transplantation82,83. Therefore, blocking the release 
of the entire mast cell secretome may interfere with the healing properties that these 
cells possess, while reducing protection towards pathogen infections. Furthermore, 
it is important to remember that mast cell activation does not necessarily mean 
degranulation. Mast cells can secrete pro-inflammatory cytokines like IL-8, in means 
that do not include release of their pre-stored granules84. A similar mode of mast cell 
activation has been previously reported through IL-1, which results in release of IL-6 
but does not involve degranulation85. Therefore, while most activation pathways lead to 
mast cell degranulation, there are means which do not elicit such an effect, but rather lead 
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to controlled cytokine release.  One additional example is the TLR activation pathway 
which results in increased cytokine production but not mast cell degranulation86. As 
mentioned before, oxLDL activates mast cells through TLR457. This states how different 
the downstream mast cells action is inside the atherosclerotic plaque. According to our 
observations, approximately 20% of human intraplaque mast cells get activated via 
pathways other than IgE, which may include cytokine release without degranulation. 
In addition, it is known that when a cell undergoes activation, the intracellular energy 
consumption, and therefore the mitochondrial machinery, can alter its metabolic status. 
In the case of mast cells, recent work has stated that IgE mediated activation induces 
both oxidative phosphorylation and glycolysis87. Considering the fact that oxLDL acts 
via the TLR pathway57 which does not elicit energy consuming degranulation86, it would 
be interesting to see if this atherosclerosis specific pathway evokes any change in the 
cell metabolism of mast cells. Overall, it is important to exactly refine these differential 
activation pathways in the future, since distinct activators possibly lead to the release of 
different mediators, in both quality and quantity. After all it is the prevalence of the net 
immune effect that shapes disease progression.
As we demonstrated, mast cells possess also immunoregulatory abilities that 
seem to surpass the classical view of a cell that goes inside the atherosclerotic plaque 
to get activated, degranulate and inflict damage. The inducible antigenic presentation 
capacity of mast cells we mentioned, is an interesting target for therapeutic development. 
In particular, MHC-II expression on foam cells was reported to increase upon oxLDL 
uptake, which triggered an autophagy mediated pathway88. Mast cell degranulation is 
also reportedly mediated by autophagy signals, in a mechanism that is separate from 
their cytokine secretion machinery89. Interestingly, MHC-II induction on the mast cells 
is stated to increase in the presence of cytokine IL-3390, a signal that also activates 
autophagy pathways91. It may therefore be that mast cell autophagy-mediated effects are 
also taking place in atherosclerosis, and affect the expression of MHC-II on the mast cell 
surface. Further exploration of such a pathway could be of importance in understanding 
the mast cell presentation capacity. Additionally, a past report indicated that MHC-II is 
stored in the intracellular mast cell compartment and fuses with the membrane upon 
degranulation92. Investigating whether disruption of this mechanism could reduce 
the established crosstalk between mast cells and CD4+ TH1 cells could be helpful in a 
therapeutic context. Here we should also mention that mast cells do not seem to affect 
the adaptive immune system only via a direct action on the CD4+ T cells, but can do 
so indirectly as well. There are studies that explore the exchange of antigenic content 
between mast cells and dendritic cells93. This can happen both through intracellular 
bridges93, but it may also happen via the secretion of exosomes94. Neither the exosomal 
release by mast cells, nor the antigen-induced crosstalk between mast cells and DCs 
has been explored in atherosclerosis. However, in our study, we did see that more mast 
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cells infiltrate the para-aortic lymph nodes upon hyperlipidemia; particularly in the 
area where DCs reside. The accumulation of mast cells in the LNs upon atherosclerosis 
progression is on its own an additional pathway to explore. Are they for instance 
travelling there through the lymphatics? Are they able to migrate from one tissue to 
the other, carrying along tissue specific antigens? Or are they newly-maturated mast 
cells deriving from bone marrow progenitors? Answering these questions may provide 
evidence towards new therapeutic interventions.
An additional pathway that needs further exploration is the epigenetic pressure 
exerted on the mast cells, inside an inflammatory tissue. The final mast cell maturation 
step takes place within the tissue94 in a multitude of organs where mast cells reside. 
This suggests that mast cells are a highly diverse population with different properties, 
depending on their place of residence. A recent study screened the transcriptome of 
mast cells collected from various tissues and confirmed this exact notion95. Mast cells 
indeed appeared to be highly sensitive depending on their surroundings. This raises a 
question regarding tissues that are characterized by chronic inflammatory pressure, 
such as the atherosclerotic plaque. Is the local environmental pressure able to alter the 
mast cell properties at a genetic level? Very recent pioneering work has in fact stated 
that mast cell tryptase can elicit epigenetic changes on the mast cell genome, through 
histone truncation96. This epigenetic effect is enhanced through time and affects the 
cellular identity of mast cells, which begin to show similarities with macrophages. It 
would be intriguing to examine if such a pathway exists also inside the atherosclerotic 
plaque. After all, epigenetic changes have gained recent attention in atherosclerosis96.
In conclusion, the above work states that it is important to target specific pathways 
involved in differential mast cell actions. This is of particular clinical importance since 
these cells are not only crucial in inflammatory conditions97, but are also the first 
responders in infections98 and potent immune regulators in cancer99. After all it is their 
balancing nature that makes mast cells a fascinating cell type in atherosclerosis, worthy 
to be explored in depth.
Lastly, it is necessary to mention the therapeutic potential that is offered in 
atherosclerosis, by targeting the overall immune response. As shown by our work on the 
LPA-receptor inhibition, systemic modulation of the immune response can efficiently 
hamper atherosclerosis progression. At this moment, pre-clinical atherosclerosis is 
being pharmacologically treated with the use of statins100. Originally, the benefits of 
statin use were appointed to the lowering of non-HDL cholesterol alone. However, it 
was the combination with lower inflammatory burden that resulted in atherosclerotic 
plaque stabilization100. Yet up to now it has not been possible to reduce the plaque burden 
of an already established human plaque101. A novel approach for the reduction of LDL 
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has been put to practice very recently. Antibody-mediated inhibition of the expression 
of the hepatic protein PCSK9 is reported to lower LDL levels by 50%, showing very 
promising potential102. However, long term assessment on this type of medication is not 
possible at the moment. Atherosclerosis research has been actively focusing on means 
to achieve plaque regression, with experimental models spanning from stimulation of 
reverse cholesterol transport by means of micro-RNA antagonism103, to inhibition of 
immune pathways, in combination with low-lipid diets104,105. Lastly, about two months 
ago, the large scale CANTOS trial, which introduced the inhibition of the inflammatory 
cytokine IL-1β, using the antibody canakinumab, met its primary clinical endpoint106. 
The results stated that patients treated with canakinumab showed a significant 
reduction in the risk of developing secondary cardiac events107. This anti-inflammatory 
therapeutic method is a scientific breakthrough comparable to the discovery of statins.
Ultimately, treating atherosclerosis is the challenge of the near future. A challenge 
that the scientific field has long accepted, in a duel that will be won. Et lux in tenebris 
lucet.
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Slagaderverkalking oftewel atherosclerose is de belangrijkste onderliggende 
oorzaak van acute cardiovasculaire syndromen zoals een hartinfarct of beroerte1. 
Hart- en vaatziekten waren in 2014 verantwoordelijk voor 1 op de 3 doden onder 
volwassenen in de Verenigde Staten, waarbij gemiddeld 1 sterfgeval per 40 seconden te 
betreuren viel2. In Europa zijn hart- en vaatziekten verantwoordelijk voor 45% van alle 
doden volgens de huidige statistieken van 20173. Hoewel het aantal doden door kanker 
de afgelopen jaren sterk gestegen is, is de mortaliteit door hart- en vaatziekten vandaag 
de dag hoger dan het aantal doden door kanker en chronische luchtwegaandoeningen 
bij elkaar1. Daarom is het onderzoek naar nieuwe therapeutische strategieën, die de 
ontwikkeling van atherosclerose vanaf een vroeg stadium tegengaan, noodzakelijk.
De ontwikkeling van een atherosclerotische plaque is een chronisch proces, 
dat voortkomt uit een verstoorde lipidenhuishouding en dysfunctie van het 
immuunsysteem4. De mestcel is een cel behorende tot dit immuunsysteem, die 
beschreven is betrokken te zijn bij de progressie van atherosclerose in zowel muizen 
als mensen5. Het aantal mestcellen, dat aanwezig is plaques in de halsslagader van 
patiënten, bleek een voorspellende waarde te hebben voor het krijgen van een 
toekomstige acute cardiovasculaire aandoening, en was ook geassocieerd met de 
aanwezigheid van intraplaque bloedingen, een karakteristiek van plaque instabiliteit6. 
Activatie van de mestcel in de plaque kan leiden tot plaque destabilisatie7, wat de kans 
op het krijgen van bijvoorbeeld een hartinfarct kan verhogen. De exacte mechanismen, 
die kunnen leiden tot mestcelactivatie in de plaque, zijn tot op heden echter niet tot in 
detail onderzocht.
In dit proefschrift hebben we de bijdrage van mestcellen aan de ontwikkeling van 
zowel experimentele als humane atherosclerose onderzocht. 
In hoofdstuk 3 hebben we de therapeutische potentie van de LPA1-3 receptor 
antagonist Ki15425, een stof die de activatie van mestcellen door lysofosfatidaat 
(lysophosphatidic acid, LPA) kan remmen, onderzocht8. In hoofdstukken 4 en 5  is 
de tot op heden onbekende bijdrage van mestcel-gemedieerde antigen presentatie aan 
atherosclerose bekeken. In hoofdstuk  6 hebben we bepaald in welke mate mestcellen 
aanwezig zijn in humane atherosclerotische plaques, en daarnaast de functie van de 
mestcel in deze plaques onderzocht om de mogelijke translatie van onze in vivo data 
naar de patient in kaart te brengen. Tenslotte is in hoofdstuk 7 de bijdrage van de 
mestcel aan atherosclerotische plaque regressie onderzocht. 
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Modulatie van de immuunrespons in atherosclerose door mestcellen
Het onderzoek naar de bijdrage van de mestcel aan de pathologie van 
atherosclerose heeft de laatste jaren in toenemende mate aandacht gekregen.  Activatie 
van mestcellen kan nadelige effecten hebben bij verschillende immuun-gerelateerde 
ziekten zoals allergie9 or reumatoïde artritis10, en het is ook noodzakelijk om de exacte 
bijdrage van deze cel aan de ontwikkeling van atherosclerose te onderzoeken. 
Hoofdstuk 2 van dit proefschrift geeft een algemeen overzicht van de effecten 
van de mestcel op hart- en vaatziekten. De effecten van de mestcel op de ontwikkeling 
van atherosclerose zijn de afgelopen 20 jaar onderzocht en dit onderzoek hebben we 
in dit hoofdstuk samengevat. Er is echter nog niet veel bekend over de effecten van 
de mestcel op ander cardiovasculaire pathologieën. In dit hoofdstuk hebben we ook 
studies naar de bijdrage van de mestcel aan dieet-geïnduceerde obesitas beschreven. 
Mestcellen kunnen infiltreren in het vetweefsel, en daar een bijdrage leveren aan 
adipogenese en obesitas. Recentelijk is echter aangetoond dat mestcellen door de 
secretie van leptine ook zouden kunnen beschermen tegen obesitas en diabetes, wat 
de tweeledige rol van de mestcel illustreert13. Dit werd nog eens bevestigd door een 
artikel waarin is beschreven dat mestcellen de vorming van bruin vet14, een type vet dat 
betrokken is bij onze temperatuurhuishouding15, kan bevorderen. Deze verschillende 
functies van de mestcel zijn ook van belang bij bijvoorbeeld een hartinfarct. Mestcellen 
zijn eerder aangetoond betrokken te zijn bij plaqueruptuur16, en ook in een recent artikel 
bleek de mestcel in verhoogde aantallen aanwezig in patiënten met zowel stabiele 
als instabiele plaques in de kransslagader, en in patiënten die zijn getroffen door een 
hartinfarct17. Mestcellen hebben daar echter niet alleen nadelige effecten, aangezien 
deze cellen ook van belang zijn bij de vorming van nieuwe bloedvaten, en bij het genezen 
van het myocardium na een acuut infarct18,19. Zeer recentelijk is zelfs aangetoond dat 
mestcellen uit het vetweefsel kunnen communiceren met cardiomyocyten, en daarmee 
de contractiliteit van de cardiomyocyten en de hartfunctie kunnen bevorderen20.
Mestcellen kunnen effecten hebben op de snelheid van het hartritme, wat 
uitermate van belang kan zijn bij aritmieën, zoals we ook beschrijven in het tweede 
hoofdstuk. Mestcellen zijn een aantal jaren geleden beschreven bij atriumfibrilleren21, 
en verschillende hartritmestoornissen, en met name atriumfibrilleren, zijn geassocieerd 
met atherosclerose1,22. Aritmie in relatie tot het immuunsysteem is tot op heden nog 
niet tot in detail onderzocht. Hoewel de mestcel ook onder gezonde omstandigheden 
al aanwezig is in het hart23, lijkt de bijdrage van de mestcel bij het ontstaan van 
hartritmestoornissen ongunstig24,25. Naast mestcellen kunnen ook macrofagen het 
hartritme beinvloeden26. Mestcellen kunnen een interactie aangaan met macrofagen 
in cardiovasculaire aandoeningen zoals atherosclerose27 en bij de vorming van een 
aneurysma28. Hoewel dit geen causaal verband bewijst, zou het zeer interessant zijn 
om de mogelijke interactie tussen weefselmacrofagen en mestcellen in het hart in 
hartritmestoornissen te onderzoeken. 
Omdat mestcellen zeer verschillende effecten op het omliggende weefsel kunnen 
hebben, en omdat atherosclerose de onderliggende pathologie is van het merendeel 
van de hart- en vaatziekten, hebben wij als doel gesteld de bijdrage van de mestcel aan 
experimentele atherosclerose en de effecten op de ontstekingsreactie te onderzoeken.
In hoofdstuk 3 hebben we de remming van LPA-gemedieerde mestcelactivatie29 
op de ontwikkeling van atherosclerose onderzocht. LPA is een bioactief lipide, dat 
accumuleert in de atherosclerotische plaque, waar het bij kan dragen aan de progressie 
van atherosclerose30,31. LPA bindt aan specifieke LPA1/3 receptoren32, die zich op 
verscheidene immuuncellen33 waaronder de mestcel29,34 bevinden.  Daarom hebben we 
in deze studie de effecten van LPA geremd door de LPA1/3 receptoren te blokkeren met 
de chemische stof Ki16425. LPA1/3 blokkade bleek een significant effect te hebben op de 
systemische immuunrespons en resulteerde in een 40% remming van plaquevorming, 
wat veroorzaakt werd door een verminderde hoeveelheid macrofagen in de plaque. 
Het beschermende effect van Ki16425 kwam door een verstoring van de CCR2-CCL2 
interactie, maar we zagen ook een toename in de hoeveelheid anti-inflammatoire 
monocyten en regulatoire T cellen. Daarnaast observeerden we ook een lichte daling in 
de circulerende LDL cholesterol niveaus. Over het geheel bekeken lijkt de blokkade van 
LPA1/3 een interessante therapeutische methode om de progressie van atherosclerose 
te remmen. Onze data laten zien dat blokkade van LPA1/3 niet alleen een verschuiving 
van een pro- naar een anti-inflammatoire respons kan induceren en plaqueprogressie 
kan verminderen, maar ook de cholesterolniveaus kan reguleren. We konden in deze 
studie echter geen effecten op mestcellen aantonen. Desalniettemin zijn er nog steeds 
aanwijzingen dat LPA de mestcel kan beïnvloeden. Er zijn bijvoorbeeld andere LPA 
receptoren die door de mestcel tot expressie worden gebracht, die niet geblokkeerd 
werden in deze studie35. Daarnaast werden de effecten van LPA op mestcellen met 
name waargenomen in vergevorderde atherosclerose29, een stadium dat we in deze 
studie niet bekeken hebben. Het gunstige effect dat wij hebben waargenomen op 
de verworven immuniteit suggereert dat blokkade van LPA1/3 ook voor een langere 
periode effectief zou kunnen zijn. Het zou daarom zeer interessant zijn om deze de 
effecten van deze stof in een langdurige studie te bekijken De toename in het aantal 
regulatoire T cellen geeft daarnaast nog eens een extra aanleiding om LPA1/3 blokkade 
nader te onderzoeken, bijvoorbeeld in plaque regressie, aangezien ook deze cellen een 
aantrekkelijk therapeutisch aangrijpingspunt zijn36,37.
De betrokkenheid van de verworven immuunrespons, en voornamelijk de 
bijdrage van de T cellen, in atherosclerose is welbekend38. CD4+ T cellen, en met name 
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de TH1 cellen, zijn in grote getalen aanwezig in de atherosclerotische plaque39. In 
hoofdstuk 4 bediscussiëren we een nieuw gevonden interactie tussen mestcellen en 
CD4+ T cellen in atherosclerose. Wetende dat mestcellen kunnen communiceren met 
T cellen in andere ontstekingsziekten40,41, en gebaseerd om nieuwe studies waarbij 
de antigen presenterende functie van mestcellen wordt beschreven42,43, hebben wij 
onderzocht of mestcellen een interactie aangaan met CD4+ T cellen in atherosclerose. We 
beschrijven in dit hoofdstuk dat mestcellen de antigen presenterende capaciteit kunnen 
verhogen gedurende hyperlipidemie door de MHC-II expressie in zowel experimentele 
atherosclerose als in humane plaques te verhogen. Hierdoor kunnen mestcellen direct 
antigenen presenteren aan CD4+ T cellen, die dan onder invloed van een hoog vet dieet 
differentiëren naar een pro-atherogeen TH1 subtype. Dit is interessant omdat mestcellen 
in allergie voornamelijk een TH2 respons bevorderen44. Mestcellen lijken daarom 
verschillende effecten te kunnen hebben op T cellen, afhankelijk van de ontsteking in 
het lokale milieu. Atherosclerose, als TH1 gemedieerde ziekte, zorgt waarschijnlijk voor 
presentatie van antigenen, die de TH1 subset beïnvloeden. In allergieën daarentegen 
lijken mestcellen een TH2 respons te bevorderen. Het zou daarom interessant zijn om te 
onderzoeken of deze mestcel-CD4+ T cel interactie resulteert in antilichaamproductie 
door B cellen. Daarnaast kunnen we bekijken of specifieke depletie van MHC-II op 
de mestcel de progressie van atherosclerose in vivo kan beïnvloeden. Daarbij weten 
we nog niet welke antigenen via MHC-II gepresenteerd worden door mestcellen 
aan CD4+ T-cellen in atherosclerose. In de toekomst zou het interessant kunnen zijn 
om MHC-II epitopen op mestcellen te screenen voor lipiden-specifieke antigenen, 
en daarnaast weten we nog niet via welk mechanisme antigenen door de mestcellen 
worden opgenomen uit de omgeving. Een laatste cruciale vraag is of mestcellen lipiden 
kunnen opnemen en opslaan als zogenaamde “foam-cellen”. Er zijn tot op heden geen 
aanwijzingen dat mestcellen klassieke opnamereceptoren hebben voor lipiden zoals 
het geval bij macrofagen en dendritische cellen, maar deze mestcellen zouden lipiden 
mogelijk kunnen opnemen via andere mechanismen, en vervolgens opslaan als neutrale 
lipiden.  
In hoofdstuk 5 hebben we de interactie tussen mestcellen en het verworven 
immuunsysteem in atherosclerose verder onderzocht door mestceldeficiente muizen 
te repopuleren met CD1d deficiënte of controle mestcellen. In deze studie hebben we 
een directe interactie tussen mestcellen en de NKT cel populatie gevonden via CD1d-
gemedieerde presentatie van lipiden. Verrassend genoeg zagen we in deze studie 
een beschermend effect van mestcellen in atherosclerose. Dit was een onverwachte 
bevinding aangezien NKT cellen, die in deze studie verminderd geactiveerd bleken, in 
de literatuur als pro-atherogeen worden aangeduid, voornamelijk via presentatie van 
lipiden door CD1d45. NKT cellen kunnen echter zowel als activator als als remmer van 
de immuunrespons functioneren, afhankelijk van het glycolipide dat aan deze cellen 
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gepresenteerd wordt46,47. Het is zelfs aangetoond dat NKT cellen CD4+ T cellen in 
atherosclerose kunnen remmen op een soortgelijk manier als wij in deze studie hebben 
geobserveerd48. Daarnaast kunnen NKT cellen een beschermende rol spelen in auto-
immuunziekten zoals obesitas49 en reumatoïde artritis50, waarbij ook mestcelen een rol 
kunnen spelen. Antigen presentatie via CD1d op mestcellen lijkt daarom, in tegenstelling 
tot de klassieke presentatie van lipide antigenen via CD1d op antigen presenterende 
cellen die atherosclerose bevorderen51,52, beschermend te werken. Hoewel het 
interessant is dat mestcellen ook in deze studie de CD4+ TH1 cel respons beïnvloeden, 
alhoewel indirect, lijkt deze interactie sterk afhankelijk van de stimulans, en is er meer 
onderzoek nodig om de exacte bijdrage van deze mechanismen in atherosclerose te 
bevestigen.
De antigeen presenterende capaciteit van humane mestcellen genoemd 
in hoofdstuk 4 was een onderdeel van een algemene karakterisatie van humane 
mestcellen zoals beschreven in hoofdstuk 6. Hoewel de mestcel de enige immuuncel 
is waarvan de correlatie met toekomstige cardiovasculaire events is beschreven6, is 
het activatiemechanisme van de mestcellen in de vergevorderde atherosclerotische 
plaque nog niet tot in detail bekend. In deze studie hebben we mestcellen uit 22 
arteriën, verkregen van endarterectomie operaties (carotis en femoralis), geïsoleerd en 
gekarakteriseerd middels flow cytometry. We hebben met de verkregen flow cytometry 
data bestaande immunohistochemische data bevestigd, waarin is beschreven dat de 
mestcellen verschillende proteasen kunnen bevatten53. De mestcellen bleken heterogene 
hoeveelheden chymase en tryptase te produceren. Van belang was dat een groot aantal 
mestcellen in de plaque geactiveerd bleek, gebaseerd op de expressie van CD63 als 
marker voor mestcelactivatie54. Van deze geactiveerde mestcellen was de meerderheid 
gesensitiseerd met IgE, wat aangeeft dat dit een belangrijk mestcelactivatie mechanisme 
kan zijn in atherosclerose. Dit is niet verrassend, aangezien mestcellen bekend staan om 
de klassieke degranulatie via antigen-gesensitiseerde IgE binding op Fcε-receptoren55, 
zoals bijvoorbeeld in allergieën. Dit zou ook kunnen verklaren waarom serum IgE 
niveaus positief correleren met de aanwezigheid van coronary artery disease (CAD)56, 
wat ook geassocieeerd is met de aanwezigheid van mestcellen6,17. Er was daarnaast 
ook een kleinere fractie mestcellen, die was geactiveerd via mechanismen anders dan 
via IgE, wat aangeeft dat er meerdere mechanismen zijn waardoor mestcellen kunnen 
worden geactiveerd in de atherosclerotische plaque. Verschillende in vivo studies 
beschrijven dat mestcellen in hart- en vaatziekten kunnen worden geactiveerd  via 
bijvoorbeeld  TLRs57, complement receptoren57 of neuropeptide receptoren58. Tot op 
heden hebben we echter nog geen indicatie voor de bijdrage van deze alternatieve 
activatiemechanismen aan humane atherosclerotische plaque destabilisatie. De 
nadelige effecten echter die mestcellen kunnen hebben op plaquestabiliteit, zoals het 
induceren van intraplaque bloedingen59, geven het belang aan van deze cellen in plaque 
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destabilisatie, en onderstrepen de potentie van therapieën die op mestcellen kunnen 
aangrijpen.  
In hoofdstuk 7 hebben we de therapeutische capaciteit van mestcellen in 
atherosclerotische plaque regressie onderzocht. In deze studie hebben mestcellen 
conditioneel gedepleteerd in de muizen, die al atherosclerose hadden ontwikkelend. 
Tegelijkertijd is ook het dieet gewisseld van een hoog vet dieet naar normaal knaagvoer. 
Met deze experimentele opzet hebben we geen effecten van mestceldepletie op de 
plaquegrootte waargenomen, wat aangeeft dat depletie van mestcellen op het moment 
dat er al een ontstekingsproces gaande is, geen bijdrage levert aan het reduceren van 
een bestaande atherosclerotische plaque. In deze studie bleek het aantal neutrofielen 
in de plaque wel sterk verlaagd na depletie van mestcellen, wat verklaard kan worden 
door de afwezigheid van chemotactische stoffen die een mestcel kan uitscheiden. 
Mestcellen kunnen door het uitscheiden van chemokines bij voorkeur neutrofielen 
naar de plaque recruiteren60. Ook bleek het collageengehalte in de plaque verlaagd door 
mestceldepletie, en dit was onverwacht aangezien mestcellen middels het uitscheiden 
van chymase61 collagen in de plaque kunnen afbreken. Tryptase kan aan de andere 
kan collageensynthese induceren, zoals is gebleken in een nierfibrose model62, wat 
de complexiteit van deze mestcellen in ziekteprocessen illustreert. Dit maakt mede 
duidelijk dat de mestcel geen celtype is wat eenduidig pro-inflammatoir is in hart- en 
vaatziekten en de functie van deze cel dient in detail per specifiek ziektebeeld te worden 
onderzocht. De data gegenereert in dit proefschrift illustreren dat we, in de zoektocht 
naar nieuwe therapeutische strategieen, niet enkel naar depletie of complete remming 
van mestcellen zouden moeten te kijken, aangezien de mestcel niet enkel nadelige 
effecten laat zien, maar ook als fine-tuner van de lokale immuunrespons kan optreden.
Op dit moment worden atherosclerose met name farmacologisch behandeld 
middels statines63, die ontwikkeld zijn als geneedmiddel om het non-HDL cholesterol te 
verlagen. Statines bleken echter ook ontstekingsremmend te werken, en dit resulteerde 
in atherosclerotische plaque stabilisatie63. Een nieuwe aanpak voor het verlagen van 
LDL is recentelijk in de praktijk gebracht. De expressie van het levereiwit PCSK9 kan 
door middel van antilichaamtherapie verlaagd worden, wat uiteindelijk leidt tot een 
50% verlaging van circulerende LDL niveaus, wat een zeer veelbelovende uitkomst 
is65. Het is tot op heden nog niet mogelijk om een bestaande atherosclerotische plaque 
te verminderen (plaque regressie)64. De lange-termijn effecten van deze therapie zijn 
nog niet bekend, maar wellicht zou regressie mogelijk zijn. Het induceren van plaque 
regressie zou een therapeutische doorbraak zijn, en het huidige onderzoek richt zich 
dan ook op het bereiken van plaque regressie. In dierexperimentele modellen worden 
bijvoorbeeld het stimuleren van reverse cholesterol transport door het antagoneren 
van specifieke micro-RNAs66, of het remmen van immuunmechanismen in combinatie 
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met lipidenverlaging onderzocht67,68. Het zou ook interessant kunnen zijn om LPA1/3 
blokkade in de context van regressie te bestuderen. 
Tenslotte heeft ongeveer twee maanden geleden de grote CANTOS trial, 
waarin remming van het proinfllammatoire cytokine IL-1β door het antilichaam 
canakinumab is onderzocht, het klinische eindpunt bereikt69. Patienten behandeld met 
canakinumab hadden een siginificante verlaging in het risico op het krijgen van een 
secundair cardiovasculair event70. Dit anti-inflammatoire geneesmiddel betekent een 
wetenschappelijke doorbraak, vergelijkbaar met de ontdekking van de statines, die de 
weg vrij maakt voor de ontwikkeling van nieuwe ontstekingsremmende geneesmiddelen 
tegen hart- en vaatziekten.
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